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Abstract 
The continuous increase of antibiotic resistant pathogens necessitates a search for new 
antibiotics. In this study a novel lantibiotic gene cluster was identified using the publicly 
available genome database. Blast searches employing the biosynthetic enzyme of the 
lantibiotic mersacidin (MrsM) in the NCBI database revealed a putative class II lantibiotic 
gene cluster in Bacillus pseudomycoides DSM 12442.  
Lantibiotics are lanthionine and methyllanthionine containing antimicrobial peptides. 
They are ribosomally synthesized antimicrobial peptides with extensive posttranslational 
modifications. During the posttranslational modification, lanthionine and methyllanthionine 
are introduced to the peptide by means of dehydration of Ser/Thr residues, followed by the 
reaction of the didehydro amino acids with cysteines to form the thioether linkages. The 
structural (lanA), modification (lanM, lanB, lanC, lanP, labKC and lanL), regulation (lanR, 
lanK), export (lanT (P)) and immunity genes (lanEFG) are organized in the biosynthetic gene 
clusters.  
The aim of the project was to characterize the putative lantibiotic gene cluster from B. 
pseudomycoides. In production assays, the cell wash extract of B. pseudomycoides showed the 
presence of an antimicrobial substance. The antimicrobial substance exhibited an activity 
against Gram-positive bacteria. The substance was partially purified by RP-HPLC, and the 
subsequent MALDI TOF MS predicted a mass of 2786.0 Da for an active peptide. The 
putative pseA and pseM genes from the predicted lantibiotic gene cluster of B. 
pseudomycoides were heterologously expressed in E. coli. The coexpression of the prepeptide 
(PseA) along with its corresponding modification enzyme (PseM) resulted in the production 
of a modified peptide, with four out of eight possible dehydrations. After the proteolytic 
removal of the leader peptide in vitro from the heterologously produced peptide, the core 
peptide showed an antimicrobial activity against the indicator strain M. luteus. The mass of 
the heterologously produced peptide was 2785.6 Da, which corresponded to the mass of the 
antimicrobial substance produced by B. pseudomycoides. This antimicrobial peptide is a novel 
class II lantibiotic and was named pseudomycoicidin. The chemical assays (IAA and βME) 
demonstrated the presence of four Lan/MeLan rings and one additional disulfide bond in the 
peptide. Further experiments are required to confirm the structure of the peptide and its mode 
of action. 
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1. Introduction 
An antimicrobial substance is an agent that kills microorganisms or inhibits their growth. The 
toxic effect of antimicrobial substance against microorganism led it to be used as an important 
agent in controlling diseases. Antimicrobials that kill microbes are called microbicidal, while 
those that merely inhibit their growth are called microbiostatic. Antimicrobial substances can 
be grouped according to the target microorganisms they act upon; such as antibacterials (or 
antibiotics) against bacteria and antifungals against fungi. Several microbes, higher plants and 
animals produce antimicrobial substances (Thompson and Wright, 1998). A large number of 
antimicrobials currently used in the clinical therapy are derived from the natural products of 
microbial origin.  
The discovery of penicillin by Alexander Fleming more than 90 years ago, made a 
revolution in medicine (Fleming, 1929). This invention saved millions of people from the 
death caused by bacterial infections. However, the wide spread use of antibiotics has caused a 
strong selective pressure resulting in the emergence of resistant strains. For example, a high 
percentage of resistance is acquired in hospitals and farming, where antibiotics are intensively 
used. In the 1960’s, Staphylococcus aureus, the most common cause of hospital acquired 
infections, developed resistance to methicillin and several other antibiotics. Consequently, 
vancomycin was only a reliable agent for treating infections due to methicillin resistant S. 
aureus (MRSA) (Rubin et al., 1999). However, due to the excessive use of vancomycin to 
treat MRSA, vancomycin resistant Enterococcus faecium (VRE) appeared.  In addition, there 
are numbers of Gram-negative pathogens such as Pseudomonas aeruginosa, Acinetobacter 
baumanii and Enterobacteriaceae which are resistant to many antibiotics (Livermore, 2004). 
Asuduzzaman et al. (2010), further conclude that today there are no antibiotics in clinical use, 
to which the resistance has not developed. Bacterial resistances to antibiotics will lead to 
treatment failure, unless new drugs are discovered. Thus, the search and the characterization 
of new drugs have become a primary concern for public health.  
In search for alternatives to antibiotics, antimicrobial agents such as antimicrobial 
peptides, bacteriophages and probiotic bacteria are now being considered. Bacteria represent 
an inexhaustible source for the discovery of new antibiotics (Newman and Cragg, 2007; 
Davies, 2011). Even those bacteria, which once thought useless, are now reconsidered for the 
production of antibiotics such as Burkholderia, Lysobacter, plant and insect associated 
bacteria like Pantoea and Photorhabdus, Janthinobacterium, and anaerobic bacteria like 
clostridia (Pidot et al., 2014). 
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1.1. Antimicrobial peptides from bacteria 
Many bacteria of different taxonomic branches and from various environments produce 
antimicrobial substances that are active against other bacteria. Both Gram-positive and Gram-
negative bacteria produce bacteriocins. The bacteriocins form a heterogenous subgroup of 
ribosomally synthesized antimicrobial peptides. Members of the Bacillus group are 
considered as the good producers of antimicrobial substances, including, peptides, 
lipopeptides antibiotics, and polyketides (Stein, 2005). Some of its members, such as B. 
subtilis, devote more than 4% of its genome for the synthesis of polyketides (PKs), non-
ribosomal peptides (NRPs), bacteriocins as well as other unusual antibiotics (Patrick, 2012).  
 
1.1.1. Non-ribosomal peptides 
Non-ribosomally synthesized peptides are produced by bacteria, fungi, and streptomycetes. 
Such peptides are synthesized in an ordered fashion by the very large multifunctional peptide 
synthetases. A single peptide synthetase gene (e.g., grsB of the gramicidin S biosynthetic 
operon) can be as large as 13 kb (4,300 amino acids) and contain four to six modules 
(resulting in the addition of four to six residues) (Krätzschmar et al., 1989). Each module 
recognizes a residue, activates it, modifies it as necessary, and adds it to the growing peptide 
chain (Felnagle et al., 2008). These modules consist of three main core domains - i) the 
adenylation domain (A), which selects and activates the cognate amino acid as an amino 
acyladenylate, ii) the thiolation domain (T), which catalyses the binding of the activated 
monomer to the synthetase through a phosphopantetheinyl arm, and iii) the condensation 
domain (C), which is responsible for the formation of the peptide linkage between the 
activated amino acids from the two adjacent T modules. The cyclic lipopeptide daptomycin 
and the glycopeptide vancomycin are examples for clinically established non-ribosomal 
peptides (Hancock and Chapple, 1999).  
 
1.1.2. Ribosomally synthesized peptides 
Ribosomally produced peptides are commonly known as bacteriocins. These peptides form a 
heterogenous group of proteinaceous antimicrobial substances. They display a high degree of 
target specificity against related bacteria, although many have a wider spectrum of activity 
(Jack et al., 1995). Characteristically, bacteriocins are gene-encoded and synthesized as 
precursors consisting of an N-terminal leader sequence and a C-terminal propeptide. The 
leader peptide has several functions: 1. it assists in the transport of the peptide through the 
cytoplasmic membrane, 2. it serves as a recognition signal for the modification machinery, 3. 
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it acts as an intramolecular chaperone, 4. it keeps the modified prepeptide inactive prior to 
export, and 5. it enhances the stability against proteolytic degradation resulting in a prolonged 
half-life of the precursor (Jack et al., 1995). The bacteriocins are classified differently at many 
instances by different authors. 
Klaenhammer (1993) defined four distinct classes of bacteriocins: a. Class I, 
lanthionine containing peptides (lantibiotics); b. Class II, non-lanthionine-containing 
relatively heat-stable small (10 kDa) membrane-active peptides; c. Class III, large (30 kDa), 
heat-labile proteins; and d. Class IV, complex bacteriocins containing essential lipid or 
carbohydrate moieties in addition to the protein. The class II bacteriocins were further divided 
into three subclasses: i. Class IIa, Listeria-active peptides with the N-terminal consensus 
sequence -Tyr-Gly-Asn-Gly-Val-Xaa-Cys-; ii. Class IIb, poration complexes requiring two 
different peptides for their activity; and iii. Class IIc, thiol-activated peptides requiring 
reduced Cys residues for their activity. 
Nes et al. (1996) and Moll et al. (1999) described three classes of bacteriocins: a. Class 
I, the small heat-stable polycyclic peptides (<5 kDa) containing unusual and 
posttranslationally modified amino acids also known as lantibiotics; b. Class II, the small 
(<10 kDa) heat-stable non-lantibiotics; and c. Class III, the large (>30 kDa) heat-labile 
bacteriocins. The class II bacteriocins were further divided into four subgroups – i. Class IIa, 
the so-called pediocin-like bacteriocins with a strong anti-Listeria activity; ii. Class IIb, the 
two-peptide bacteriocins; iii. Class IIc, the sec-dependent bacteriocins; and iv. Class IId, the 
bacteriocins not included in the previous class II subgroups. 
 
1.1.2.1. Thiazole oxazole modified microcins (TOMMs) 
The TOMMs are ribosomally produced peptides with posttranslationally installed 
heterocycles derived from Cys, Ser and Thr residues (Melby et al., 2011). The TOMM 
precursor peptide has an N-terminal region and a C-terminal region. The N-terminal region of 
the precursor peptide is known as the leader peptide, which contains basic recognition motifs 
for the biosynthetic machinery. The C-terminal region is known as the core peptide. The core 
peptide is rich in heterocyclizable residues and can be the site for numerous other 
posttranslational modifications (Oman and van der Donk, 2010). The TOMMs are encoded by 
the structural genes that code for peptides of 50 - 70 amino acids, and are rich in Cys, Ser, Thr 
and Gly residues. These amino acids are often found in repetitive motifs and serve as a 
precursor amino acids for the class-specific thiazoles and oxazoles (Haft, 2009; Melby et al., 
2011) (Figure 1). Microcin B17 (Li et al., 1996), thiopeptides (Bagley et al., 2005), 
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cyanobactins (Sivonen et al., 2010) and goadsporins (Onaka et al., 2005) are few examples of 
TOMMs. Lee et al. (2008) described a wide spread distribution of biosynthetic gene clusters 
for producing a subclass of toxins with thiazole and oxazole rings. During TOMM 
biosynthesis, the BCD synthetase complex binds to the precursor peptide through the specific 
motifs within the N-terminal leader sequence (Roy et al., 1999; Mitchell et al., 2009). This 
synthesis is completed in two enzymatic steps (Scholz et al., 2011). At first, Cys and Ser/Thr 
residues are converted into the corresponding thiazolines and (methyl) oxazolines. This step is 
catalyzed by a cyclodehydratase enzyme. In the second step, the thiazoline and oxazoline 
rings are oxidised to yield thiazole and (methyl) oxazole rings, with a net loss of 20 Da. This 
step is catalyzed by a dehydrogenase enzyme. Finally, the prepeptide is proteolytically 
cleaved and thus the leader peptide is removed from the modified peptide. The fully matured 
TOMMs are then actively exported from the cell by an ABC transport system. In addition to 
cyclodehydratase and dehydrogenase, TOMMs have a docking protein (Haft, 2009; Melby et 
al., 2011). The docking protein is often fused to C-terminus of cyclodehydratase. Such 
docking proteins regulate the cyclodehydratase and assemble the active synthetic complex. 
Furthermore, TOMM like biosynthetic gene clusters may contain additional modification 
enzymes (Lee et al., 2008). For example, the cluster of goadsporin contains acyltranferases 
and lantibiotic dehydratases (Onaka et al., 2005).  
 Recently, a new family of TOMMs was identified (Haft et al., 2010). The precursor 
peptides of this family possess very long leader sequences and share homology either to the 
alpha subunit of the enzyme nitrile hydratase (NHase) (Nitrile hydratase related leader 
peptides, NHLP) or to the nitrogen fixing proteins from cyanobacteria (NiF11). NHLPs are 
found adjacent to cyclodehydratase scaffold docking proteins.  
 Likewise, thiopeptides are another group of TOMMs having thiazole-containing 
compounds (Bagley et al., 2005). Most thiopeptides are characterized by a macrocyclic core 
consisting of thiazoles / thiazolines. These thiazoles are joined together by a six-membered 
heterocycle such as pyridine, hydroxypyridine or dehydropiperidine (for example in 
thiostrepton). Examples of such thiopeptides are thiostrepton (Kelly et al., 2009), thiocillin 
(Brown et al., 2009), siomycin (Liao et al., 2009), thiomuracin (Morris et al., 2009) and 
nosiheptide (Yu et al., 2009). The leader sequences (34–48 residues) of thiopeptides are rich 
in aspartate and glutamate and have some highly conserved hydrophobic residues. Several 
leader peptides have the typical double glycine motif (Oman and van der Donk, 2010). The 
modification of thiopeptides occurs in three main steps: (i) Ser and Thr are dehydrated to 
dehydroamino acids by the enzymes that are similar to the lantibiotic dehydratases, (ii) 
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thiazoles and thiazolines are formed by enzymes that have homology to the cyanobactin, 
microcin B17 and SLS biosynthetic enzymes, and (iii) two dehydroalanines are cyclised to 
produce the central six-membered heterocycle compound. Additionally, in some cases 
compound-specific modifications also occur, which complete the maturation process.  
 The TOMM-like compounds have different activities such as antifungal, antibacterial, 
antimalarial, antitumor, etc. The activities of these compounds depend upon membrane 
depolarization, inhibition of DNA gyrase and inhibition of the protein biosynthesis (Lee et al., 
2008; Melby et al., 2011).  
 
 
 
 
Figure 1: The biosynthesis and structure of thiazole/oxazole containing Microcin B17 
compound. Figure adapted from Melby et al. (2011). 
 
1.1.2.2. Lantibiotics 
Lantibiotics are small, heat-stable, ribosomally synthesized, and posttranslationally modified 
antimicrobial peptides (bacteriocins) produced by Gram-positive bacteria (Schnell et al., 
1988; Arnison et al., 2012). The lantibiotics, unlike other bacteriocins, are characterized by 
the presence of thioether amino acids, lanthionine (Lan) and 3-methyllanthionine (MeLan) 
and various modified amino acids, such as didehydroalanine (Dha) and didehydrobutyrine 
(Dhb) (Schnell et al., 1988). The structures of some representative groups of lantibiotics are 
shown in Figure 2. Lantibiotics are initially synthesized as the inactive linear prepeptides that 
later undergo subsequent extensive modifications to be biologically active. The modifications 
include the dehydration of serine and threonine residues to form the didehydro amino acids 
Dha and Dhb, respectively. Later, the Dha and Dhb react with the nearby C-terminally located 
Cys residues to form a thioether linkage forming Lan and MeLan, respectively. Finally, in 
order to be active, the modified peptide is exported and cleaved from its leader. 
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Figure 2: Structures of representative members of the lantibiotics. Post translational 
modifications are represented by its abbreviations: Abu - 2-aminobutyric acid; Ala-S-Ala - 
lanthionine (red); Abu-S-Ala - 3-methyllanthionine (blue); Dha - dehydroalanine and Dhb - 
dehydrobutyrine (green). All other post-translational modifications including Asp-OH, b-
hydroxy aspartate, are shown in purple. Figure adapted from Xie and van der Donk (2004) 
and Goto et al. (2010). 
 
Although, the first characterized lantibiotic, nisin, was discovered over eighty years 
ago (Rogers and Whittier, 1928), the ribosomal origin of such modified peptides were 
revealed only after 60 years, when epidermin biosynthetic gene cluster from Staphylococcus 
epidermidis Tü 3298 was sequenced (Schnell et al., 1988). Since then, around 100 lantibiotics 
have been described, and most of which are produced by Gram-positive bacteria (Emma et al., 
2013). In addition, numbers of actinomycete lanthipeptide biosynthetic gene clusters have 
been characterized - cinnamycin from Streptomyces cinnamoneus DSM 40005 (Widdick et 
al., 2003), SapB from Streptomyces coelicolor (Kodani et al., 2004), SapT from Streptomyces 
tendae (Kodani et al., 2005), actagardine from Actinoplanes garbadinensis (Boakes et al., 
2009), deoxyactagardine B (DAB) from Actinoplanes liguriae (Boakes et al., 2010), 
venezuelin from Streptomyces venezuelae (Goto et al., 2010), and microbisporicin from 
Microbispora corallina (Foulston et al., 2010). Furthermore, lanthipeptide gene clusters are 
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not limited to the firmicutes and actinomycetes, but are also found in proteobacteria, 
chlamydiae, bacteroidetes and cyanobacteria (Li et al., 2010; Marsh et al., 2010).  
 
1.1.2.2.1. Lantibiotic gene cluster  
The genes for lantibiotic biosynthesis are generally found in clusters. The generic locus is 
designated by the symbol ‘lan’, with a more specific designation for each lantibiotic member 
e.g. nis for nisin, gdm for gallidermin, and cin for cinnamycin. Gene clusters can be found on 
conjugative transposable elements (e.g., nisin), on the chromosome of the host (e.g., subtilin), 
or on the plasmids (e.g., epidermin, lacticin 481) (Chatterjee et al., 2005b). A biosynthetic 
gene cluster consists of several genes encoding the prepeptide (LanA), the modification 
enzymes (LanB, LanC, LanM, LanL and LabKC) that introduce the thioethers, an ABC 
transporter (LanT) that exports the modified prepetide and removes the leader, and / or 
extracellular protease (LanP) that removes the leader, and finally immunity proteins [LanI (H) 
and/or LanFEG] that protect the producer. Usually, parts of the cluster are organized in 
operons that allow the co-expression of proteins that are involved in the similar functions. The 
structural gene (LanA) is often clustered with the genes of modification enzymes in a 
biosynthetic operon, and it is usually the first ORF. Besides this, there is no uniform gene 
order in the individual gene clusters (Siezen et al., 1996; Willey and van der Donk, 2007). 
The genes that are necessary for modification, transport, processing, self protection, and 
regulation are found in close proximity to the structural genes. Some representative 
biosynthetic gene clusters are shown in Figure 3. 
 
 
 
Figure 3: Representative biosynthetic gene clusters of the lantibiotics nisin (Kuipers et al., 
1993), epidermin (Schnell et al., 1992), mersacidin (Altena et al., 2000), cinnamycin 
(Widdick et al., 2003), lacticin 3147 (McAuliffe et al., 2001), venezuelin (Goto et al., 2010). 
Figure adapted from Xie and van der Donk (2004). 
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1.1.2.2.3. Biosynthesis and modification 
Post translational modifications and proteolytic removal of the leader peptide converts the 
inactive propeptide to their active forms. In general modification occurs in a two-step reaction 
– a dehydration step and a cyclization step. In dehydration step, Ser and Thr residues 
dehydrate to form didehydroamino acids: dehydroalanines (Dha) (from Ser) and 
dehydrobutyrines (Dhb) (from Thr) (Figure 4). This step is catalysed by a dehydratase. Later, 
in a cyclization step, following the regio- and stereoselective Michael addition reaction, a 
sulfhydryl-group of a neighboring Cys residue is linked to the unsaturated double bond of the 
didehydro amino acid, resulting in the generation of lanthionine (Dha + Cys) and 
methyllanthionine (Dhb + Cys) (Ingram, 1969; 1970; Toogood, 1993). This step is catalyzed 
by a cyclase. Although, the dehydration and cyclization steps are catalyzed by different 
enzymes, in some cases, a single enzyme carries out both steps. So far, five different 
modification enzymes are identified to be involved in the lanthionine formation - LanB, 
LanC, LanM, RamC/LabKC and LanL. Recently, an in vitro study in nisin showed that the 
dehydratase enzyme dehydrates its substrate in the presence of glutamate, ATP, Mg
2+
 and the 
ribosomal / membrane fraction of the bacterial cell extract (Garg et al., 2013). Likewise, the 
lantibiotic cyclase utilizes zinc for activation of a thiol of its substrate (Mathews et al., 1997; 
Okeley et al., 2003).  
In addition to the dehydration and cyclization steps, some lantibiotics undergo other 
additional modifications. For example, in labyrinthopeptins, labionin (Lab) is formed through 
a subsequent 2-fold Micheal type addition cyclization, which is induced by the nucleophilic 
attack of a C-terminal cysteine side chain (Meindl et al., 2010). Likewise, in epidermin and 
mersacidin, the oxidative decarboxylases (EpiD and MrsD) catalyze the oxidative 
decarboxylation of the C-terminal cysteine to form S-Aminovinyl-D-cysteine (AviCys) and S-
Aminovinyl-3-Methyl-D-cysteine (MeAviCys) (Figure 4) (Kupke and Götz, 1996). In 
cinnamycin, a lysinoalanine bridge is formed by addition of the ε-amino group of Lys to Dha 
(Kaletta et al., 1991; Zimmermann et al., 1993). Apart from these modifications in the 
peptides that result in the cyclic structures, many peptides undergo large number of structural 
modifications that do not necessarily result in the cyclic structures. Among such modifications 
are the hydroxylations of Asp in cinnamycin and duramycins (Kaletta et al., 1991), 
hydroxylation of Pro and chlorination of Trp in microbisporicin (Knerr and van der Donk, 
2012), and allo-Ile in cypemycin, and D-Ala in lacticin 3147 and lactocin S. Furthermore, 
Dha and Dhb residues, that are N-terminally exposed after leader peptide processing, 
spontaneously hydrolyze to yield a 2-oxopropionyl (OPr) moiety in lactocin S, and a 2-
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oxobutyryl (OBu) group in Pep5. OPr may be further modified by its reduction to a 2-
hydroxypropionyl (Hop) residue in epilancin 15X, epilancin K7, and epicidin 280 (Kellner et 
al., 1989; van de Kamp et al., 1995; Ekkelenkamp et al., 2005). Such structural modifications 
improve the peptide stability and protect the peptide from proteolysis (Knerr and van der 
Donk, 2012). 
The removal of the leader peptide from the modified peptide activates the lantibiotic. 
In nisin like peptides and lactocin S, the removal of the leader peptide from the modified 
peptide is catalysed by the subtilisin like serine protease (LanP). This event can occur, both 
before and after the export from the cell by the ABC transporter LanT. Those lantibiotics, 
which contain the double Gly cleavage site in their prepeptides, possess LanT transporters. 
These LanT transpoters perform both the cleavage and the export reactions (Sahl and 
Bierbaum, 1998). In contrast, with the cytolysins, this processing by the transporter, does not 
lead to the activation of the peptides. After secretion, the prepeptides are cleaved for the 
second time by the specialized serine protease CylA (Booth et al., 1996).  
 
 
 
Figure 4: Structural motifs found in lantibiotics that are introduced by post translational 
modification. Figure adapted from Xie and van der Donk (2004). 
 
1.1.2.2.2. Regulation of lantibiotic biosynthesis 
Production of a lantibiotic is energy–intensive, and therefore, this process should be tightly 
regulated. Regulation of lantibiotic production is important for the producer strain to maintain 
the bacteriocin production and immunity to its product. Production of many lantibiotics e.g. 
nisin, subtilin, mersacidin, streptococcin AFF22 and salivaricin A is regulated either by two 
component regulatory systems or by growth phase dependent mechanisms (Chatterjee et al., 
2005b). Many regulatory mechanisms belong to the quorum-sensing systems. Quorum-
sensing is an intraspecies communication process that allows cells to sense other organisms in 
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their surroundings in a cell-density-dependent manner. The typical two component regulatory 
system consists of a receptor-histidine kinase (LanK) and a transcriptional response regulator 
(LanR) (McAuliffe et al., 2001; Bierbaum and Sahl, 2009). The receptor histidine kinases 
possess extracellular loops and are involved in detecting extracellular changes, leading to a 
signal cascade initiated by autophosphorylation of a histidine residue. Subsequently, the 
phosphate group is transferred to the appropriate response regulator, that often functions as a 
transcriptional activator (van Kraaij et al., 1999), and regulates transcription of the target 
genes (Yonezawa and Kuramitsu, 2005; Willey and van der Donk, 2007).  
In most of the cases, the extracellular lantibiotic functions as an auto inducer for its 
production. Only in a few exceptions, such as in epidermin production by Staphylococcus 
epidermis, the regulation is not autoinduced (Kies et al., 2003). In case of the nisin regulatory 
system, the phosphoryl group from NisK is transferred to an aspartate in NisR, which initiates 
its binding to the NisA and NisF operators (Chatterjee et al., 2005b). This in turn, activates 
transcription of the nisABTCIP and the nisEFG operon which are involved in nisin 
biosynthesis and self protection respectively. 
Some lantibiotic gene clusters (e.g. mersacidin and cinnamycin) contain an extra 
regulatory gene apart from the two component regulatory gene. In the mersacidin gene 
cluster, in addition to the two component regulatory system, MrsR2 and MrsK2, which 
activate the transcription of the immunity genes, the MrsR1 is also present, which activates 
biosynthesis (Guder et al., 2002). Likewise, in the cinnamycin gene cluster, apart from the 
two component regulatory system, CinK/CinR, the extra regulator CinR1 is also present. At 
first CinK and CinR transcriptionally activate CinR1 which in turn induces the transcription 
of CinA (Widdick et al., 2003). 
Many lantibiotics contain orphan regulators in their gene cluster e.g. MutR in mutacin 
II, EpiQ in epidermin, LtnR in lacticin 3147 and RamR in SapB. These genes positively 
regulate the production of these lantibiotics (Bierbaum and Sahl, 2009; Li et al., 2012). Other 
regulators can also influence the production of  lantibiotics, such as the quorum sensing 
regulator accessory gene regulator (Agr), which is involved in the regulation of the epidermin 
protease (EpiP) (Kies et al., 2003). Likewise, the two-component lantibiotic cytolysin is also 
regulated by a cell-density-dependent mechanism. In the absence of target cells, the cytolysin 
production is repressed by CylR1. When the target cells are present, CylLL binds to 
cholesterol lipid bilayers (phospatidylcholine), leading to its inability to titrate any free 
CylLS. This accumulation of the free CylLS results in a high level of cytolysin expression 
(Coburn et al., 2004). 
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The gene cluster of lacticin 481 lacks any regulatory genes. Lacticin 481 transcription 
is regulated by pH mediated control of P1 and P3 promoters located upstream of lctA. During 
growth of L. lactis, it produces lactic acid, which leads to a decrease in the pH of the growth 
medium from 7 to 5.8. This natural acidification correlates with the amount of lacticin 481 
produced by L. lactis (Chatterjee et al., 2005a). Since the lacticin 481 does not contain a 
dedicated regulation system, transcription from the P1 and P3 promoters is probably governed 
by a general regulatory system such as a broad specificity quorum sensing system (Hindre et 
al., 2004). 
In some cases, lantibiotic production can also be regulated by the other environmental 
conditions. For example, normally nisin biosynthesis by Lactococcus lactis is autoregulated 
by signal transduction via the two component regulatory system. However, during the growth 
in the presence of galactose, transcription of NisA is also induced by galactose, even in the 
absence of NisRK (Chandrapati and O’Sullivan 1999, 2002). 
 
1.1.2.2.4. Self protection/ immunity 
Any bacterial strain that produces lantibiotics, which are active against closely related 
bacteria, must protect itself from the inhibitory action of its own product (Chatterjee et al., 
2005b). Immunity may be mediated by: i) the immunity genes (lanI) and ii) the ABC 
transport protein consisting of two or three subunits (LanEFG).  
The immunity gene lanI is found in the gene clusters of lantibiotics like cytolysin, 
epicidin 280, Pep5 and lactocin S. The LanI proteins or peptides are highly specific and do 
not show similarity to each other (McAuliffe et al., 2001; Bierbaum and Sahl, 2009). PepI was 
the first LanI protein described for lantibiotics. PepI is a short peptide (57 - 69 amino acids) 
attached to the outer side of the membrane and is thought to shield the membrane from the 
pore forming activity of Pep5. The gene clusters of nisin, subtilin and cytolysin contain larger 
LanI proteins known as NisI, SpaI and CylI respectively. NisI and SpaI carry an N-terminal 
lipoprotein sequence. These proteins become peripheral membrane proteins, and are attached 
to the membrane by lipids (McAuliffe et al., 2001). It is known that the C-terminal domain of 
NisI is involved in the binding of nisin and most probably it interacts with NisFEG via its N-
terminal part (Bierbaum and Sahl, 2009). Studies on nisin and lacticin 3147 showed that their 
immunity peptides directly interact with the corresponding lantibiotic, resulting in the 
formation of an insoluble complex (Stein et al., 2003; Draper et al., 2009).  
Some gene clusters possess an additional LanH protein for immunity. In epidermin the 
LanH protein acts as an ancillary peptide for the transport (Peschel et al., 1997). In contrast, in 
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the nukacin ISK-1 immunity system, the membrane protein NukH recognizes the C-terminus 
of nukacin. Nukacin is bound by NukH and subsequently removed from the membrane by 
NukFEG (Okuda et al., 2008).  
The ABC transporter proteins LanEFG are found in the gene clusters of nisin, 
epidermin, mersacidin, lacticin, etc. In the subtilin system, the ABC transporter involved in 
immunity is encoded by the two genes, spaF and spaG (Klein et al., 1994). Similar to the 
HisP family of translocators (Blight et al., 1990), SpaF contains both an ATP-binding domain 
at N-terminus and a membrane – spanning domain at the C-terminus (Klein et al., 1994). The 
lacticin 3147 gene cluster harbours genes encoding an ATP-binding domain (LtnF) and 
membrane-spanning domain (LtnE) of an ABC transporter (McAuliffe et al., 2000). Peschel 
and Götz (1996) proposed that the LanEFG proteins could mediate immunity, either by active 
extrusion of the respective peptide, which would keep the lantibiotic concentration in the 
membrane below a critical level, or by the uptake and intracellular degradation. 
 
1.1.2.2.5. Classification of lantibiotics 
Previously, based on structural similarities, charges and sizes of the active peptide, lantibiotics 
were classified into two groups - type A and type B. The members of type A were strongly 
cationic peptides with 2 - 7 positive charges and their molecular mass was greater than 2.1 
kDa. In contrast the members of type B were weakly cationic peptides and their molecular 
mass was smaller than 2.1 kDa with complex ring structures (Jung, 1991). The type A 
lantibiotics were further divided into two subgroups - type A-I and type A-II, based on the 
presence or absence of the FNLDV motif in their leader sequences respectively (de Vos et al., 
1995). 
Recently, the lantibiotics have been categorized into four new classes, on the basis of 
their biosynthetic enzymes (Figure 5), mature peptide structure, leader peptide sequence, and 
antimicrobial activity (Willey and van der Donk, 2007). The detailed classification of 
lantibiotics is presented in Table 1, page 15. 
In class I lantibiotics, the peptide is dehydrated by LanB followed by its cyclization by 
LanC. The LanB dehydratases (Figure 1) convert Ser and Thr to didehydroalanine (Dha) and 
Z-didehydrobutyrine (Dhb), respectively. A subsequent intramolecular addition of Cys thiols 
to Dha / Dhb is catalyzed by LanC cyclases and form the characteristic lanthionine (Lan from 
Ser) and methyllanthionine (MeLan, from Thr) thioether crosslinks. Then the mature 
prepeptide is transported by an ABC transporter LanT. The leader is cleaved intracellularly or 
extracellularly by the protease LanP (van der Meer et al., 1993; Meyer et al., 1995) or by 
 13 
 
another protease of the producers. The leader peptide of class I lantibiotics contains a 
characteristic F (N/DL (E/N/D) motif at -20 to -15 towards the cleavage site (van der Meer et 
al., 1993; Oman and van der Donk, 2010). The conserved FNLD box of the leader peptide is 
an important component for efficient in vivo production of the lantibiotic (Knerr and van der 
Donk, 2012). 
In class II lantibiotics, a bi-functional LanM modifying enzyme carries the function of 
both dehydratase and cyclase. The C-terminal cyclase domain of LanM proteins has sequence 
homology to the LanC enzymes, but the N-terminal dehydratase domain of LanM proteins has 
no homology with LanB enzymes (Siezen et al., 1996) (Figure 5). According to Paul et al. 
(2007), ATP hydrolysis is required for the dehydration reactions. LanM protein consists of 
three zinc binding ligands, which are essential for the cyclase activity (Willey and van der 
Donk, 2007). Here, the zinc ions are involved in the activation of the Cys derived SH-group 
into an ethiolate, which subsequently reacts with the didehydro-amino acid to form the 
thioether-amino acid (methyl-) lanthionine (Zhu et al., 2003; Li et al., 2006). Also, the 
secretion and leader processing is performed by a single, multifunctional protein with a 
conserved N-terminal cysteine protease domain. The LanT of class II lantibiotics is a member 
of the ABC transporter maturation and secretion (AMS) protein family. Members of ABC 
transporter sub family are involved in the secretion of the peptides, and contain an additional 
N-terminal domain involved in the processing of their substrates at the GG site at the C-
terminal end of the leader peptide (Nishie et al., 2011). The class II peptides, usually have a 
double glycine cleavage site (GG) and a leader motif ELXX(V/L/I)X (Patton et al., 2008). In 
some cases GG cleavage site is altered to GA or GS (Chatterjee et al., 2005b). Within the 
class II lantibiotics, there are the two-component lantibiotics; here two peptides assemble to 
form the mature antibiotic. Each peptide is encoded by its own structural gene and is modified 
by separate LanM enzyme. However, a single LanT protein removes the leader peptide and 
secretes both products (Willey and van der Donk, 2007). 
In class III lantibiotics, the lanthionine containing peptides lack antimicrobial activity; 
instead they perform morphogenic and signalling functions for the producer cells. These 
peptides are modified by RamC whose C-terminal cyclase domain bears homology to LanM 
but lacks zinc ligands (Figure 5). This indicates that their maturation mechanism may be 
different (Kodani et al., 2005; Willey and van der Donk, 2007). The leader peptides often 
have GG protease sites and additionally a conserved helical region at their N-termini (Müller 
et al., 2011). Likewise, the labyrinthopeptins are also classified as the class III lantibiotics, 
because they are also posttranslationally processed by the RamC-like kinase-cyclase LabKC 
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enzyme (Meindl et al., 2010). LabKC shows little sequence similarity to a LanC-like domain 
and lacks active sites like zinc motifs. It catalyzes all necessary modification reactions such as 
serine phosphorylation, formation of didehydroalanines, and subsequent 2-fold Micheale-type 
addition cyclizations. It requires GTP for its kinase activity (Müller et al., 2010). The gene 
clusters of the labyrinthopeptins also possess two LanT like transporters without a dedicated 
protease (Müller et al., 2011, Knerr and van der Donk, 2012).  
In class IV lantibiotics, the peptides are modified by the lanthionine synthetase LanL 
(Goto et al., 2010). The LanL contains a LanC-like cyclase domain in its C-terminal part with 
the conserved zinc binding sites. In its N-terminal part, it contains an OspF-like lyase domain 
and a central serine/threonine kinase domain, both of which align well with the class III 
synthetase RamC. But unlike RamC, the C-terminal cyclase domain of LanL possesses the 
zinc-binding motif (Figure 5). Goto et al. (2010) postulated that the Thr/Ser residues are 
phosphorylated followed by phosphate elimination to generate dehydrated amino acids. LanL 
requires ATP and MgCl2 for the dehydration reaction. Similar to the enzymes of the class III 
lantipeptides, it also has a LanT-like transporter, but no dedicated protease or protease domain 
(Goto et al., 2010, Knerr and van der Donk, 2012).  
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Putative Cyclase
domain
Lyase
domain
Kinase
domain
Lyase
domain
Kinase
domain
Zinc Ligands
 
Figure 5: Schematic representation of four classes of biosynthetic enzymes. Zinc ligands are 
highlighted. Abbrebiations: LanB- lanthipeptide dehydratase; LanC- lanthipeptide cyclase; 
LanM- class II lanthipeptide synthetase; LabKC- labionin synthetase; RamC, SapB - 
modifying synthetase; LanL- class IV lanthipeptide synthetase. Figure adapted from Knerr 
and van der Donk (2012).  
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Table 1: Classification of lantibiotics. 
 
Class Sub 
Class 
Name Producer MW 
(Da) 
aa Charge Total 
rings 
Other residues Reference 
C
la
ss
 I
, 
L
an
B
C
 m
o
d
if
ie
d
 p
ep
ti
d
es
 
N
is
in
 l
ik
e 
la
n
ti
b
io
ti
cs
 
 
NisinA Lactococcus lactis ATCC 11454 3353 34 +3 5 Dha, Dhb Gross and Morell, 1971 
Nisin Z Lactococcus lactis n8, NIZO22186 3330 34 +3 5 Dha, Dhb Mulders et al., 1991 
Nisin Q Lactococcus lactis 61-14 3327 34 +3 5 Dha, Dhb Zendo et al., 2003 
Nisin U Streptococcus uberis 42 3029 34 +3 5 Dha, Dhb 
Wirawan et al., 2006 and 
2007 
Nisin F Lactococcus lactis F10 3457 34 +3 5 Dha, Dhb 
de Kwaadsteniet et al., 
2008 
Subtilin Bacillus subtilis 3317 32 +2 5 Dha, Dhb Gross et al., 1973 
Ericin S Bacillus subtilis A1/3 3442 32 +1 5 Dha Stein et al., 2002 
Ericin A Bacillus subtilis A1/3 2986 29 +2 5 Dha Stein et al., 2002 
Planosporicin  
(LAB97518) 
Planomonospora sps. 2194 24 -1 5 Dha, Dhb 
Maffioli et al., 2009 
Castiglione et al., 2007 
Streptin 1 Streptococcus pyogens M25 2424 23 +3 3 Dhb Karaya et al., 2001 
Streptin 2 Streptococcus pyogens M25 2821 23 +3 3 Dha 
Wescombe and Tagg, 
2003 
Entianin Bacillus subtilis DSM 15029T 3348 32 +2 5 Dha, Dhb Fuchs et al., 2011 
Salivaricin D Streptococcus salivarius 5M6c 3475 34 +1 4 Dha, Dhb Birri et al., 2012 
Geobacillin I Geobacillus thermodenitrificans NG80-2 
 
34 
 
7 Dhb Garg et al., 2012 
E
p
id
er
m
in
 l
ik
e 
la
n
ti
b
io
ti
cs
 
Epidermin Staphylococcus epidermidis 2167 22 +3 4 Dhb, AviCys Allgaier et al., 1986 
Epidermin (Val1,Leu6) Staphylococcus epidermidis 2151 22 +3 4 Dhb, AviCys Israil et al., 1996 
Gallidermin Staphylococcus gallinarum Tü3928 2165 22 +3 4 Dhb Kellner et al., 1988 
Staphylococcin T Staphylococcus cohnii 
    
  Furmanek et al., 1999 
BsaA2, Staphylococcin 
Au-26 
Community acquired MRSA 2089 22 +2 4 Dha, Dhb, AviCys Daly et al., 2010 
Mutacin B-Ny266 Streptococcus mutans 2270 22 +3 4 Dhb, AviCys Mota-meira et al., 1997 
Mutacin 1140            
Mutacin II 
Streptococcus mutans 2263 22 +3 4 AviCys 
Hillman et al., 1998; Qi 
et al., 1999 
Mutacin I Streptococcus mutans 2364 24 +2 4 AviCys Qi et al., 2000 
Clausin Bacillus clausii OC 
 
22 0 4 Dha,Dhb, AviCys Bouhss et al., 2009 
Microbisporocin Microbispora sps. (corallina) 2246 24 +1 5 AviCys 
Castiglione et al., 2008 
(Different variants) Microbispora sps. (corallina) 2230 24 +1 
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 Contd... 
Class Sub 
Class 
Name Producer MW 
(Da) 
aa Charge Total 
rings 
Other residues Reference 
C
la
ss
 I
, 
L
an
B
C
 m
o
d
if
ie
d
 p
ep
ti
d
es
 
  
P
ep
5
 l
ik
e 
la
n
ti
b
io
ti
cs
 
 
Pep5 Staphylococcus epidermidis 3488 34 +7 3 Dha, 2-oxobutyryl Kaletta et al., 1989 
Epilancin K7 Streptococcus epidermidis K7 3032 31 +5 3 
Dha, Dhb, 2-
hydroxypropionyl 
van de Kamp et al., 1995 
Epilancin 280 Streptococcus epidermidis 3133 30 +4 3 2-hydroxypropionyl Heidrich et al., 1998 
Epilancin 15X Streptococcus epidermidis 3173 30 +7 3 Lactate 
Ekkelenkamp et al., 
2005 
Epicidin 280 Staphylococcus epidermis BN280 3133 30 +4 3 
Dhb, 2-
hydroxypropionyl 
Heidrich et al., 1998 
Elgicin AI Paenibacillus elgii B69 4536 
   
  
Teng et al 2012 
 
Elgicin AII Paenibacillus elgii B69 4593 
   
  
Elgicin B Paenibacillus elgii B69 4706 
   
  
Elgicin C Paenibacillus elgii B69 4820 
   
  
C
la
ss
 I
I,
 L
an
M
 m
o
d
if
ie
d
 p
ep
ti
d
es
 
 
L
ac
ti
ci
n
 4
8
1
li
k
e 
 
Lacticin 481 Lactococcus lactis CNRZ 481 2901 27 0 3 Dhb Piard et al., 1993 
Mutacin II, JT-8, H-29B Streptococcus mutans T8 3245 27 +1 3 none Novak et al., 1994 
Nukacin ISK-1 Staphylococcus warneri 2960 27 +3 3 Dhb Sashihara et al., 2000 
Nukacin KQU131 Staphylococcus hominis KQU-131 3004 27 +3 3 Dhb Wilaipun et al., 2008 
Mutacin K8 Streptococcus mutans K8 2734 
   
  Robson et al., 2007 
Streptococcin SA-FF22 Streptococcus pyogene SA-FF22 2795 26 +2 3 Dhb Jack et al., 1994 
Streptococcin AM 49 Streptococcus pyogenes 
    
  Hynes et al., 1994 
Macedocin Streptococcus macedonicus ACA-DC 198 
    
  Georgalaki et al., 2002 
Macedocin A1 Streptococcus macedonicus ACA-DC 198 
 
23 0 3 Dha Papadelli et al., 2007 
Macedovicin Streptococcus macedonicus ACA-DC 198 3428 33 +2 2 Disulfide bridge Georgalaki et al., 2013 
Variacin Kocuria varians 2658 25 -1 3 Dhb Pridmore et al., 1996 
Plantaricin C Lactobacillus plantarum 2880 27 +1 4 Dha Gonzalez et al., 1994 
Ruminococcin A Ruminococcus gnavus 2675 24 0 2 none Dabard et al., 2001 
Butyrivibriocin OR79A Butyrivibrio fibrisolvens 2910 25 0 3 Dhb Kalmokoff et al., 1999 
Butyrivibriocin OR36  Butyrivibrio fibrisolvens  25 0 3 Dhb Whitford et al., 2001 
Butyrivibriocin OB247  Butyrivibrio fibrisolvens  25 0 3 Dhb  Dufour et al., 2007 
Salivaricin A Streptococcus salivarius 20P3 2315 22 0 3 None Ross et al., 1993 
Salivaricin B Streptococcus salivarius K12 2740 25 0 3 
Putative lanA; 
structure predicted 
based on similarity 
to lacticin 481 
Hyink et al., 2007 
  
1
7
 
Contd... 
Class Sub 
Class 
Name Producer MW 
(Da) 
aa Charge Total 
rings 
Other residues Reference 
C
la
ss
 I
I,
 L
an
M
 m
o
d
if
ie
d
 p
ep
ti
d
es
 L
ac
ti
ci
n
 4
8
1
li
k
e 
 
Salivaricin A1 
Streptococcus agalactiae 120 
 
22 0 
 
Unknown structure 
Nakagawa et al., 2003 Streptococcus pyogenes MGAS315 
 
22 0 
 
Unknown structure 
S. pyogenes M1 
 
22 0 
 
Unknown structure 
S. pyogenes MGAS10394  
 
22 0 
 
Unknown structure  Banks et al., 2004 
Salivaricin A2 Streptococcus salivarius 
 
22 0 
 
Unknown structure 
Wescombe et al., 2006 
Salivaricin A3 Streptococcus salivarius 
 
22 0 
 
Unknown structure 
Salivaricin A4 Streptococcus salivarius 
 
22 0 
 
Unknown structure 
Salivaricin A5 Streptococcus salivarius 
 
22 0 
 
Unknown structure 
Salivaricin 9 Streptococcus salivarius strain 9 2560 24 +2 3 Dhb Wescombe et al., 2011 
Plantaricin C Lactobacillus plantarum 2880 27 +1 4 Dha Gonzalez et al., 1994 
Bovicin HJ50 Streptococcus bovis HJ50 3428 33 +2 2 Disulfide bridge Xiao et al., 2004 
Thermophilin 1277 Streptococcus thermophilus 
   
2 Disulfide bridge Kabuki et al., 2007 
Perecin Clostridium perfringens D str. JGS1721 3514 33 
 
2 Disulfide bridge 
Wang et al., 2014 Cerecin Bacillus cereus As 1.348 
 
34 
 
2 Disulfide bridge 
Thuricin Bacillus thuringiensis As 1.013 3728 34 
 
2 Disulfide bridge 
M
er
sa
ci
d
in
 l
ik
e 
la
n
ti
b
io
ti
cs
 
 
Mersacidin Bacillus amyloliquefaciens 1825 20 0 4  Dha, MeAviCys Chatterjee et al., 1992 
Actagardine Actinoplanes liguriae 1890 19 0 4 
LanO (lanthionine 
sulphoxide) 
Zimmermann et al., 1995 
Ala(O)-Actagardine Actinoplanes liguriae 1961 20 0 4 
LanO (lanthionine 
sulphoxide) 
Vertesy et al., 1999 
Deoxy-actagardine B 
(DAB) 
Actinoplanes liguriae NCIMB 41362 
 
19 0 4 
LanO (lanthionine 
sulphoxide) 
Boakes et al., 2010 
Michiganin A Clavibacter michiganesis 2145 21 0 3 Dhb Holtsmark et al., 2006 
Nai-802 Actinoplanes sps. 104802/104771 
 
20 +1 4 
Structure predicted 
based on similarity 
to actagardine 
Simone et al., 2013 
C
in
n
am
y
ci
n
 
li
k
e 
la
n
ti
b
io
ti
cs
 Cinnamycin; lantibiotic 
Ro 09-198 
Streptomyces Cinnamoneus/ 
griseoverticillatus 
2042 19 +1 4 Asp-OH,LysAla 
Marki et al., 1991; 
Fredenhagen et al., 1990 
Duramycin Streptomyces cinnamoneus 2014 19 0 3 Asp-OH,LysAla 
Duramycin B Streptomyces verticillium sps. 1951 19 0 3 Asp-OH,LysAla 
Duramycin C Streptomyces griseoluteus 2008 19 -1 3 Asp-OH,LysAla 
Ancovenin Streptomyces sps. 1959 19 0 3  Dha Kido et al., 1983 
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Contd... 
Class Sub 
Class 
Name Producer MW 
(Da) 
aa Charge Total 
rings 
Other residues Reference 
C
la
ss
 I
I,
 L
an
M
 m
o
d
if
ie
d
 p
ep
ti
d
es
 
 
T
w
o
- 
p
ep
ti
d
e 
la
n
ti
b
io
ti
cs
 
Lacticin 3147 
Lactococcus lactis subsp.lactis 
DPC3147 
3322 30 0 4 Dhb, D-Ala 
Ryan et al., 1996 
2847 29 +1 3 2-Oxobuturyl; D-Ala 
Staphylococcin 
C55 
Staphylococcus aureus C55 
3339 30 0 3 Dha, Dhb, D-Ala Navaratna et al., 
1998 2993 37 -1 3 Dha, Dhb 
Plantaricin W Lactobacillus plantarum  
3223 29 0 3 Disulfide bridge 
Holo et al., 2001 
3099 32 +6 4 Dhb 
Haloduracin Bacillus halodurans C-125 
3043 28 +1 3 Disulfide bridge McClerren et al., 
2006 2330 24 +1 4 Dha, Dhb 
Smb Streptococcus mutans GS5  
30 +2 3 Dha, Dhb Yonezewa et al., 
2005 
 
32 +2 3 Dha, Dhb 
BHT Streptococcus ratti BHT 
3375 32 +1 3 Dha, Dhb 
Hyink et al., 2005 
2802 30 +2 3 Dhb 
Lichenicidin 
Bacillus licheniformis DSM 
13/VK 21/ATCC14580 
3250 32 +1 4 Dha, Dhb, 2-oxobuturyl Begley et al., 2009; 
Dischinger et al., 
2009; Shenkarev et 
al., 2010; Caetano et 
al., 2011  
3021 32 +2 4 Dha, Dhb, 2-oxobuturyl 
Cytolysin Enterococcus faecalis 
4164 21 +1 2 Dhb 
Booth et al., 1996 
2631 38 +1 1 
Unknown structure, 1 thioether 
bridge confirmed 
Pneumococcin Streptococcus pneumonia R6  
38 +1 
 
2 thioether bridge confirmed of a 
NisBC modified chimeric peptide 
Majchrzykiewicz et 
al., 2010 
 
30 +4 
 
Enterocin W Enterococcus faecalis NKR-4-1 
3256 30 0 3 Disulfide bridge 
Sawa et al., 2012 
2728 29 +2 4 Dha, Dhb 
C
la
ss
 I
II
 l
an
ti
b
io
ti
cs
, 
la
ck
 o
f 
an
ti
b
io
ti
c 
ac
ti
v
it
y
, 
b
u
t 
sh
o
w
s 
m
o
rp
h
o
g
en
et
ic
 f
u
n
ct
io
n
s 
 
SapB Streptomyces coelicolor 2026 21 0 2 Dha Kodani et al., 2004 
SapT Streptococcus tendae 2032 21 0 4 none Kodani et al., 2005 
AmfS Streptococcus griseus 
 
19 -1 
 
Unknown structure Ueda et al., 2002 
Prochlorosin Prochlorococcus MIT9313 
 
17 
  
  Li et al., 2010 
Geobacillin II 
Geobacillus 
thermodenitrificans  
35 
 
4 Dhb Garg et al., 2012 
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Class Sub 
Class 
Name Producer MW 
(Da) 
aa Charge Total 
rings 
Other residues Reference 
C
la
ss
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 l
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b
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L
ab
y
ri
n
th
o
p
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n
s,
 L
ab
K
C
 m
o
d
if
ie
d
, 
la
b
io
n
in
 c
o
n
ta
in
in
g
 p
ep
ti
d
e 
Labyrinthopeptin 
A1 
Actinomadura namibiensis DSM 
6313  
20 -1 2 
Labionin, disulfide bridge, 
Dhb 
Müller et al., 2010 
Labyrinthopeptin 
A2 
Actinomadura namibiensis DSM 
6313 
1923 18 -1 2 Labionin, disulfide bridge,  Müller et al., 2010 
Labyrinthopeptin 
A3 
Actinomadura namibiensis DSM 
6313  
21 -1 
 
Labionin, disulfide bridge, 
Dhb 
Müller et al., 2010 
Avermipeptin Streptococcus avermitilis 
 
22 0 
4 (2 lan, 2 
labionin) 
Dha Völler et al., 2012 
Erythreapeptin 
Saccharopolyspora erythreae 
NRRL 2328  
27 0 
4 (2 lan, 2 
labionin) 
Dha Völler et al., 2012 
Griseopeptin 
Streptomyces griseus DSM 
GO236  
22 -1 
4 (2 lan, 2 
labionin) 
none Völler et al., 2012 
Curvopeptin Thermomospora curvata 
   
2 Dha Krawczyk et al., 2012 
Catenulipeptin 
Catenulispora acidiphila DSM 
44928  
27 
 
2 labionin 
Wang and van der Donk, 
2012 
L
an
ti
b
io
ti
c 
w
it
h
o
u
t 
cl
as
si
fi
ca
ti
o
n
/ 
 
u
n
k
n
o
w
n
 s
tr
u
ct
u
re
 a
n
d
  
b
io
sy
n
th
es
is
 
Lactosin S Lactobacillus sake L-45 3764 37 +1 2 Dha, Dhb, D-Ala 
Mortvedt and Nes, 1990; 
Skaugen and Nes, 1994 
Pediocin PD-1 Pediococcus damnosus 2866 27 
  
Only partially identified, no 
structure 
Bauer et al., 2005 
Carnocin UI 49 Carnibacterium pisciola 4635 
35 
  
Only partially identified       
( N-terminus), no structure 
Stoffels et al., 1992 
37 
  
Paenibacillin Paenibacillus sps. 2983 30 +4 5 Dha, Dhb, N-acetylalanine He et al., 2007 
Unnamed Bifidobacterium longum DJO10A 
    
Predicted LanD- AviCys or 
AviMeCys, unknown 
structure 
Lee et al., 2011 
Venezuelin Streptomyces venezuelae 
   
4   Goto et al., 2010 
Subtilomycin Bacillus subtilis MMA7 3234 32 
  
5 thioether rings proposed Phelan et al., 2013 
Amylolysin Bacillus amyloliquefaciens GA1 3318 31 
   
Arguelles Arias et al., 
2013 
 L
an
ti
b
io
ti
c 
re
la
te
d
 p
ep
ti
d
e 
(f
o
rm
er
ly
 
fa
ls
el
y
 
cl
as
si
fi
ed
 a
s 
la
n
ti
b
io
ti
c)
  Cypemycin Streptomyces sps. 2094 22 +1 
 
AviCys; Linearidin 
Komiyama et al., 1993; 
Claesen and Bibb, 2010 
Sublancin 168 Bacillus subtilis 3876 3876 37 +3 
 
Disulfide bridge; 
Glycosylation; S-linked 
glycopeptides 
Paik et al., 1998, Oman et 
al., 2011 
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1.1.2.2.6. Role of the leader peptide 
The role of the leader peptide is not yet fully elucidated.  The leader peptides are important to 
increase the dehydration activity of the LanM enzymes and also for processivity and possibly 
directionality, as in lacticin 481 (Levengood et al., 2007). Furthermore, in some lantibiotics 
e.g. nisin, the leader peptides keep the lantibiotics inactive inside the cell, thereby protecting 
the producer cell. There are some evidences that, the leader peptides could interact with the 
propeptides and stabilize its conformation (Sahl et al., 1998). Likewise, for modification of 
the core peptide, the N-terminal residues are critical in class I (Plat et al., 2011) and class III 
lantibiotics (Müller et al., 2011), whereas the C-terminus seems more important for class II 
lantibiotics (Xie et al., 2004). Recently it was shown for the labyrinthopeptins, a class III 
lantibiotic, that the substrate modifications do not occur if the leader peptide is not directly 
attached to the core peptide (Müller et al., 2011).  
 
1.1.2.2.7. Mode of action of lantibiotic 
The activities of lantibiotics depend on different killing mechanisms (Asaduzzaman and 
Sonomoto, 2009). While the lantibiotics provide a good protection against Gram-positive 
bacteria, they are relatively ineffective against Gram-negative bacteria (Castiglione et al., 
2008). Gram-negatives are generally not affected by lantibiotics due to the prevention of 
access to the cytoplasmic membrane by the protective outer membrane. But some lantibiotics 
e.g. nisin Z at higher concentrations can affect E. coli and other Gram-negatives like Neisseria 
or Helicobacter pylori. This inhibitory effect of nisin Z is probably due to self-promoted 
uptake or a lantibiotic based destabilization of the outer membrane of the bacteria by binding 
to their lipopolysaccharides (Nagao et al., 2009). In this context, lantibiotics from 
Actinobacteria such as microbisporicin are promising, because they exhibit an antimicrobial 
activity also against some Gram-negative bacteria such as Moraxella catarrhalis, Neisseria 
sp., and Haemophilus influenza (O’Sullivan and Lee, 2011). Likewise, lantibiotic produced by 
Bifidobacterium longum DJO10A has a potential to inhibit members of the 
Enterobacteriaceae. The antibacterial activities of lantibiotics are primarily based on two 
mechanisms: pore formation and inhibition of peptidoglycan synthesis (Brötz et al., 1998b). 
 
a. Pore formation 
Pore formation is an important mechanism for the mode of action of many lantibiotics. The 
pore formed by the lantibiotics may have the life time of few to several hundred milliseconds, 
and a diameter up to 2 nm. Many lantibiotics use lipid II as a docking molecule, which 
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mediates a targeted pore formation (Brötz et al., 1998). The binding of lipid II appears to 
enable the peptides to integrate into the membrane (van Heusden et al., 2002). Furthermore, 
lipid II stabilizes the resulting pores (Breukink et al., 1999; Wiedemann et al., 2004).  
The mechanism of pore formation has been extensively studied for the nisin (Figure 
6A). The first evidence of pore formation due to nisin was described by Ramseier (1960). 
While treating Clostridial cells with nisin he observed a leakage of intracellular compounds. 
Later, Brötz et al. (1998b) and Breukink et al. (2003) determined that nisin binds to lipid II, 
using it as a docking molecule to form a stable and highly efficient pore. Nisin binds to the 
pyrophosphate moiety of lipid II using five hydrogen bonds. This interaction occurs 
specifically with its two N-terminal lanthionine rings (Hsu et al., 2003) and results in the 
insertion of the elongated C-terminus of nisin into the membrane (van Heusden et al., 2002; 
Hasper et al., 2004). This insertion of nisin causes an efflux of ions and small cytoplasmic 
compounds, leading to the dissipation of the membrane potential. Although, nisin causes both 
the pore formation and inhibition of the peptidoglycan biosynthesis, pore formation is likely 
the primary cause for its antimicrobial activity. This is based on the fact that the pore 
formation results in a rapid killing, before the inhibition of peptidoglycan biosynthesis can 
take effect (Brötz et al., 1998b; Wiedemann et al., 2001).  
The two peptide lantibiotics, lacticin 3147 (Morgan et al., 2005) and haloduracin 
(Oman et al., 2011) also form pores by binding to lipid II. In lacticin 3147, the A1 peptide 
binds to lipid II to form a complex. Later, the A2 peptide binds to the complex of peptide A1 
and lipid II to form a trivalent complex. This results in the deeper insertion of the complex 
into the membrane (Figure 6 B) (Deegan et al., 2006; Wiedemann et al., 2006; Oman and van 
der Donk 2009). This complex arrangement allows the A2 peptide to adopt a transbilayer 
orientation, thereby resulting in the pore formation. These pores were found to be 
significantly smaller (0.6 nm) than those formed by the nisin (Bonelli et al., 2006).  
Other lantibiotics, such as streptococcin A-FF22 and Pep5 can form unstable pores. 
These pores then dissipate the membrane potential but do not release the large molecules from 
the cell (Kordel et al., 1988; Jack et al., 1994). Likewise, the ability of small peptides such as 
gallidermin and epidermin to form pores depends on the thickness of the membrane (Bonelli 
et al., 2006). Thus, the bactericidal effect of epidermin and gallidermin may not always be due 
to pore formation but could also be due to inhibition of peptidoglycan synthesis (Xiulan et al., 
2012). 
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Figure 6: Pore formation by lantibiotics: (A) Nisin using lipid II as a docking molecule and 
(B) The two peptide lantibiotic lacticin 3147. Figures taken from Ryan et al. (2002), and 
Asaduzzaman and Sonomoto (2009). 
 
b. Inhibition of peptidoglycan synthesis 
The inhibition of peptidoglycan biosynthesis is another mode of action of lantibiotics. Lipid I 
and lipid II are the essential precursors for cell wall biosynthesis (Linett and Strominger, 
1973). Lantibiotics bind to these precursors, in consequence, the transpeptidase and 
transglycosylase will not be able to utilize lipid II, which ultimately inhibits the peptidoglycan 
biosynthesis.   
 
A)                
B)                
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Nisin inhibits the synthesis of peptidoglycan by accumulation of lipid I (Reisinger et 
al., 1980). Brötz et al. (1998b) suggested that the nisin and epidermin may also inhibit the 
conversion of lipid I to lipid II. Likewise, in the nisin-like lantibiotics with the conserved two 
N-terminal lanthionine rings dissipate the lipid II from its functional location in the cell wall 
biosynthesis complex (Hasper et al., 2006). This dissipation of lipid II results in the 
accumulation of UDP-linked peptidoglycan precursors in the cytoplasm, ultimately inhibiting 
peptidoglycan synthesis (Castiglione et al., 2007, 2008). 
Other lantibiotics such as mersacidin, actagardine, and cinnamycin also inhibit cell 
wall biosynthesis by binding to lipid II, but they do not form pores (Brötz et al., 1997; Hsu et 
al., 2003). Specifically, these compounds inhibit the activity of transglycosylases (Brötz et al., 
1997). It is believed that the lantibiotics of the mersacidin group target the acetylglucosamine 
moiety and most probably the sugar and phosphate residues of the lipid II. All mersacidin-like 
lantibiotics possess a conserved TxS/TxEC motif (Hsu et al., 2006; Böttiger et al., 2009). 
Especially, the Glu residue in the motif is essential for the antibacterial action of mersacidin 
(Szekat et al., 2003). This motif is found within its essential C-ring, which is involved in lipid 
II binding although it differs from lipid II binding pocket of nisin. This essential C-ring is 
similar to the A-ring of the lacticin 481 subfamily peptides (Zimmermann and Jung, 1997). 
Moreover, the bioactivity of mersacidin is ion dependent, since, the presence of calcium ions 
increases its activity in vivo. Since lipid II is mostly negatively charged, calcium ions can 
transfer a net positive charge to the neutral peptides like mersacidin, which might result in 
enhanced membrane interaction and consequently in deeper membrane insertion (Böttiger et 
al., 2009). For positively charged peptides like plantaricin C, calcium might stabilize the 
conformation that promotes the membrane insertion. An ion independent mode of action was 
observed for an uncharged lacticin 481. It contains a positively charged amino acid on its N-
terminus that might be sufficient for membrane interaction and formation of lipid II 
complexes (Böttiger et al., 2009).  
 
1.1.2.2.8. Other biological functions 
Many lantibiotics have other biological activites apart from pore formation and inhibition of 
cell wall biosynthesis. Class III lantibiotics like SapT and SapB exhibit a morphogenetic 
rather than an antibacterial effect. Because of their amphiphilic nature, both peptides serve as 
the biosurfactants, facilitating the emergence of aerial hyphae (Kodani et al., 2004, 2005). 
Nisin and Pep5 also induce autolysis of certain staphylococcal strains, leading to a 
break down of the cell wall at the septa of dividing cells (Bierbaum and Sahl, 1985, 1987). 
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Likewise, nisin, subtilin and sublancin inhibit the outgrowth of spores from Bacillus and 
Clostridium species (Hurst, 1981; Paik et al., 1998).   
The lantibiotics of cinnamycin subgroup (duramycin, duraycin B, duramycin C, 
cinnamycin and ancovenin) have a restricted antibactericidal activity. They target only a few 
bacterial strains and Bacillus sp. In particular, duramycin impairs ATP dependent protein 
translocation (Chen and Tai, 1987) and interferes with calcium uptake (Navarro et al., 1985). 
In addition, duramycin blocks the transport of chloride, sodium and potassium (Xie et al., 
1983; Stone et al., 1984) and inhibits the proton pump of clathrin coated vesicles (Nakamura 
et al., 1984). However cinnamycin is also known as immunopotentiator peptide (Hosoda et 
al., 1996). Cinnamycin-like peptides inhibit phospholipase A2 by binding the 
phosphatidylethanolamine (PE) or lysophosphatidylethanolamine (lysoPE) in the cell 
membrane (Choung et al., 1988; Marki et al., 1991). Both cinnamycin and duramycin 
promote their binding to PE-containing membrane by deforming membrane curvature 
(Iwamoto et al., 2007).  
Likewise, nukacin ISK-1 has a bacteriostatic mode of action rather than a bactericidal 
effect. It does not affect the membrane potential or form pores, but it reduces the width of the 
cell wall, causing incomplete formation of the septum, and thus preventing active growth 
(Assaduzzaman and Sonomoto, 2009).  
 
1.1.2.2.9. Applications of lantibiotics 
Lantibiotics have notable characteristics such as low MW, a broad range of antimicrobial 
activity, lack of toxicity and low immunogenicity (Asaduzzaman and Sonomoto, 2009; 
Dischinger et al., 2014). These characteristics make them suitable for applications in multiple 
areas such as food industries, health care, biomedical and medical applications. Nevertheless, 
lantibiotics have to overcome some obstacles before they may be used in the medical 
applications. Nisin for instance has drawbacks such as a low stablility at the physiological pH 
of the gastrointestinal tract, a low solubility, and has the tendency to interact with the blood 
components (Dischinger et al., 2014). 
At present, nisin is the only lantibiotic used commercially. Since it has no known 
toxicity to humans, it has been used as a powerful and safe food preservative in processed 
dairy products, canned fruits and vegetables (Delves-Broughton, 1990). Since its first 
introduction as food preservative fifty years ago, many new applications have been 
investigated. Nisin exhibits an antimicrobial activity against food spoilage bacteria like 
Listeria monocytogenes (Cotter et al., 2005). It is applied in veterinary medicine for treatment 
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of bovine mastitis (Broadbent et al., 1989). In addition, as nisin is effective against clinically 
relevant human pathogens, like Helicobacter pylori, it is effective in peptic ulcer treatment 
too. Likewise, it is also used in treatment of oral decay, enterococcal infections and treatment 
of enterocolitis (Ryan et al., 2002; Nascimento et al., 2006). Other applications of nisin 
include the inhibition of experimental vascular graft infections caused by methicillin-resistant 
Staphylococcus epidermidis (Ghiselli et al., 2004). In addition to its antibiotic effect, nisin 
also inhibits sperm motility, showing its potential as a contraceptive agent (Aranha et al., 
2004). 
Beside nisin, other lantibiotics have also been investigated for their possible 
applications as antimicrobials. Mersacidin and actagardine show a remarkable activity against 
MRSA, bacterial mastitis, oral decay, acne, etc (Limbert et al., 1991). Likewise, gallidermin 
and epidermin are affective against acne, eczema, follicultis, and impetigo, thus, they might 
be used for personal care products. Pep5 and epidermin prevent the adhesion of coagulase-
negative staphylococci, specifically S. epidermidis, to siliconisated catheters (Fontana et al., 
2006). Likewise, cinnamycin might be used against inflammation and viral infections, and for 
blood pressure regulation (Ryan et al., 2002). Similarly, mutacin 1140 may prevent dental 
cavities. Duramycin and ancovenin can be used for inflammation and blood pressure 
regulation respectively. Lacticin 3147 prevents Propionibacterium acnes from causing acne, 
thus these substance may also be used as additives in cosmetics and personal care products 
(Kellner et al., 1988; Lawton et al., 2007). Salivaricins are effective against Streptococcus 
pyogenes strains. Therefore, the salivaricin A producer was supplemented as a probiotic to 
milk drinks. The strain was demonstrated to persist in the oral cavity, and resulted in the 
prevention of S. pyogenes infections (Dierksen et al., 2007). Moreover, chewing gums and 
lozenges containing salivaricin-producing strains have been developed (BLIS Technologies). 
Recently, several actinomycete lanthipeptides of clinical interest have been described. 
NVB302 (an actagardine derivative) and Moli1901 (also known as lancovutide or duramycin, 
a structural analogue of cinnamycin) successfully completed Phase I and Phase II clinical 
trails for the treatment of Clostridium difficle infections (Crowther et al., 2013) and cystic 
fibrosis (Grasemann et al., 2007; Oliynyk et al., 2010). Likewise, NAI-107 (also known as 
microbisporin) is in a late stage of preclinical development for the treatment of multi drug 
resistant Gram-positive pathogens (Jabes et al., 2011). Besides medical applications, 
lantibiotics could also be used in the food products.  Lacticin 3147 or lacticin 481 producing 
Lactococcus lactis-starter cultures could be used to inhibit Listeria monocytogenes in cheese 
production (McAuliffe et al., 1999; Rodriguez et al., 2001).  
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Furthermore, the use of biosynthetic enzymes of lantibiotics in vivo and in vitro to 
design novel lantibiotics could be another promising application. The lantibiotic biosynthetic 
enzymes are able to modify the peptides also in vitro. This allows the introduction of 
didehydro amino acids and thioether rings even into chemically synthesized substrates 
(Chatterjee et al., 2005b). Several experiments have shown that the novel antibiotics could be 
designed, by introduction of novel modified residues into peptides or existing lantibiotics 
(Sahl and Bierbaum, 1998; Kluskens et al., 2005; Rink et al., 2005). The optimization of 
lantibiotics is the most important goal for possible biotechnological and medical applications. 
In this context, it has been shown that the stability and specific activity of subtilin was 
increased by exchanging Glu4 for Ile (Liu et al., 1992). Nisin peptides were engineered for an 
improved stability by exchanging Dha5 for Dhb in nisin Z (Rollema et al., 1995). Likewise, 
the solubility of nisin was improved by replacing Asn27 and His31 with Lys in nisin Z. 
Similarly, Leevengood et al. (2007) established an in vitro mutasynthesis method to introduce 
unnatural amino acid side chains to improve the class II lantibiotic lacticin 481. 
Hence, lantibiotics can be promising candidates as alternatives for traditional 
antibiotics, preservatives, probiotics, and additives in food or cosmetic industry as well as in 
human and veterinary medicine. 
 
1.2. Bacillus pseudomycoides 
Bacillus pseudomycoides is a Gram-positive bacterium that shows a false fungus-like growth 
(Nakamura, 1998). It is mainly isolated from soil. Vegetative cells are non-motile, 1 µm wide 
and 3 - 5 µm long and occur singly or in short chains. The cells produce ellipsoidal spores that 
do not distend the mother cell. On an agar plate, colonies are white to cream, opaque, and 
usually rhizoidal. The species is facultatively anaerobic. The optimum temperature for its 
growth is 28 °C, with a maximum at 40 °C, and a minimum at 15 °C. 
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1.3. Aim of the study 
The intensive use of antibiotics led to the emergence of resistant bacterial strains such as 
methicillin resistant Staphylococcus aureus and vancomycin resistant enterococci (VRE) 
(Novak et al., 1999; Weigel et al., 2003). The constant rise in multi drug resistant 
microorganisms has increased the need to investigate and develop new antibacterial 
compounds. There are a few antimicrobial compounds, such as antimicrobial peptides, 
probiotic bacteria, and bacteriophages which are considered as alternatives to antibiotics. 
Among them, lantibiotics have become promising candidates for the future antibiotics. 
Lantibiotics have a high potency to inhibit diverse pathogenic bacteria and are less likely to 
select for resistance (Fickers et al., 2012). About 100 lantibiotics have been discovered from 
bacterial sources today; however there are many bacterial strains that remain to be explored 
for the production of lantibiotics. Thus, the objective of this study was to investigate a novel 
lantibiotic. 
 
The specific aim of this project was to investigate a novel putative lantibiotic gene cluster 
from Bacillus pseudomycoides. This was addressed using the following approaches: 
1. Prediction of lantibiotic gene cluster from the genomic data mining. 
2. Production of the antimicrobial substance by B. pseudomycoides. Purification and 
characterization of the antimicrobial substance by activity assay, stability assay and 
MALDI TOF MS. 
3. Heterologous expression of the predicted structural gene and corresponding 
modification enzyme as His-tagged protiens in E. coli.  
4. Purification and characterization of the heterologously produced peptide by MALDI 
TOF MS. 
5. In vitro leader processing by factor Xa to produce the biologically active peptide. 
6. Prediction of the ring topology of the heterologously produced peptide by creating 
LanA analogs by mutagenesis. 
7. Initial approaches to elucidate the mode of action of the peptide by lipid II interaction 
assays. 
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2. Materials and Methods 
2.1. Chemicals, solvents and enzymes 
 
Table 2: Chemicals, solvents and enzymes used in this study. 
Chemicals Manufacturer 
Acrylamid : Bisacrylamid (37,5:1), 40% (w/v) Serva Electrophoresis, Heidelberg, Germany 
Agar, BactoTM Becton Dickinson & Company (BD), Heidelberg, 
Germany 
Agarose, Top VisionTM,  LE GQ Fermentas, St. Leon-Rot, Germany 
Ammoniumphosphate, #75568  Sigma-Aldrich, Taufkirchen, Germany 
Ampuwa®-Water, “PCR-H2O”  Fresenius Kabi, Bad Homburg, Germany 
APS Bio-Rad, München, Germany 
DMSO  Amersham Biosciences, Freiburg, Germany 
DNase I, from bovine pancreas  Sigma-Aldrich, Taufkirchen, Germany 
DTT (DL-), #43819  Sigma-Aldrich, Taufkirchen, Germany 
Ethidiumbromide Sigma-Aldrich, Taufkirchen, Germany 
Factor Xa NEB, Frankfurt am Main, Germany 
Formaldehyde Sigma-Aldrich, Taufkirchen, Germany 
Urea Sigma-Aldrich, Taufkirchen, Germany 
IAA Sigma-Aldrich, Taufkirchen, Germany 
TCEP  Sigma-Aldrich, Taufkirchen, Germany 
IPTG  Fermentas, St. Leon-Rot, Germany 
Lysozyme, #62971  Sigma-Aldrich, Taufkirchen, Germany 
PMSF Merck, Dramstadt, Germany 
EDTA Merck, Dramstadt, Germany 
Triton X-100 Sigma Aldrich, Taufkirchen, Germany 
Chymotrysin Sigma Aldrich, Taufkirchen, Germany 
Trypsin  Serva Electrophoresis, Heidelberg, Germany 
Pronase E Merck, Dramstadt, Germany 
Proteinase K Sigma Aldrich, Taufkirchen, Germany 
Ni-NTA Agarose Qiagen, Hilden, Germany 
Nucleotide (dNTPs) Fermentas, St. Leon-Rot, Germany 
Primer, DNA-Oligonucleotide  Metabion, Martinsried, Germany and Microsynth, 
Lindau, Switzerland 
PhusionTM High Fidelity DNA Polymerase Finnzymes, sales: NEB, Frankfurt am Main, 
Germany 
Restrictions enzyme buffers Roche, Mannheim / Fermentas, St. Leon-Rot, 
Germany 
RNase A, from bovine pancreas  Sigma-Aldrich, Taufkirchen, Germany 
TEMED Bio-Rad, München, Germany 
β Mercaptoethanol Sigma-Aldrich, Taufkirchen, Germany 
TLC aluminium sheet E. Merck, Dramstadt, Germany 
Phosphomolybdic acid Fulka chemika, Sigma-Aldrich, Germany 
Quick change site directed mutagenesis kit Agilent, USA 
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2.2. Antibiotics and antimicrobial peptides 
 
Table 3: Antibiotics and antimicrobial peptides used in this study. 
Antibiotic/peptide Solvents Source 
Ampicillin MilliQ water Sigma-Aldrich, Taufkirchen, Germany  
Kanamycin MilliQ water Sigma-Aldrich, Taufkirchen, Germany  
Nisin 0.05% Acetic acid Michaele Josten, University of Bonn, Germany  
Mersacidin MilliQ water Aventis, Frankfurt, Germany 
 
2.3. Instruments / Equipments 
 
Table 4: Instruments and equipments used in this study. 
Equipments   Manufacturer 
Agarose gel electrophoresis chamber (40 ml) Peqlab Biotechnology, Erlangen, Germany 
Agarose gel electrophoresis chamber, Model 
B3 (60 ml) 
OWL, Sales: Peqlab Biotechnology, Erlangen, 
Germany 
Gene PulserTM (Electroporation)  Bio-Rad, München, Germany 
Mini-PROTEAN® II Electrophoresis Cell  Bio-Rad, München, Germany 
Multifuge 1 S-R (Rotor #75003348 & 
FA12.94) 
Heraeus / Thermo Fisher Scientific, Waltham, MA, 
USA 
NanoDrop® ND-1000 Spectrophotometer 
(220-750 nm) 
NanoDrop Technologies Inc., DE, Wilmington, 
USA 
Photometer, UV-160 Shimadzu Deutschland GmbH, Duisburg, Germany 
Power Pac 200 (Gel electrophoresis Power 
supply) 
Bio-Rad, München, Germany 
Pulse Controller (Electroporation) Bio-Rad, München, Germany 
Ultrapure water installation, MilliQ Biocel 
System A10 
Millipore GmbH, Schwalbach/Ts., Germany 
Shaking water bath SW20 und SW22 Julabo GmbH, Seelbach, Germany 
Shaker, Certomat U B.  Braun, Melsungen, Germany 
Shaking, Titertek  Flow Laboratories, Meckenheim, Germany 
SensoQuest Thermocycler (labcycler) SensoQuest Biomed. Electronic GmbH, Göttingen, 
Germany 
Sonicator Sonoplus HD2200 Bandelin, Berlin, Germany 
Sorvall Evolution (Rotor SLC-4000)  Thermo Fisher Scientific, Waltham, MA, USA 
Sorvall Discovery M120SE (Rotor S80 AT-3 
& S120 AT-2) 
Thermo Fisher Scientific, Waltham, MA, USA 
UV-Imager, ImageMaster VDS  Amersham Biosciences, Freiburg, Germany 
UV-Board, Chroma 43 (302 nm) Vetter GmbH, Wiesloch, Germany 
Vortexer, MS 2 Minishaker IKA -  Werke GmbH & Co. KG, Staufen, Germany 
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Contd... 
Equipments   Manufacturer 
XCell SureLock® Mini-Cell (Electrophoresis 
chamber) 
Invitrogen, Karlsruhe, Germany 
Centrifuge RVC 2-18, Typ 100218 Martin Christ Gefriertrocknungsanlagen GmbH, 
Osterode, Germany 
HPLC  Gilson BV, Germany 
MALDI TOF Bruker Biflex, Bruker Daltonics, Bremen, Germany 
Rotory evaporator Rotavapor Re11, Essen, Germany 
LCMS Bruker Daltonics, Bremen, Germany 
Tandem MSMS Bruker Daltonics, Bremen, Germany 
 
2.4. Microbiological methods 
 
2.4.1. Bacterial strains, culture media, growth conditions  
The Trypticase Soy Broth (TSB) was from Difco (Detroit, MI, USA), and Luria Bertani (LB), 
Müller Hinton Broth (MHB), Brain Heart Infusion (BHI) and Nutrient Broth (NB) were from 
Oxoid Basingstoke, UK. Trypsin, chymotrypsin, proteinase K and pronase E were from 
Sigma (St. Louis, MO, USA). All other media and reagents were from Merck (Darmstadt, 
Germany). All the media used in this study are listed in Table 5. 
The producer strain B. pseudomycoides DSM 12442 was purchased from the German 
Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany). B. 
pseudomycoides strain was grown aerobically in NB or on nutrient agar. All the bacterial 
strains used in this study are listed in Table 7. For stock preparation, the cells were cultivated 
overnight, mixed with sterile glycerol (final concentration of 50% v/v) and stored at -70 °C. 
Strains were recovered from frozen samples by streaking out on appropriate agar plates. 
Liquid cultures were incubated in a shaking water bath (200 rpm for Bacillus strains, 100-160 
rpm for all other strains) or on an orbital shaker (170 rpm). For preparation of solid culture 
media, 14 g agar (Oxoid, Wesel, Germany) were added to 1 L of liquid medium prior to 
autoclaving. Agar plates were cultivated in incubators. Bacillus strains were grown in TSB, or 
on tryptic soy agar (TSA, Oxoid). For aerobic cultivation, Erlenmeyer flasks filled with liquid 
medium (1/100 of the total volume) were used and were closed by a silicon vent containing an 
ultra-fine glass microfiber filter (BugStopper™, Whatman/GE Healthcare, USA) or cotton 
plugs. Streptococci, enterococci and staphylococci were grown on Columbia blood agar 
plates. For antimicrobial activity testing, indicator strains were grown in MH broth and on 
MH agar plates. Escherichia coli strains were cultivated on LB agar. 
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To examine the antimicrobial activity, the following indicator strains were used: 
Gram-positive bacteria - Bacillus cereus DSM 31, B. halodurans DSM 18197 (producer of the 
two peptide lantibiotic haloduracin; DSMZ), B. licheniformis MW3 (Waschkau et al., 2008), 
B. megaterium KM3 (ATCC 13632), B. subtilis 186 (DSM 402), B. amyloliquefaciens 
FH1856, Enterococcus faecium L4001 (clinical isolates), E. faecalis 017940 (clinical isolate), 
Lactobacillus sake 790 E2 (laboratory stock), Lactococcus lactis NCTC 497, Micrococcus 
flavus DSM 1790, M. luteus ATCC 4698 (used as standard indicator strain), Staphylococcus 
aureus 825/96 (MRSA), S. aureus 635/93 (MRSA), S. aureus Cowan (ATCC 12598), S. 
aureus 1000/93 (MRSA), S. aureus 2747/97, S. aureus SG511 (Sass et al., 2009), S. aureus 
Wood 46 (ATCC10832), S. carnosus TM300 (Schleifer et al., 2002), S. aureus COL, S. 
aureus Mu50, S. aureus Sanger, S. saprophyticus DSM 20229, S. simulans 22 (Bierbaum et 
al., 1987), S. epidermidis 5, Streptococcus G 3645”10”, S. pyogenes O-19310 (clinical 
isolate). Gram-negative bacteria – Citrobacter freundii, E. coli JM109 (Yanisch-Perron et al., 
1985), E. coli 7118, E. coli BHH71-18, Klebsiella pneumonia, Proteus mirabilis and 
Pseudomonas aeroginosa. Yeast - Candida albicans.  
 
Table 5: Media used in this study. 
Medium  Ingredients / Source 
Nutient broth (NB) Peptone 5.0 g/l , meat extract 3.0 g/l 
Luria-Bertani broth (LB) 10.0 g/l BactoTM Tryptone (BD); 5.0 g/l Yeast extract 
powder LP0021 (Oxoid); 10.0 g/l NaCl; pH adjusted to 
7.5 
Müller Hinton broth (MH) Beef, dehydrated infusion from 300 g/l, Casein 
hydrolysate 17.5 g/l, Starch 1.5 g/l; pH 7.3 ± 0.1 
Trypticase soy broth (Soybean-Casein 
Digest Medium) (Oxoid; CM0129) (TSB) 
Pancreatic digest of casein 17.0 g/l, Enzymatic digest 
of soybean meal 3.0 g/l, NaCl 5.0 g/l, Dipotassium 
phosphate 2.5 g/l, Glucose 2.5 g/l; pH 7.3 ± 0.2  
Brain heart infusion (BHI) Calf brain (Infusion solids) 12.5 g/l, Beef heart 
(Infusion solids) 5.0 g, Proteose peptone 10.0 g/l, 
Glucose 2.0 g/l, NaCl 5.0 g/l, Disodium phosphate 2.5 
g/l; pH 7,4 ± 0.2 
Müller Hinton II agar Becton Dickinson GmbH, Germany 
Columbia agar with 5% sheep blood Becton Dickinson GmbH, Germany 
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Table 6: Preparation of 2× BPM (Bacillus production medium).  
Medium Ingredients 
Wolfe’s mineral salts  Titriplex I (500 mg/l); ZnSO4·7 H2O (180 mg/l); CuSO4·5 H2O (50 
mg/l); CoCl2·6 H2O (170 mg/l); CaCl2·2 H2O (130 mg/l); NaMoO4·1 
H20 (11 mg/l); Al2 (SO4) 3 (26 mg/l); H3BO3 (10 mg/l); 1 M NaOH (5 
ml/l)  
Mineral salt 10 mM CaCl2; 2 mM FeSO4; 1 mM MnSO4  
2× BPM 0.25 M (NH4) 2SO4 (20 ml); 0.1 M MgSO4 (2 ml); 2 M K-P-buffer pH 
7.0 (2 ml); 0.5 M Tris-maleate pH 7.0 (20 ml); Wolfe’s mineral salts (2 
ml); D/W (27.5 ml); after autoclaving 2.5 M glucose (16 ml); mineral 
salts (10 ml) were added to a total volume of 100 ml. 
Source: Bierbaum et al. (1995) 
 
Table 7: Bacterial strains used in this study.  
Strain Characteristics Source/References 
B. pseudomycoides Antimicrobial substance producer DSMZ, Germany 
E.coli SCS110 Intermediate cloning host for recombinant 
plasmids 
Yanisch-Perron et al., 1985  
E. coli JM109/ E. coli 
JM83  
Intermediate cloning host for recombinant 
plasmids 
Yanisch-Perron et al., 1985  
E. coli BL21 Strain for recombinant protein expression, 
λDE3-lysogen, T7 RNA polymerase under 
control of the lacUV promotor  
Studier and Moffatt, 1986  
E. coli C41/ E. coli C43 BL21(DE3) derivatives for expression of 
toxic proteins  
Miroux and Walker, 1996  
E. coli XL10 Gold Cloning host for mutagenic recombinant 
plasmid construction 
Agilent, Germany 
B. subtilis TMB016 Reporter strain containing peptide-sensing 
and detoxification module (LiaRS) 
Burkhard and Stein, 2005 
B. subtilis TMB299 Reporter strain containing peptide-sensing 
and detoxification module (YxdJK-LM) 
Starón et al., 2011 
B. subtilis TMB588 Reporter strain containing peptide-sensing 
and detoxification module (PsdRS-AB) 
Starón et al., 2011 
 
2.4.2. Sterilization of media, equipment and bacterial cultures 
Media, plastic wares and chemicals were autoclaved at 121 °C for 20 min (Varioklav 75S, 
H+P Labortechnik AG, Oberschleißheim, Germany). Heat labile solutions were sterilized by 
filtering through sterile syringe filters of 0.2 or 0.4 μm pore size (Supor®Membrane; Pall Life 
Science Corporation, Ann Arbor, USA). Glasswares and metallicwares were heat sterilized 
for 4 h at 200 °C (Kelvitron®, Heraeus). Bacterial cultures, disposables substances and 
contaminated labwares were autoclaved at 134 °C for 30 min. 
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2.4.3. Determination of optical density of bacterial culture 
The optical density of bacterial culture was determined by an UV-160 spectral photometer at a 
wavelength of 600 nm (O.D. 600). Cultures with higher optical density were diluted in an 
appropriate medium before measurement. 
 
2.4.4. Detection of protease activity  
Protease activity in cell-free culture supernatants was detected on skim milk agar plates (3 g/l 
yeast extract, 5 g/l peptone, 2.5 g/l skim milk powder and 15 g/l agar, at pH 7.2). The well 
was introduced into the agar surface with a sterile cork borer and 50 µl of fresh filter-sterilized 
supernatant was loaded into it. Protease activity was determined by the appearance of clear 
zones around the well after incubation at 37 °C overnight.  
 
2.4.5. Detection of haemolytic activity 
The haemolytic activity was tested on Columbia blood agar (CA) plate. B. pseudomycoides 
was streaked on the CA plate. Likewise, 10 µl of each, isopropanol cell wash extract and 
pseudomycoicidin were spotted on the CA plate. Then the plates were incubated at 37 °C 
overnight. After overnight incubation, the plates were observed for possible zones of 
haemolysis. 
 
2.4.6. Reporter gene assay 
For the assay, the reporter strains B. subtilis TMB016, B. subtilis TMB299 and B. subtilis 
TMB588 were selected. Three TSA plates supplemented with X-gal were seeded with each of 
the 3 reporter strains. The isopropanol cell wash extract (50 µl) was loaded into wells and the 
plates were incubated at 37 °C for 24 h. Similarly, 5 - 10 µl of pseudomycoicidin was spotted 
on an agar plate. After 24 h of incubation, the plates were inspected for a blue coloration 
around the zone of inhibition. 
 
2.4.7. Growth of the test microorganism in the presence of antimicrobial agent 
M. luteus and S. aureus SG 511 were grown in MH broth at 37 °C. After 5 h, 500 µl of the 
partially purified antimicrobial compound was added to 20 ml of culture and the culture was 
further incubated. As a control, 20 ml of the culture was incubated without addition of the 
antimicrobial compound. Aliquots were taken at 1 h intervals and O.D. was measured. 
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2.5. Methods in molecular genetics 
 
2.5.1. Purification of nucleic acids 
Genomic DNA was prepared using PrestospinD Bug mini column kit (Molzym, Bremen, 
Germany). This kit works on the principle of binding the nucleic acid to clay minerals. Clay 
minerals reversibly bind DNA, so that the cell constituents and salts can be removed by 
washing with specially developed buffers and 70% ethanol. Finally, bound DNA is eluted 
with a small volume of TE buffer. Genomic DNA from Bacillus sp. was prepared according to 
the protocol of the supplier with some modifications - 1. for lysis, cells were incubated at 37 
°C for 30 min in buffer 1 that had been supplemented with 10 μl lysozyme (100 mg/ml) and 2. 
DNA was eluted in 100 μl pre-heated (70 °C) MilliQ water and was stored at -20 °C. 
Plasmid DNA was isolated using the Gene-JetTM Plasmid Miniprep Kit (Fermentas) 
according to the protocol of the supplier. The kit utilizes a silica based membrane technology 
for the isolation. Cell lysis of Bacillus was achieved by adding 10 µl of lysozyme (100 mg/ml) 
in the resuspension buffer and incubating it at 37 °C for 30 min. The plasmid DNA was eluted 
in 50 μl MilliQ water. For elution of plasmids larger than 5 kb, MilliQ water was pre-heated 
up to 80 °C. All plasmids used in this study are listed in Table 8. Quality and quantity of the 
nucleic acids were analysed by agarose gel electrophoresis and spectrophotometry. 
 
Table 8: Plasmids used in this study. 
Plasmid Properties Source 
pUC 19 shuttle vector; AMPr, CMr  Yanisch-Perron et al., 1985  
pET22b∆pelB pET22 derivative, expression vector with 
C-terminal 6XHis-tag, pelB leader 
sequence deleted, T7 lac-Promotor, AmpR 
Sass and Bierbaum, 2007 
pET22b∆pelBlanM pET22 derivative harbouring C-terminally 
His-tagged lanM 
This study 
pET28b His-tag expression vector, kanaR  Novagen 
pET28blanA pET22 derivative harbouring N-terminally 
His-tagged lanA 
This study 
pET28blanAXa pET22 derivative harboring the N-
terminally his-tagged lanA including a 
factor Xa cleavage site  
This study 
pET28blanAXaC52A pET22 derivative harboring the N-
terminally His-tagged lanA including a 
factor Xa cleavage site with C52A 
This study 
pET28blanAXaC56A pET22 derivative harboring the N-
terminally His-tagged lanA including a 
factor Xa cleavage site with C56A 
This study 
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Contd... 
Plasmid Properties Source 
pET28blanAXaC62A pET22 derivative harboring the N-
terminally His-tagged lanA including a 
factor Xa cleavage site with C62A 
This study 
pET28blanAXaC65A pET22 derivative harboring the N-
terminally His-tagged lanA including a 
factor Xa cleavage site with C65A 
This study 
pET28blanAXaC70A pET22 derivative harboring the N-
terminally His-tagged lanA including a 
factor Xa cleavage site with C70A 
This study 
pET28blanAXaC75A pET22 derivative harboring the N-
terminally His-tagged lanA including a 
factor Xa cleavage site with C75A 
This study 
 
2.5.2. Determination of the concentration and purity of nucleic acids 
The concentration and purity of nucleic acids were determined by the nanodrop spectrometer 
at 260 nm. The purity was determined by the ratio of the spectrometric absorbance of the 
sample at 260 nm and 280 nm. 
 
2.5.3. DNA sequencing 
DNA sequencing was performed by Sequiserve (Vaterstetten, Germany), Seqlab (Göttingen, 
Germany) and Microsynth (Balgach, Switzerland) by the Sanger chain determination method 
(Sanger et al., 1977). 
 
2.5.4. Agarose gel electrophoresis 
DNA fragments were analysed by standard agarose gel electrophoresis in a horizontal 
electrophoresis apparatus. DNA was loaded on agarose gel (0.8 - 1% in 1× TAE buffer) and 
run in 1× TAE buffer applying a voltage of 80 - 120 volt. DNA was stained with ethidium 
bromide and visualized under the UV-imager. 
 
2.5.5. Polymerase chain reaction (PCR) 
PCR is a method of amplifying the DNA of a certain length and sequence. The PCR 
amplification was performed in 50 µl reaction mixtures in a PCR express Thermal cycler 
(Hybaid, ThermoLifeScience, Engelsbach, Germany) or the SensoQuest Labcycler 
(SensoQuest, Göttingen, Germany). DNA was amplified using the Phusion
TM
 HF polymerase 
(NEB, Frankfurt/ Main, Germany) and deoxynucleotide triphosphates (premixed solutions, 25 
mM each, Fermentas). All the primers were synthesized by Microsynth (Balgach, 
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Switzerland) or Metabion (Martinsried, Germany). Primers were designed using the Primer 3 
tool: http://biotools.umassmed.edu/bioapps/primer3_www.cgi, and are listed in Table 9. 
 
2.5.6. Enzymatic digestion of DNA 
For ligation or examination of clones, PCR products and plasmid DNA were digested by the 
Fast digest® restriction enzymes or conventional restriction enzymes (Fermentas or NEB). 
Digestions were performed as explained in the manual. 
 
2.5.7. Purification of DNA fragments and gel extraction 
To purify the PCR product, the Gene Jet PCR purification kit was used. This kit utilizes a 
silica based membrane technology for the removal of the impurities from the PCR product. 
The purification was executed as described in the manual. The PCR product was eluted from 
the column by MilliQ or Elution buffer. 
 
2.5.8. DNA ligation 
The ligation was carried out to ligate a DNA fragment into a plasmid vector. The reaction was 
performed either by T4 ligase (5 U/µl) (Fermentas) in 20 µl total volume for 1 h or by T4-
ligase (6 U/µl) (Roche) in 10 µl total volume overnight. 
 
2.5.9. Site directed mutagenesis 
In order to introduce a point mutation or to replace an amino acid, the Quick Change 
Lightning Site-Directed Mutagenesis Kit (Agilent) was used. This kit utilizes the double 
stranded DNA vector with the insert of interest and two oligonucleotide primers containing 
the desired mutation. The recombinant vectors were used as templates and the PCR was 
performed using both mutagenic primers employing PfuUltra HF DNA polymerase (Agilent) 
without primer displacement. Mutagenesis was performed following the supplier’s 
instructions. Primers containing the desired exchanges were designed by the following tool: 
http://www.genomics.agilent.com/ CollectionSubpage.aspx? PageType=Tool&SubPageType= 
ToolQCPD&PageID=2296. Primers used for mutagenesis are listed in Table 9. Parental 
plasmids, that lacked the desired mutations, were digested by DpnI, specific for (hemi) 
methylated DNA. Subsequently, batches were transformed into super-competent E. coli 
XL10-Gold cells (Agilent). The medium used in the transformation is listed in Annex XVI. 
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Table 9: Primers used in this study. 
Primers Template Restriction enzyme Primer sequence (5’-3’) 
PseAfor 
lanA 
BamHI AAAGGATCCAAGTGTCAAATACATATATAACGGATAAA 
PseArev HindIII AAAAAGCTTTCTGATCATGATTCGAACAGC 
PseAforI lanA NdeI AAACATATGAATGATAAAATTATCCAATACTGGAA 
PseArevI  XhoI AAACTCGAGTTAGCAAGACCAGCTCCAACAA 
PseMfor 
lanM 
NcoI AAACCATGGGGATGCTTGCAA ATCAAGCCTT AAAA 
PseMrev XhoI AAACTCGAGTTTTAGTGCTGTTATAGACTCCAA 
PseMfor3 
Internal lanM primers for sequencing lanM - 
GGA CGA GGC CTC AAC ATA AG 
PseMrev3 GAG CCA GCT GAA CCG TCT AT 
PseAXafor 
pET28blanA - 
GCTTTCAGACGCTGATCTGGATAAAATAGAGGGTCGTGGTGATTGCGGT 
PseAXarev ACCGCAATCACCACGACCCTCTATTTTATCCAGATCAGCGTCTGAAAGC 
LanAXaC52Afor 
pET28blanAXa - 
TAAAATAGAGGGTCGTGGTGATGCCGGTGGTACTTGTACA 
LanAXaC52Arev TGTACAAGTACCACCGGCATCACCACGACCCTCTATTTTA 
LanAXaC56Afor 
pET28blanAXa - 
TGGTGATTGCGGTGGTACTGCTACATGGACAAAAGATTGC 
LanAXaC56Arevr GCAATCTTTTGTCCATGTAGCAGTACCACCGCAATCACCA 
LanAXaC62Afor 
pET28blanAXa - 
TGGTACTTGTACATGGACAAAAGATGCCTCAATTTGTCCATCATGG 
LanAXaC62Arev CCATGATGGACAAATTGAGGCATCTTTTGTCCATGTACAAGTACCA 
LanAXaC65Afor 
pET28blanAXa - 
CTTGTACATGGACAAAAGATTGCTCAATTGCTCCATCATGGTCTTGT 
LanAXaC65Arev ACAAGACCATGATGGAGCAATTGAGCAATCTTTTGTCCATGTACAAG 
LanAXaC70Afor 
pET28blanAXa - 
GTTAGCAAGACCAGCTCCAAGCAGACCATGATGGACAAATTG 
LanAXaC70Arev CTTGTTGGAGCTGGTCTGCCTAACTCGAGCACCACC 
LanAXaC75Afor 
pET28blanAXa - 
CTTGTTGGAGCTGGTCTGCCTAACTCGAGCACCACC 
LanAXaC75Arev GGTGGTGCTCGAGTTAGGCAGACCAGCTCCAACAAG 
PseAgap G. DNA from B. pseudomycoides  ATCGTTCACCGTCGTGATGC 
Gapfor G. DNA from B. pseudomycoides - TGCACAGCATTATGTAGAAGAGTT 
Gaprev G. DNA from B. pseudomycoides - GCTGGGGCATTCCAGTATT 
Gapfor2 Internal primer for sequencing - CCT TTT CGA AGA AGA AAG CTA CC 
Gaprev2 Internal primer for sequencing - TCA TGC GTG AAA TTA CCT CTT T 
Gapfor3 Internal primer for sequencing - GGT CGT TTT CTC CTA ATA ATC GC 
Gapfor4 Internal primer for sequencing - AAA ATC CCC TCC ATA GTA AAC AGA 
GapIIfor G. DNA from B. pseudomycoides - ACA GCA ACT GGC GAT GGT AG 
GapIrev G. DNA from B. pseudomycoides - ATT TCC TGC AGG GAT TAC TGG 
GapIIfor1 Internal primer for sequencing - GGG CGA AAG ATT TGG AAG AGC 
GapIIfor2 Internal primer for sequencing - TGG TAT TGT AAA TTA CTC GTC ATC AA 
GapIIfor3 Internal primer for sequencing - GGT ATT GTA AAT TAC TCG TCA 
GapIIfor4 Internal primer for sequencing - TGG TGC ACG GAA ACC TCT TT 
FPgap1 G. DNA from B. pseudomycoides - GAC CAG CTC CAA CAA GAC CA 
RPgap1 G. DNA from B. pseudomycoides - CAG CAA CTG GCG ATG GTA GT 
rPCRFP1 G. DNA from B. pseudomycoides PsiI CAT CTG ACC TAC CAA CAG CT 
rPCRRP1 G. DNA from B. pseudomycoides PsiI/ BstBI AGT ATT GGA TGA TTT TAT CAT GC 
rPCRFP2 G. DNA from B. pseudomycoides BstBI CTT TCA GCA GCA GAA CTT AGC 
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2.5.10. Transformation of E. coli 
 
2.5.10.1. Preparation of electrocompetent E. coli cells 
For generation of electro-competent E. coli strains, the method described by Dower et al. 
(1988) was used.  The desired strain of E. coli was freshly streaked on an LB plate. A single 
colony was picked to inoculate 5 ml of LB broth and incubated at 37 °C overnight. 500 ml 
LB, inoculated with 500 μl of the overnight culture, was grown to 0.5 O.D.600 units. After 
incubation on ice for 30 min, the cells were harvested by centrifugation (5,000 × g, 4 °C, 10 
min) followed by three washing steps with 500 ml and 250 ml pre-chilled MilliQ water and 
with 20 ml pre-chilled 10% glycerol solution. Finally, the cells were resuspended in 0.8 ml 
glycerol (10%) and frozen for long time storage at -75 °C in 50 μl aliquots. 
 
2.5.10.2. Preparation of chemocompetent E. coli cells  
For the preparation of chemocompetent cells, the method described by Morrison (1977) was 
used. The desired strain of E. coli was freshly streaked on an LB plate. A single colony was 
picked to inoculate 5 ml of LB broth and incubated at 37 °C overnight. The E. coli culture 
(100 µl) was inoculated into 50 ml of TYM broth and grown at 37 °C with shaking to 0.6 
O.D.600 units. Subsequently, the flask was kept on ice and shaken to cool the culture. The cells 
were harvested (5,000 × g, 4 °C, 5 min, Acc. 9, Br. 7) and the resulting cell pellets were 
resuspended in 5 ml of pre-chilled and filter-sterilized TFBI. After centrifugation, the cells 
were resuspended in 2.5 ml pre-chilled TFBII medium and aliquoted into 100 μl samples. 
Cells were shock-frozen in liquid nitrogen and stored at -75 °C until further use. Media used 
during the preparation of competent cells are listed in Table 10. 
 
Table 10: Media for preparation of chemocompetent cells.  
Medium Volume Ingredients 
TYM broth 100 ml 2 g Bacto-Trypton (Difco); 0.5 g yeast extract (Difco); 584.4 mg NaCl; 
246.48 mg MgSO4  
TFBI 50 ml 5 M potassium acetate (0.3 ml); MnCl2 (495 mg); 2 M KCl (2.5 ml); 1 
M CaCl2 (0.5 ml) and glycerol (7.5 ml)  
TFBII 50 ml 2 M MOPS pH 7 adjusted with 5 M KOH (2.5 ml); 2 M KCl (0.25 ml); 
1 M CaCl2 (3.7 ml) and glycerol (7.5 ml)  
 
2.5.10.3. Transformation of electrocompetent E. coli 
The electroporation apparatus was set to the appropriate program settings. Frozen cells were 
thawed on ice and immediately mixed with 3 μl of ligation batches or 100 ng of plasmid 
 39 
 
DNA. The mixture was electroporated employing a pre-chilled electro cuvette (1 mm) in a 
gene pulser (program EC2, Bio-Rad, Munich, Germany). The cells were resuspended in 1 ml 
LB and incubated at 37 °C under shaking for up to 1 h for regeneration. Finally, 100 µl of 
each, undiluted, 10 fold diluted and 100 fold diluted cell suspension, were plated on three 
selective agar plates respectively. The rest of cell suspension was centrifuged (15000 rpm, 1 
min, RT, Br. 9), and the recovered pellet was resuspended in about 100 µl LB and plated on 
selective agar plate. 
 
2.5.10.4. Transformation of chemocompetent E. coli 
Frozen chemo-competent E. coli cells were thawed on ice before use. 10 - 20 μl of a ligation 
batch or 100 - 200 ng of plasmid DNA was mixed with 50 μl competent cells and incubated 
on ice for 30 min. For transformation, the cells were exposed to a heat shock treatment at 42 
°C for 30 s followed by incubation on ice for 3 min. Transformed cells were resuspended in 1 
ml pre-warmed LB and incubated at 37 °C for 45 - 60 min with shaking. Finally, 100 μl of 
each, undiluted, 10 fold diluted and 100 fold diluted cell suspension, were plated on selective 
agar plates respectively. The rest of cell suspension was centrifuged (15000 rpm, 1 min, RT, 
Br. 9), and the recovered pellet was resuspended in about 100 μl LB and plated on selective 
agar plate.  
 
2.5.11. Analysis of biosynthetic gene cluster 
Information about the lantibiotic gene cluster of B. pseudomycoides was accessed via National 
centre for Biotechnology Information (NCBI, http://blast.ncbi.nlm.nih.gov/Blast.cgi) with the 
accession number CM000745 ACMX01000000. 
 
2.5.12. Bioinformatic tools  
 
Table 11: Bioinformatic tools used in this study. 
Tools Sources 
Blast NCBI: http://blast.ncbi.nlm.nih.gov/Blast.cgi. 
GC content Genomatix: http://www.genomatix.de/cgi-bin/tools/tools.pl 
Protease cleavage site on the 
peptide 
ExPASY peptide cutter: 
http://www.expasy.ch/tools/peptidecutter/ 
Multi sequence alignments ClustalW:  
http://www.ebi.ac.uk/Tools/msa/clustalw2/MultiAlin: 
http://multalin.toulouse.inra.fr/multalin/ 
Restriction analyses NEBcutter: http://tools.neb.com/NEBcutter2/index.php  
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Contd... 
Tools Sources 
Transmembrane sequences TMHMM web server v. 2.0.:  
http://www.cbs.dtu.dk/services/TMHMM/.  
Subcellular localizations of the 
proteins 
CELLO v.2.5: http://cello.life.nctu.edu.tw/. 
Molecular weight of the peptide ExPASY ProtParam: 
http://web.expasy.org/protparam/.ExPASY Peptide mass:  
http://web.expasy.org/peptide_mass/ 
Vector cards pDRAW32 version 1.1.114 
 
2.5.13. Cloning of the pseA and pseM genes. 
Genomic DNA was isolated from an overnight culture of B. pseudomycoides using a Mini 
Spin Column Kit according to the supplier’s manual (Molzym, Bremen, Germany). The pseA 
(lanA) was PCR amplified by 30 cycles of denaturing (98 °C for 3 min), annealing (64.4 °C 
for 30 s), and extending stages (72 °C for 1 min). The genomic DNA isolated from B. 
pseudomycoides was used as a template and PseAforI and PseArevI were used as primers 
(Table 9). Amplifications were confirmed by 1% agarose gel electrophoresis, and the PCR 
products were purified using a PCR Purification Kit (Fermentas). The insert DNA fragment 
and pUC19 vector (Table 8) were double digested in separate reactions containing 1× fast 
digest green buffer (Fermentas) with BamHI and HindIII for 1 h at 37 °C. The resulting DNA 
products were ligated at 25 °C for 10 min in 1× T4 DNA ligase buffer with T4 DNA ligase 
(0.7 U / μl). Again, the lanA gene was amplified from the genomic DNA by PCR using 
PseAfor and PseArev as primer pair (Table 9). The obtained insert DNA fragment and the 
pET28b vector (Table 8) were double digested in separate reactions containing 1× fast digest 
green buffer (Fermentas) with NdeI and XhoI for 1 h at 37 °C. The resulting DNA products 
were ligated at 25 °C for 10 min in 1× T4 DNA ligase buffer with T4 DNA ligase (0.7 U / μl). 
E. coli JM109 cells were transformed with 6 µl of the ligation product by heat shock, and the 
cells were plated on LB-kanamycin agar plates and grown overnight at 37 °C. Several 
colonies were picked and used to inoculate separate 5 ml cultures of LB-kanamycin medium. 
The cultures were grown at 37 °C for 12 h, and plasmids were isolated using a Spin Miniprep 
Kit (Fermentas). The sequences of the inserts of the plasmids were confirmed by DNA 
sequencing.  
The lanM gene was PCR amplified by using the genomic DNA isolated from B. 
pseudomycoides as template and PseMfor and PseMrev as primers (Table 9). The cycler 
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program for amplification is presented in Annex XVII. Amplifications were confirmed by 1% 
agarose gel electrophoresis, and the PCR products were purified using a PCR Purification Kit 
(Fermentas). The insert DNA fragment and the pET22b∆pelb vector (Table 8) were double 
digested in separate reactions containing 1× fast digest green buffer (Fermentas) with NcoI 
and XhoI for 30 min at 37 °C. The resulting DNA products were ligated at 25 °C for 10 min in 
1× T4 DNA ligase buffer with T4 DNA ligase (0.7 U / μl). E. coli JM109 cells were 
transformed with 6 μl of the ligation product by heat shock and the cells were plated on LB-
ampicillin agar plates and grown at 37 °C for 15 h. Several colonies were picked and used to 
inoculate separate 5 ml cultures of LB-ampicillin medium. The cultures were grown at 37 °C 
for 12 h, and plasmids were isolated using a Gene Jet Plasmid Miniprep Kit (Fermentas). The 
sequences of the inserts of the plasmids were confirmed by DNA sequencing.  
 
2.5.14. Molecular engineering of a factor Xa cleavage site into the pseA gene. 
A site-directed mutagenesis approach was used to install a proteolytic cleavage site directly 
N-terminal to the core peptide of LanA. The primers were designed to contain the nucleotide 
sequences necessary to encode the amino acids IEGR in place of four wild-type peptide 
residues (VVGA). The plasmid pET28b_ lanAXa (Table 8) was PCR amplified according to 
the Quick Change Lightining Site-Directed Mutagenesis Kit using PseAXafor and PseAXarev 
(Table 9) as primers and pET28b_ lanA (Table 8) as template. The amplification was 
confirmed by 1% agarose gel electrophoresis. To digest the methylated template prior to 
transformation, 2 μl of DpnI was added to the PCR product and the digest was incubated at 37 
°C for 5 min. XL10-Gold ultracompetent cells were transformed with 2 µl of the digest 
product by heat shock, and cells were plated on LB-kanamycin agar plates and grown 
overnight at 37 °C. Several colonies were picked and used to inoculate separate 5 ml cultures 
of LB-kanamycin medium. The cultures were grown at 37 °C overnight, and the plasmids 
were isolated using a Gene Jet Plasmid Miniprep Kit (Fermentas). The sequences of the 
resulting plasmid products were confirmed by DNA sequencing. 
 
2.5.15. Attempts to sequence the gap upstream of the gene cluster 
Since the structural gene is encoded in the 5’ end of contig 00045, the upstream sequences of 
the gene cluster are not yet clear. According to NCBI, contig 00074 (bpmyx0001_45890- 
thioredoxine reductase) is located adjacent to contig 00045 with a gap of approximately 100 
bp. To fill the gap upstream of pseA, PCR and rPCR were performed. The primers used for 
PCR and rPCR are listed in Table 9. The genomic DNA extracted from B. pseudomycoides 
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was used as a template for the PCR. The PCR products were gel extracted and purified. 
Purified PCR products were sent for DNA sequencing. 
 
2.6. Protein and biochemical methods 
 
2.6.1. Production of antimicrobial substance from B. pseudomycoides 
To detect the production of an antimicrobial substance, B. pseudomycoides was cultured in 
TSB, LB, MHB, BHI, NB and 2× BPM (Table 6) media at different incubation temperatures 
(28 °C, 30 °C, 37 °C and 40 °C) and incubation periods (24, 45, 48, 68 and 71 h). After 
incubation the cells were pelleted by centrifugation at 10,000 × g and 4 °C for 30 min. For 
further analysis, the culture supernatant was sterilized by filtration and stored at -20 °C. The 
cell pellet was resuspended in 35 ml, 70% isopropanol (adjusted to pH 2 with HCl) and 
incubated at 4 °C for 4 h with continuous stirring. The cells were removed by centrifugation 
and the supernatant was sterilized by filtration and stored at -20 °C. Antimicrobial activity 
from the supernatant and isopropanol cell wash extract was examined by an agar well 
diffusion assay against M. luteus and several other indicator strains. After incubation at 37 °C 
overnight, inhibition zones were measured.  
 
2.6.2. Purification of the antimicrobial substance from B. pseudomycoides 
Prior to purification, isopropanol from the cell wash extract was removed by rotary 
evaporation (Rotavapor Re11, Essen, Germany). Various chromatographic purification 
methods were tested for the purification of the cell wash extract from B. pseudomycoides as 
explained below. 
 
2.6.2.1. SerdolitR PAD I adsorption 
The 10 g of PAD I resin was soaked in 50% of methanol and stored at 4 °C. Before use, 
methanol was removed from resin by washing with deionised distilled water for several times. 
Then the resin was poured into the column. The antimicrobial substance (10 ml) was loaded 
onto the column with the PAD resin. Then the column was washed with water and eluted with 
different percentages of methanol, acetronitrile and isopropanol (Annex X). The collected 
fractions were evaporated to remove the solvents. Then each fraction was tested for 
antimicrobial activity by an agar well diffusion assay. 
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2.6.2.2. Cation and anion exchange chromatography 
Both the cation exchanger (HI Trap SP column) and the anion exchanger (HI Trap Q HP 
column) were equilibrated by start buffer with a flow rate of 1 ml/min. In both 
chromatographic methods, 10 ml of isopropanol cell wash extract was loaded onto the 
respective columns. Both the columns were washed with 25 ml of start buffer to remove the 
unbound compounds. The samples were then eluted with 30 ml elution buffer. Buffers used 
for cation and anion exchange chromatography are listed in Annex VIII and IX respectively. 
Fractions of 1 ml were collected and tested for an antimicrobial activity. 
 
2.6.2.3. High performance liquid chromatography (HPLC) 
For the purification of the antimicrobial substance, Poros (10R2, 100 x 4.6 mm, Perseptive 
Biosystems, Freiburg, Germany) and C18 (3C18, 250 x 4.6 mm, Schambeck SFD GmbH, 
Rheindorfer, Germany) HPLC columns were used. The gradient was generated by water with 
0.1% TFA and acetonitrile with 0.1% TFA. The empty column was first washed with 
acetonitrile with 0.1% TFA followed by equilibration with water supplemented with 0.1% 
TFA. Then, 2 ml cell wash extract was loaded onto the poros column. Elution was performed 
by using the linear gradient of 0 - 100% acetonitrile with 0.1% TFA at a flow rate of 1 ml/min 
for 30 min. The peaks were detected at the absorbance of 220 nm. Fractions were collected, 
and assayed for their antimicrobial activity against M. luteus by an agar well diffusion assays. 
The active fractions were then analysed by MALDI TOF MS. All the active fractions from the 
Poros column were then pooled and further purified by the C18 HPLC column. Again, the 
peaks were detected at an absorbance of 220 nm and 266 nm. The fractions were collected and 
assayed for an antimicrobial activity against M. luteus by an agar well diffusion assays and 
analysed by MALDI TOF MS. 
For the purification of the heterologously produced peptide, a C4 RP-HPLC column 
was used. The peptide was loaded onto the column and was eluted using a gradient of 0 - 
100% of ACN in 0.1% TFA for 30 min. The peaks were detected at an absorbance of 220 nm 
and 266 nm. The fractions were collected and assayed for an antimicrobial activity against M. 
luteus by an agar well diffusion assay and further analysed by MALDI TOF MS. 
 
2.6.3. Mass spectrometry analysis  
The mass spectrometric analysis of the peptide preparations was performed using a MALDI 
TOF mass spectrometer (Bruker Biflex, Bruker Daltonics, Bremen, Germany). Aliquots of 1 
µl of the isopropanol cell wash extracts were mixed with 2 µl matrix (α-cyano-4- 
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hydroxycinnamic acid in ACN: 0.1% TFA in water (1:3) or sinnapinic acid in ACN: 0.1% 
TFA in water (1:3)). For MALDI TOF analysis of the active HPLC fractions, 20 µl of each 
fraction was concentrated at the ratio of 1:10 using a Rotational Vacuum Concentrator (RVC 
2-18, Christ, Osterode, Germany). The samples were then spotted onto the MALDI target and 
dried in air. Mass spectra were measured in the positive ion mode in the range of 1500 to 4000 
Da for the cell wash extract or at a range of 1000 to 20,000 Da for the heterologously 
produced peptide. The peaks were determined using Flexanalysis 2.0 (Bruker Daltonics). 
The heterologously produced PseAXa and its mutant variants were analysed by LC-
MS and MS-MS. LC-MS was performed using Agilent 1200 series HPLC with a reverse-
phase column (KNAUER Eurospher II 100-5 RP C-18, 5 um, 4.0 mm x 250 mm) coupled 
with an ESI-micrOTOF-Q (Bruker Daltonics) mass spectrometer and were operated at a flow 
rate of 1.0 ml/min, for 50 min using 75% ACN and 25% water supplemented with 0.1% TFA 
(v/v). The wavelength for detection was set at 273 nm. The spectra were recorded by infusion 
into the ESI source using methanol as the solvent. The instrument was first autotuned on the 
m/z value of the ion to be fragmented. Then, the [M+H]
+ 
ion of each compound was isolated 
in the linear ion trap and fragmented by CID. Sets of consecutive, high-resolution, full 
MS/MS scans were acquired. Mass spectra were measured in the range of 200 - 3000 Da and 
finally analysed by Bruker Compass DataAnalysis 4.0 (Bruker Daltonics). 
 
2.6.4. Agar well diffusion assay  
The antimicrobial activity of culture supernatants, cell wash extracts and HPLC fractions was 
determined by an agar well diffusion assay. One colony of the indicator strain was suspended 
in 5 ml MH broth. One ml of this diluted cell suspension was used to inoculate a second 5 ml 
MH broth, and was used for seeding MH agar plates with the indicator strains. For seeding, 
the surface of the agar plates was overlaid with the cell suspension. The cell suspension was 
then removed by pipetting, followed by incubation for 15 min at RT to air-dry the plates. 
Wells (7 mm diameter) were introduced into the surface of the agar plate using a sterile cork 
borer. 50 μl of each sample were loaded into a well, and dried for 15 min at RT. The plates 
were then incubated at 37 °C overnight. The activity was expressed in the diameter (cm) of 
the inhibition zones formed around the wells. 
For the determination of the activity of heterologously produced peptides, each peptide 
(5 - 10 μl) was directly pipetted on the surface of agar plates seeded with indicator strain (also 
known as spot on the lawn method). M. luteus was used as a standard indicator strain as it is 
 45 
 
known to be one of the most sensitive indicator strains for lantibiotics. Buffer used during 
factor Xa cleavage was used as a control. 
 
2.6.5. Stability assay  
To determine the sensitivity of the antimicrobial substance to different temperatures, pH, 
enzymes and organic solvents, a stability assay was performed. The thermal stability of the 
antimicrobial compound was tested by incubating 2 ml of the isopropanol cell wash extract at 
25 °C, 37 °C, 45 °C, 65 °C, 80 °C and 100 °C for 4 h. The stability of the antimicrobial 
activity against enzymes were determined by adding several enzymes - 10 mg/ml of 
proteinase K (pH 7), pronase E (pH 7), α-chymotrypsin (pH 7.6), and trypsin (pH 7.6) to the 
cell wash extract. The samples were incubated at 37 °C for 1 h. The influence of pH on the 
antimicrobial activity was examined by adjusting the pH to 3, 4, 5, 6, 7, 8, 9 and 11 by sodium 
phosphate buffer and incubating them for 4 h at RT. The stability of the antimicrobial 
compound against organic solvents was determined by adding organic solvents - ethanol, 
methanol, acetone, acetonitrile and 2-propanol to the cell wash extract and left for incubation 
up to 4 h at RT. The residual antimicrobial activity was then determined by an agar well 
diffusion assay against M. luteus.  
 
2.6.6. SDS-PAGE and the NuPAGE  
The protein and peptide profile of fractions was determined by standard SDS-PAGE 
(Laemmli, 1970) in a Mini Protean III vertical electrophoresis apparatus (BioRad) or the 
NuPAGE electrophoresis system (XCell SureLock® Mini-Cell, Invitrogen). The Tris glycine 
buffer system or NuPAGE
®
 MES running buffer was used for the separation of proteins 
(Annex XII). For small peptides like LanA, 20 - 24% SDS-gels or commercially available 4 - 
12% gradient Novex Bis-Tris gels were used. LanM proteins were analysed on 10% SDS-
gels. 10× LDS sample buffer (Invitrogen) was added to the samples, which were heated (70 
°C) for 10 min prior to electrophoresis. Prestained (10-250 kDa) or unstained protein (5- 200 
kDa) ladders (Fermentas) were used as a protein markers. Gels were stained with the 
PageBlue™ Protein Stain (Fermentas) or Coomassie staining (Annex XIII) or silver staining 
(Annex XIV) according to Heukeshoven and Dernick (1988).  
Aliquots of the partially purified cell wash extract were verified on polyacrylamide gel 
20% SDS-gels. After electrophoresis, the gels were washed with sterile distilled water for the 
removal of SDS. Then the gels were cut into two parts. One part of the gel was used for the in 
situ overlay assay and the other part for staining. For the in situ overlay, the gels were placed 
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on the MH agar plate seeded with M. luteus. The plates were incubated at 37 °C for 24 h and 
the presence of inhibitory zones was observed. Later, the other part of gel was stained with 
page blue staining solution to detect the peptide bands. Low molecular weight standard 
(Sigma) was used as a protein marker.  
 
2.6.7. Dialysis of peptides 
After Ni-NTA chromatography, the peptide eluate contained a high amount of salts. Thus, it 
was necessary to remove salts from the peptide before conducting further experiments with 
the peptide. Removal of the salt from the peptide was achieved by a dialysis in a semi 
permeable membrane. The dialysis cassettes (slide-A-Lyzer ® system, Thermo Fisher 
Scientific, MWCO 2,000; 0.1 - 0.5 ml and MWCO 10,000; 0.1-0.5 ml) were used for the 
removal of the salt. For maldi analysis, dialysis was performed in 0.05% HCl, and for the 
Factror Xa cleavage assay, dialysis was done in buffer solution containing 20 mM Tris-HCl 
(pH 8), 100 mM NaCl and 2 mM CaCl2. Dialysis was performed in two steps: (i) the eluate 
buffer was exchanged with a dialysis buffer at 4 °C for 2 h with stirring and (ii) it was further 
dialysed in fresh buffer at 4 °C overnight with stirring. Finally, all peptides were stored at -20 
°C for further experiments. 
 
2.6.8. Determination of peptide concentration  
The concentration of the peptide was determined by Bradford assay according to Bradford 
(1976). In this method, the pigment (Coomassie Brilliant Blue G-250) binds to the protein, 
allowing the detection of the peptide concentration, indirectly from its emission spectra. The 
binding of the dye to the protein causes a shift in the absorption maximum of the dye from 
365 to 595 nm. This increase in absorption at 595 nm is monitored to quantify the protein 
concentration.  
The working solution of the Coomassie Brilliant Blue G-250) (BioRad) was prepared 
by diluting it to 1:5 ratio using MilliQ. The calibration curve was prepared from different 
concentrations, mg/ml (0.125, 0.25, 0.5, 0.75, 1, 1.5, and 2) of Bovine Serum Albumin (BSA). 
10 µl of each BSA standard solution was mixed with 90 µl of MilliQ to make 100 µl solution 
in the cuvette. The peptide eluate of 5 µl was mixed with 95 µl MilliQ to make 100 µl 
solution in the cuvette. 3 ml of reagent was added to both the standards and the peptide 
sample, and was incubated at room temperature for 5 min. The absorbance of standards and 
samples were measured against a blank (100 µl MilliQ + 900 µl reagent) at 595 nm in the 
spectrophotometer. The absorbance of each standard was plotted to create a standard 
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calibration curve. The concentration of the peptide was determined by comparing its 
absorbance value to the standard curve. 
 
2.6.9. Peptide desalting by ZipTip  
After factor Xa cleavage and chemical modification assays, the peptides were desalted by 
ZipTip (Millipore protocol). The solutions used for the purification were freshly prepared 
before purification (Table 12). The final pH of the sample was maintained below 4 as required 
for the ZipTip purification. The ZipTip column was equilibrated with the wetting solution 
before loading the sample. To bind the sample to the tip, the sample was aspirated and 
dispensed for 7-10 times. The tip was washed twice with washing solution to remove 
impurities and then the peptide sample was eluted using the elution solution. 
 
Table 12: Solutions used for the ZipTip purification. 
Solution Composition 
Wetting solution 100% acetonitrile  
Equilibration solution 0.1%  trifluoroacetic acid (TFA) in MilliQ water 
Washing solution 0.1%  trifluoroacetic acid (TFA) in MilliQ water + 5% methanol 
Elution solution 0.1% TFA/90% ACN + 0.1% formic acid 
 
2.6.10. Overexpression and purification of PseM 
The chemocompetent E. coli BL21 strain was transformed with the pET22b∆pelb_lanM 
(Table 8) construct containing C-terminal hexa-histidine pseM fusion. The cultures were 
inoculated from a single colony of transformants and were grown overnight at 37 °C in LB 
broth supplemented with 80 µg/ml ampicillin. The overnight grown culture was used to 
inoculate 1 L of LB broth, and the cells were grown at 37 °C to 0.5 - 0.6 O.D.600. Expression 
was induced by the addition of 1 mM IPTG, and the culture was incubated at 18 °C for 
additional 20 h. The cells were harvested by centrifugation at 6500 × g for 20 min at 4 °C. 
The pellet was resuspended in 10 ml lysis buffer and lyzed by sonication at 65% intensity for 
15 min. DNase and RNase were added to the sample, vortexed carefully and incubated on ice 
for 30 min. The sample was centrifuged at 15,000 × g for 20 min at 4 °C. The cell free 
supernatant was filtered through a 0.45 µm filter. It was purified by IMAC using a 2 ml Ni
2+
 
column. After the sample had been applied to the column, it was washed with two column 
volumes of wash buffer 1, 2 and 3 consecutively. The protein was eluted with two column 
volumes of elution buffer 1 and 2 (Table 13). The fractions were analysed by SDS-PAGE; 
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those containing PseM protein were pooled and desalted via dialysis. The protein was stored 
in storing buffer at -80 °C. 
 
Table 13: Buffers used in the purification of PseM. 
Buffer Chemical Ingredients 
Lysis Buffer 20 mM Tris pH 7.6, 500 mM NaCl, 10% Glycerol 
Wash Buffer 1 20 mM Tris pH 7.6, 500 mM NaCl, 10% Glycerol, 25 mM Imidazole 
Wash Buffer  2 20 mM Tris pH 7.6, 500 mM NaCl, 10% Glycerol, 50 mM Imidazole 
Wash Buffer 3 20 mM Tris pH 7.6, 500 mM NaCl, 10% Glycerol, 75 mM Imidazole 
Elution Buffer 1 20 mM Tris pH 7.6, 500 mM NaCl, 10% Glycerol, 200 mM Imidazole 
Elution Buffer 2 20 mM Tris pH 7.6, 500 mM NaCl, 10% Glycerol, 500 mM Imidazole 
Storing Buffer 20 mM Tris pH 7.6, 100 mM KCl, 10% Glycerol 
 
2.6.11. Overexpression and purification of PseA and PseAXa 
The chemocompetent E. coli BL21 strains were transformed with pET28b_lanA and 
pET28b_lanAXa (Table 8) constructs respectively. The construct contained N-terminal hexa-
histidine pseA and pseAXa fusions. The cultures were inoculated from a single colony of 
transformants and grown overnight at 37 °C in LB broth supplemented with 50 µg/ml 
kanamycin. The overnight culture was used to inoculate 1 L of LB broth, and the cells were 
grown at 37 °C to 0.6 - 0.8 O.D. 600. Expression was induced by the addition of 1 mM IPTG, 
and the culture was incubated at 37 °C for additional 4 h. The cells were harvested by 
centrifugation at 6500 × g for 20 min at 4 °C. The pellet was resuspended in 10 ml start buffer 
and lysed by sonication at 65% intensity for 15 min. DNase and RNase were added to the 
sample, vortexed and incubated on ice for 30 min. Later, the sample was centrifuged at 15,000 
× g for 20 min at 4 °C. The supernatant was discarded and the pellet was resuspended in 10 ml 
start buffer (Table 14). The sonication and centrifugation steps were repeated and the pellet 
was resuspended in 10 ml of buffer 1. The sample was sonicated and centrifuged and the 
supernantant was filtered through a 0.45 µl filter. It was purified by IMAC using a 2 ml Ni
2+
 
column. The extracted sample was loaded onto the column, and the column was washed with 
two column volumes of buffer 1 followed by two column volumes of buffer 2 (Table 14). 
Then the sample was eluted with two column volumes of elution buffer. Fractions were 
analysed by SDS-PAGE; those eluates containing the peptide were pooled and desalted via 
dialysis. Reverse phase HPLC was performed on a C4 column using a gradient of 0 - 100% of 
ACN in 0.1% TFA. 
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Table 14: Buffers used in the purification of PseA. 
Buffer Chemical Ingredients 
Start Buffer 20 mM Sodium phosphate pH 7.5, 500 mM NaCl, 20% Glycerol, 0.5 mM 
Imidazole 
Buffer 1 6 M Guanidine hydrochloride, 20 mM Sodium phosphate pH 7.5, 500 mM NaCl, 
0.5 mM Imidazole 
Buffer 2 4 M Guanidine hydrochloride, 20 mM Sodium phosphate pH 7.5, 300 mM NaCl, 
30 mM Imidazole 
Elution Buffer  4 M Guanidine hydrochloride, 20 mM Sodium phosphate pH 7.5, 100 mM NaCl, 
1M Imidazole 
 
2.6.12. Purification of PseA from inclusion bodies 
The chemocompetent E. coli BL21 strain was transformed with the pET28b_lanAXa or 
pET28b_lanA construct containing the N-terminal hexa-histidine pseAXa or pseA fusions. 
Cultures were inoculated from a single colony of the clones and were grown overnight at 37 
°C in LB broth supplemented with 50 µg/ml kanamycin. The overnight culture was used to 
inoculate 1 L of LB broth, and cells were grown at 37 °C to 0.6 - 0.8 O.D.600. Expression was 
induced by the addition of 1 mM IPTG, and the culture was incubated at 37 °C for additional 
3 h. The centrifuge bottle was weighed before adding the culture. The cells were harvested by 
centrifugation at 6000 × g for 20 min at 4 °C. Again the bottle with pellet was weighed and 
the weight of pellet was calculated. 3 ml of buffer A (Annex XV) per gram of pellet was 
added and the pellet was resuspended. The suspended pellet was transfered into 50 ml falcon 
tubes and 100 mM PMSF was added to make 1 mM final concentration. 16 µl of lysozyme 
(50 mg/ml) was added to the cell suspension and mixed thoroughly. It was then placed in a 
water bath at 37 °C until the solution consistency became viscous. The sample was sonicated 
and then centrifuged at 18000 rpm for 30 min. The supernatant was collected and saved for 
SDS-PAGE and the recovered pellet was resuspended in buffer B (Annex XV) (3 ml/g of 
cell). The same amount of PMSF as in the previous step and 10 µl of TritonX-100 per ml of 
solution were added to the resuspended pellet. It was centrifuged at highest speed for 20 min 
and the supernantant was collected. The remaining pellet (inclusion bodies) was resuspended 
in 20 ml of 8 mM urea with DTT and was heated at 37 - 50 °C to dissolve the pellet. Urea was 
removed by dialysis in 4 L of 50 mM Tris-HCl buffer solution at pH 8.5 using 2 kDa MWCO 
dialysis cassettes for 2 days. The sample was recovered and centrifuged at 20000 rpm for 30 
min and the supernantant was collected and stored in the freezer at -20 °C. After that, the 
extracted protein was purified by HPLC as explained elsewhere. 
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2.6.13. Cotransformation and coexpression 
Equal amounts of pET28b_lanAXa and pET22b∆pelb_lanM, pET28b_lanA and 
pET22b∆pelb_lanM (Table 8) were used to cotransform chemocompetent E. coli BL21 and E. 
coli C41/C43 strains. The transformed competent cells were plated on LB agar plates 
containing kanamycin and ampicillin. 
The cells carrying pET28b_lanAXa and pET22b∆pelb_lanM, and pET28b_lanA and 
pET22b∆pelb_lanM were grown overnight at 37 °C in LB broth supplemented with 
kanamycin and ampicillin. The overnight culture was used to inoculate 1 L of LB broth, and 
the cells were grown at 37 °C to 0.5 - 0.8 O.D. 600. Expression was induced by the addition of 
0.8 mM IPTG, and the culture was incubated at 37 °C for additional 4 h. 2 ml of the culture 
was employed for plasmid extraction and to verify whether both plasmids were maintained for 
20 h after induction. Cells were harvested by centrifugation at 6500 × g for 20 min at 4 °C. 
The pellet was resuspended in 10 ml start buffer and stored at -20 °C. 
 
2.6.14. Purification of modified PseAXa and PseA peptides  
The pellet resuspended in 10 ml start buffer was lysed by sonication at 65% intensity for 15 
min. The sample was centrifuged at 15,000 × g for 20 min at 4 °C. The supernatant was 
discarded and the pellet was resuspended in 10 ml of start buffer. The sonication and 
centrifugation steps were repeated and the pellet was resuspended in 10 ml of buffer 1. Then 
the sample was sonicated and centrifuged. The supernantant was filtered through a 0.45 µl 
filter, and was purified by IMAC using a 2 ml Ni
2+
 column. After loading the sample onto the 
column, it was washed with two column volumes of buffer 1 followed by two column 
volumes of buffer 2. The protein was then eluted with two column volumes of elution buffer. 
Fractions were analysed by SDS-PAGE; those eluates containing the protein were pooled and 
desalted via dialysis. Dialysis was performed using 2,000 MWCO dialysis cassettes, in which 
the peptide sample buffer was exchanged for 0.05% HCl. The sample was further purified 
using a C4 RP-HPLC column and was analysed by MALDI TOF MS. The concentration of 
the peptide was estimated in the Bradford assay.  
 
2.6.15. Factor Xa cleavage of peptide leader sequence 
The protein sample buffer was exchanged for 20 mM Tris-HCl (pH 8) with 100 mM NaCl and 
2 mM CaCl2. Factor Xa (New England Biolabs) was used to remove the leader sequence from 
the PseAXa peptide. Factor Xa was added directly to the PseAXa at a final concentration of 
0.075 mg/ml. The sample was incubated at 4 °C overnight to fully proteolyze the peptide. The 
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reaction was stopped with 0.1% TFA. Then the peptide was desalted by ZipTipC18 and was 
analysed by MALDI TOF MS. The peptide mixture contains both the core peptide and the 
leader peptide. Thus, to separate the core peptide from the leader peptide, a C18 HPLC 
column was employed. The peptide mixture containing the core and the leader was 
centrifuged at 15000 rpm for 2 min, and the resulting supernatant was loaded to the C18 
HPLC column. Finally, all the fractions were analysed by MALDI TOF MS.  
 
2.6.16. Construction of PseAXa mutants 
To elucidate the presence of lanthionine rings in PseAXa, after its modification by PseM, a 
series of PseAXa analogs were made. A single Cys residue on PseAXa was replaced with an 
Ala residue yielding several analogs viz. PseAXaC52A, PseAXaC56A, PseAXaC62A, 
PseAXaC65A, PseAXaC70A and PseAXaC75A (Table 8). Each PseAXa analog was 
coexpressed with the PseM. Then, the modified peptides were purified by IMAC using a 2 ml 
Ni
2+
 column. The fractions were analysed by SDS-PAGE; those eluates containing the protein 
were pooled and desalted via dialysis. Dialysis was performed using 2,000 MWCO dialysis 
cassettes in which the peptide sample buffer was exchanged for 0.05% HCl. Finally, the 
dialysed peptide sample was analysed using MALDI TOF MS. 
 
2.6.17. Iodoacetamide modification assay for detection of free cysteines  
To detect the presence of free cysteine thiols in modified PseAXa, an iodoacetamide assay 
was performed. The modified peptide was incubated with IAA (10 mM) (Sigma Aldrich 
Chemie GmbH, Taufkirchen, Germany) and Tris buffer (50 mm, pH 8.3), in the presence and 
in absence of reducing agent TCEP (1 mM) (Sigma Aldrich Chemie GmbH, Taufkirchen, 
Germany). The reaction mixture was incubated at 25 °C / RT for 45 min in dark. Then, the 
samples were purified by ZipTipC18 and subjected to MALDI TOF MS. Similarly, the IAA 
assay was performed for all the PseAXa mutants, and their masses were analysed by MALDI 
TOF MS.  
 
2.6.18. Trypsin digestion of the peptide 
The modified PseAXa peptide and its mutants were incubated with trypsin (pH 7.6) at 37 °C 
up to 4 h. The samples were drawn after 1 h and 4 h of incubation for MALDI TOF MS.  
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2.6.19. Determination of free didehydro amino acids in the modified peptide 
Mercaptoethanol (βME) was employed to determine the presence of free Dha residues in the 
peptide following Wang et al., (2012). The modified peptide was incubated with 5 mM βME 
in Tris buffer (pH 8.5) for 2 h at 30 °C. The reaction mixture was purified by ZipTipC18 and 
then subjected to MALDI TOF MS.  
 
2.6.20. Determination of minimal inhibition concentration (MIC) 
MIC determinations were carried out in 96 well polypropylene microtiter plates (NuncTM; 
Thermo Fischer Scientific, Schwerte, Germany) employing the standard broth dilution method 
in MH broth with 1.25 mM CaCl2. Test strains were grown to 1 O.D.600 and subsequently 
diluted to 2×10
5
 cells/ml. The peptide was diluted in the range of 12 µM to 0.005 µM by two-
fold dilution steps. 50 µl of the bacterial suspension was mixed with 50 µl of the peptide 
solution, and the inoculated microtiter plate was incubated for 10 min at RT on a microtiter 
shaker (Titertek; Flow laboratories, Mechenheim, Germany). The MIC was read after 24 h of 
incubation at 37 °C without agitation. The results presented are the mean values of at least two 
independent experiments.  
Later the effect of lipid II on the MIC of the peptide was determined. To this end, 
concentrations ranging from 0.25 fold to 3 fold MIC were tested. The peptide and the lipid II 
were mixed in an estimated ratio of 1:1 and 1:2 (peptide: lipid II) with 1.25 mM CaCl2. The 
effect of lipid II on the antibacterial activity of the peptide was observed after 24 h of 
incubation at 37 °C without agitation. 
 
2.6.21. Phosphate determination 
The phosphate determination was performed according to Rouser (1970). To this end, the 
lipid samples were transferred to the phosphate free glass tubes (prepared by rinsing the glass 
tubes with chloroform) and dried at 140 °C for 20 min. Afterwards, 0.3 ml HClO4 (70%, v/v) 
was added, and the tubes were incubated in a block heater at 180 °C for 1 h. After cooling to 
RT, released inorganic phosphate was reduced by adding 1 ml MilliQ water, 0.4 ml 
ammonium molybdate (1.25%, w/v) and 0.4 ml freshly prepared ascorbic acid (5%, w/v) to 
the tube. Then, the tube was incubated in a boiling water for 5 min. The absorption spectrum 
of the blue-coloured complex was read at 795 nm and the phosphate concentrations of the 
samples were calculated by using a standard curve of 0 - 30 nmol inorganic phosphate (stock 
solution: 1 mM KH2PO4). 
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2.6.22. Lipid II binding assay 
In order to detect the binding ability of the active peptide to the lipid II, a lipid II binding 
assay was performed on a TLC sheet. For the binding assay, the substrate lipid II and the 
peptides (at an estimated molar ratio of 1:1, 1:2, 1:3) were incubated at RT for 30 min.  The 
assay was performed in presence and in absence of CaCl2 (final concentration, 1.25 mM). The 
reaction mixture was analysed by TLC using chloroform-methanol-water-
ammoniumhydroxide (88:48:10:1, v/v) as a solvent. Spots or lanes were visualized using 
PMA (2.5%, w/v) staining reagent. Nisin and mersacidin were used as controls. 
 
 54 
 
3. Results 
3.1. The novel lantibiotic gene cluster from Bacillus pseudomycoides DSM 12442 
The genomic data mining found a putative class II lantibiotic gene cluster in Bacillus 
pseudomycoides DSM 12442. Thus, a detailed bioinformatic analysis of the gene cluster was 
performed. The putative structural and modification genes from the cluster were 
heterologously expressed in E. coli. Thus produced proteins were purified and characterized 
by stability assays and MALDI TOF analysis. 
 
3.1.1. Bioinformatic analysis  
A novel putative lantibiotic gene cluster was found in Bacillus pseudomycoides DSM 12442 
(Gene bank accession no NZ_CM000745 NZ_ACMX01000000) (Figure 7) (Zwick et al., 
2012). B. pseudomycoides DSM 12442 is also known as NRRL B-617 (T), and is deposited in 
the Agricultural Research Service Culture Collection, Peoria, IL, USA (Nakamura, 1998). The 
hypothesis proposed for this study is that the putative gene cluster found in B. 
pseudomycoides would result in the production of a novel lantibiotic. Applying the common 
nomenclature for lantibiotic biosynthetic genes, the genes of a putative biosynthetic gene 
cluster in B. pseudomycoides were referred to by ‘pse’.  
The putative lantibiotic structural gene pseA (bpmyx0001_45460) had 40% identity to 
the mrsA gene, which encodes the mersacidin precursor peptide (Bierbaum et al., 1995; 
Chatterjee et al., 1992). Similarly, pseA had 40% identity to amlA, which encodes the 
amylolysin peptide (Arguelles Arias et al., 2013). The downstream ORF (bpmyx0001_45470) 
was predicted to encode the enzyme that performs the post translational modification resulting 
in thioether formation, and was designated pseM. It showed 36% identity to the mersacidin 
modifiying enzyme MrsM of Bacillus amyloliquefaciens (Altena et al., 2000), 37% identity to 
the haloduracin modifying enzyme (HalM1, BH0455) of Bacillus halodurans C-125 
(McClerren et al., 2006; Takami et al., 2000) and 36% identity to the lichenicidin modification 
enzyme LicM1 (Begley et al., 2009; Dischinger et al., 2009; Caetano et al., 2011). As in other 
class II LanMs, PseM contains the conserved Zn-binding motives (Figure 8) GXXHGXXG, 
WCXG and CHG/CCG (Paul et al., 2007). Located immediately downstream of the pseA and 
pseM, pseT (bpmyx0001_45480) was predicted to encode a lantibiotic ABC exporter. PseT 
contains an N-terminal double-glycine peptidase domain and the ATP binding site and shares 
42% identity with the mersacidin exporter (MrsT) (Altena et al., 2000). This ABC exporter 
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may be responsible for the removal of the leader peptide from the modified prepeptide and for 
the export of the modified core peptide. The ORFs bpmyx0001_45490, bpmyx0001_45500 
and bpmyx0001_45510 were predicted to encode the subunits of another ABC transporter and 
may be responsible for self-immunity of the producer strain. They showed 59%, 33% and 
29% similarity to the mersacidin immunity transporter MrsFEG respectively (Altena et al, 
2000 Altena et al., 2000). In addition, there were other ORFs downstream of the gene cluster 
that cannot be directly linked to the lantibiotic gene cluster. Bpmyx0001_45520 is a 
hypothetical protein which has some similarity (27%) to a hypothetical protein BH0831 of B. 
halodurans C-125 (Takami et al., 2000). Likewise, bpmyx0001_45530 is a hypothetical small 
multidrug export protein that has 49% similarity to a hypothetical protein BH1312 of B. 
halodurans C-125. However, both of these proteins were not located within the haloduracin 
gene cluster (McClerren et al, 2006), therefore the corresponding genes of B. pseudomycoides 
were also assumed not to be part of the pseudomycoicidin gene cluster. Bpmyx0001_45540 is 
a hypothetical protein that has similarity to the putative lipoprotein YgaO of B. 
amyloliquefaciens (Blom et al., 2012; Hao et al., 2012). Further downstream 
bpmyx0001_45550 constitutes a helix-turn-helix XRE family like protein that is similar to a 
transcriptional regulator found in some bacilli and might be involved in regulation. In 
conclusion, the biosynthetic gene cluster in B. pseudomycoides represented at least 6 ORFs, 
comprising one of each lantibiotic structural gene (pseA), modification gene (pseM), ABC 
transporter (pseT) and immunity genes (pseFEG) (Figure 7, Table 15). 
In addition to this lantibiotic gene cluster, a  further search for proteins that might be 
involved in antibiotic biosyntheses was performed and indicated the presence of several ORFs 
with similarity to parts of non-ribosomal peptide synthetases, encoded e. g. by 
bpmyx0001__50260 to bpmyx0001_50280 on contig00057 (acc. no. ACMX01000094). 
Contig00076 (acc. no. ACMX01000261) and contig00431 (acc. no. ACMX01000147) also 
represent parts of non-ribosomal peptide biosynthesis operons. Likewise, bpmyx0001_45430 
is similar to the gramicidin S biosynthesis protein GrsT of Aneurinibacillus megulanus 
(Kraetzschmar et al., 2004). Bpmyx0001_52750 constitutes a nonribosomal peptide 
synthetase C that has 48% similarity to the surfactin synthetase subunit 2 of Brevibacillus 
laterosporus GI-9 (NCBI ref seq: WP_003339100.1), 45% similarity to a linear gramicidin 
synthase subunit C of Brevibacillus laterosporus LMG 15441 (NCBI ref seq: 
WP_003337597.1).  
Just upstream of pseA, a short ORF is present which might encode a peptide. This 
sequence (NHYISHYKRGNFTHDKIIQYWNAPARCSTLSTAELSKIPVIPAGNALTKLSSDLPTA 
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LKCQIHIRINFKNFKKYKIYIAFLYKMLIYFRGGI) has 71% identity to the leader peptide of 
PseA. The genome of the producer strain has been deposited in NCBI as a scaffold of 305 
contigs (Zwick et al., 2012). According to the NCBI entry, this sequence is located right at the 
5’ end of contig00045. Since the structural gene is encoded at the 5’ end of contig 00045, the 
upstream sequences of the gene cluster are not yet clear. In the PubMed graphic assembly of 
the genome contigs, contig 00074 is located adjacent to contig 00045. The adjacent gene on 
contig00074 is annotated as a thioredoxin reductase gene (bpmyx0001_45890). The sequence 
in the gap between these two contigs is unknown, however the gap was predicted to have 100 
bp (URL: http://tinyurl.com/k7hhj66). In order to fill this gap, PCR and sequencing were 
performed. Genomic DNA from B. pseudomycoides was used as template for the PCR. 
However, it was not possible to obtain a PCR product that harboured the overlapping 
sequences with contig 00045 and contig 00074. Attempts to use reverse PCR employing the 
primer pairs- rPCRFP1 and rPCRRP1, and rPCRFP2 and rPCRRP1 were also unsuccessful. 
 
 
 
 
Figure 7: Hypothetical lantibiotic gene cluster in Bacillus pseudomycoides. The numbers 
indicate the locus tags of genes, pseA – structural gene, pseM – modification gene, pseT (P) – 
transporter gene, and pseEGF – immunity genes. The arrows indicate the relative direction of 
transcription.  
 
Table 15: Comparision of the putative lantibiotic proteins from B. pseudomycoides with the 
known mersacidin (Mrs) proteins. 
Putative protein from  
B. pseudomycoides  
(no. of aa) 
Mersacidin (Mrs) protein % 
Identity 
Name  
(no. of aa) 
Producer strain Function Reference 
PseA (75) MrsA (68) Bacillus species HIL-
Y85/54728 
Mersacidin 
precursor 
CAB60258 40 
PseM (833) MrsM (822) B. sp HIL-Y85/54728 Modification CAB60261 36 
PseT (729) MrsT (730) B. sp HIL-Y85/54728 ABC 
transporter 
CAB60262 42 
PseG (258) MrsG (252) B. sp HIL-Y85/54728  CAB60256 29 
PseE (248) MrsE (244) B. sp HIL-Y85/54728 Permease CAB60257 34 
PseF (304) MrsF (303) B. sp HIL-Y85/54728 ABC 
transpoter 
CAB60255 58 
 
Bpmyx0001_ 
        
pseA pseM pseT(P) pseEGF 
45460 45470 45480 45490 45500 45510 
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Figure 8: Partial sequence alignment of putative LanM proteins. The aa sequence of 
modification enzyme PseM is compared with MrsM (mersacidin), CinM (cinnamycin), NisC 
(nisin), EpiC (epidermin), HalM (haloduracin), SpaC (subtilin) (Gross et al., 1973; Allgaier et 
al., 1986; McClerren et al., 2006; Marki et al., 1991; Chatterjee et al., 1992; Ryan et al., 
1996). The conserved zinc binding motifs (Zhu et al., 2003; Li et al., 2006; Paul et al., 2007) 
are highlighted in grey.  
901 950 
PseM  FGEHILQKAI PQATGI.GWK ISVSED.... .....A...L P.GFSHGTSG 
HalM  CSEHLMKNAI KTDQGI.GWK PPWEVT.... .....P...L T.GFSHGVSG 
MrsM  CGNRLIQNIN VMEKGV.GWK VPANPT.... .....P...A S.GFAHGASG 
CinM  CAEHLLRHAE DDGTTL.SWP PSAADE.... .....TYGNL T.GFSHGSGG 
NisC  FLSNLTK... .ENNGLISLY IKSENQMSQS ESEMYPLGCL NMGLAHGLAG 
SpaC  YLVRLTEDII VDGEKVPGWH IPSQHQFTDI EKKAYPYGNF NMGLAHGIPG 
EpiC  HILNYFKTIH YSKDN...WL VSNEHQFLDI DKQNFPSGNI NLGLAHGILG 
 
951       1000 
PseM  IVWAL.HELY QLTGEQMLYD ALKQGLAYER SLYMEEKRNW A......... 
HalM  VMASF.IELY QQTGDERLLS YIDQSLAYER SFFSEQEENW L......... 
MrsM  IIWAL.YEIY AITKQTVFKE VAEKALEFER TLFIPEKNNW ADI......K 
CinM  IGWAL.IQLG RHTGRSDYIE AGRKAFAYED RHVDEQEKDW YDL......R 
NisC  VGCILAYAHI KGYSNEASLS ALQKIIFIYE KFELERKKQF LWKDGLVADE 
SpaC  PICVLSSALI QGIKVKGQEA AIEKMANFLL EFSEKEQDSL FWKGIISFEE 
EpiC  PLSLTALSKM NGIEIEGHEE FLQDFTSFLL KPEFKNNNEW FDRYDI.LEN 
 
1001      1050 
PseM  LPSAAELP.. .QLPCAWCHG AAGVVLSRLL LKKA.GYSDS LIDIEIRVGL 
HalM  TPNK.ETP.. .VV..AWCHG APGILVSRLL LKKC.GYLDE KVEKEIEVAL 
MrsM  LENGQFRN.. .DNFVAWCNG AAGIGLSRIL ILPH.NQ.NE LIKDEAHVAI 
CinM  INNGSAVKGA RHFSNAWCNG AAGIGLARIS SWAALDRSDE QLLRDAQQAL 
NisC  LKKEKVIREA SFIRDAWCYG GPGISLLYLY GGLALDN.DY FVDKAEKILE 
SpaC  YQYGSPPNAV NFSRDAWCYG RPGVCLALVK AGKALQN.TE LINIGVQNLR 
EpiC  Y...IPNYSV ...RNGWCYG DTGIMNTLLL SGKALNN.EG LIKMSKNILI 
 
1051      1100 
PseM  ETIIK.EGFG RDHSLCHGDT GNSAVLLLAS KVLKEDLWKQ YSYAVGEHVL 
HalM  STTIR.KGLG NNRSLCHGDF GQLEILRFAA EVLGDSYLQE VVNNLSGELY 
MrsM  NTTLK.YGFE HDQSLCHGDL GNLDILMYAA ENFNKKLSVN VT.ELSHKIL 
CinM  SATLRNFPRL KNHTLCHGTS GNAELLLRFA RLSDEPAFQL EANVQVQALW 
NisC  SAMQRKLG.I DSYMICHGYS GLIEICSLFK RLLNTKKFDS YMEEFNVNSE 
SpaC  YTISDIRG.I FSPTICHGYS GIGQILLAVN LLTGQEYFKE ELQEI...KQ 
EpiC  NIIDKNNDDL ISPTFCHGLA SHLTIIHQAN KFFNLSQVST YIDTI...VR 
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3.1.2 Bioinformatic analysis of putative lantibiotic prepeptide PseA 
The prepetide PseA encodes a peptide of 75 amino acid residues, with a predicted 48-residue 
leader sequence and 27–residue core peptide (Figure 9 A). The leader sequence shows highest 
(37%) similarity to the leader sequence of mersacidin (Bierbaum et al., 1995).The core 
peptide of PseA is rich in Ser (5 residues) and Thr (3 residues). Those residues may dehydrate 
to the corresponding didehydro amino acids. Likewise, the Cys (6 residues) present in the core 
peptide of PseA might form rings with the dehydrated amino acids. The amino acid sequence 
of the predicted prepeptide PseA was compared with the previously known class II 
lantibiotics, e.g. mersacidin, actagardine and haloduracin alpha peptide. (Figure 9 B). As other 
class II prepeptides, PseA contains a GA/GG type of cleavage site. The N-terminus of the core 
peptide contains the conserved lipid II binding motif of class II lantibiotics (CTxS/TxE/DC). 
This motif might be involved in binding of lipid II. In contrast to the leader sequence, the aa 
sequence of the core peptide of PseA does not show significant similarities to any known 
lantibiotic other than the lipid II binding motif.  In addition, the core peptide is characterized 
by a repeating ‘SWSCWSWSC’ motif (Figure 9), which is not common in class II peptides. 
Such motives are also found in the heterocycloanthracins (Haft et al., 2009) and have not yet 
been observed in lantibiotics; the first member of the heterocycloanthracin group, sonorensin 
from Bacillus sonorensis MT93, contains five repeated SCWSC motives and has recently 
been purified (Chopra et al, 2014). 
 
 
 
 
 
 
Figure 9: A) Amino acid sequence of PseA. The Cys residues and possible dehydration sites 
are indicated in grey letters. The cleavage site is highlighted inside the box and the putative 
core region is underlined. B) Sequence alignment of PseA by Clustal W. The amino acid 
sequence of PseA is compared to class II lantibiotics: haloduracin alpha peptide (HalA1), 
mersacidin (MrsA) and actagardine (ActA). AA similarities are highlighted in light grey, 
while the lipid II binding motif (CTxS/TxE/DC) is highlighted in dark grey. (Note: aa 
alignment of the PseA core peptide with other additional peptides is provided in Figure 36, 
page no. 97). 
(A) 
(B) 
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3.2. Characterization of B. pseudomycoides DSM 12442 
Bacillus pseudomycoides DSM 12442 is a Gram-positive, rod shaped and spore forming 
bacterium. It was sensitive to chloramphenicol and erythromycin (data not shown). It grows as 
rapidly spreading rhizoidal colonies on agar plates (Figure 10), and does not produce a zone 
of haemolysis on blood agar plates. 
 
 
 
Figure 10: Rapidly growing rhizoidal colonies of B. pseudomycoides on an agar plate 
incubated at 37 °C overninght. 
 
3.3. Production of an antimicrobially active substance by B. pseudomycoides  
B. pseudomycoides DSM 12442 produced an antimicrobial substance, when it was grown in 
50 ml TSB, LB or NB in 500 ml flasks, at 30 °C or 37 °C with agitation after 21, 24, 45 or 48 
h; although the highest yield was observed in TSB broth incubated at 30 °C after 24 h. Cells 
were removed by centrifugation and the supernatant was collected. The pellet was 
resuspended in 70% isopropanol and incubated at 4 °C for 4 h under continuous stirring. The 
cells were removed by centrifugation and the cell wash extract was collected. Finally, the 
isopropanol was removed from the extract by evaporation. 
The crude culture supernatant and the isopropanol cell wash extract were assayed for 
their antimicrobial activity in an agar well diffusion assay against different indicator strains. 
The crude culture supernatant did not show antimicrobial activity (Figure 11). However, the 
isopropanol cell wash extract exhibited antimicrobial activity against most of the Gram-
positive bacteria, such as Micrococcus luteus, Staphylococcus aureus, S. simulans, Bacillus 
sp., Enterococcus sp., Lactococcus sp., Streptococcus sp., etc, but not against Gram-negative 
bacteria and yeasts (Figure 12). An analysis of the isopropanol cell wash extract by MALDI 
TOF MS showed a distinct mass signal at m/z 2786.5 that might correspond to the active 
compound. 
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Figure 11: Agar well diffusion assay. The isopropanol cell wash extract (I) showed 
antimicrobial activity against M. luteus, but not the supernatant (II).   
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Figure 12: Antimicrobial spectrum of the isopropanol cell wash extract produced by B. 
pseudomycoides against selected bacteria (Gram-positive and Gram-negative) and the yeast C. 
albicans. Antimicrobial activity was determined by an agar well diffusion assay. 
 
3.4. Purification of the antimicrobially active substance from B. pseudomycoides 
The first attempts to purify the antimicrobially active substance by (NH4)2SO4 precipitation 
failed. Hence, a commercially available anion exchange column, a cation exchange column 
and an XAD column were tested for the purification. The antimicrobial substance was loaded 
onto these columns and eluted with the appropriate buffer solutions. On all of three columns, 
the active fraction was either eluted in the flowthrough fraction or the active fraction was not 
I 
II II 
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eluted from the column at all. Thus, the purification of the active compound using these 
columns was unsatisfactory. 
 
HPLC purification and MALDI TOF analysis 
A Poros RP-HPLC column and a C18 HPLC column were employed for further purification. 
2 ml cell wash extract, containing 0.1% trifluoroacetic acid (TFA, Sigma-Aldrich, 
Taufkirchen, Germany) was loaded onto a Poros column and eluted in a gradient of 20% to 
100% ACN (containing 0.1% TFA). The peaks were detected at an absorbance of 220 nm 
(Figure 13). The fractions were collected and assayed for the antimicrobial activity against M. 
luteus ATCC 4698 in an agar well diffusion assay. The fraction collected at 20 - 30% of ACN 
showed a zone of inhibition. The active fraction was analysed by MALDI TOF MS in the 
range of 1500 to 4000 Da, which showed the mass signal at m/z 2786.5. The fraction was 
further purified by rechromatography on a C18 column. The peaks were detected by an 
absorbance at 220 nm and 266 nm (Figure 14). Different fractions were collected and assayed 
for the antimicrobial activity against M. luteus in an agar well diffusion assay. The active 
fraction was analysed by MALDI TOF MS. Again, the MALDI TOF analysis yielded a mass 
signal at m/z 2786.026 for the active fraction (Figure 15). The minor signals m/z 1731.3 and 
2818.6 (two fold dehydrated) were also observed in MALDI TOF MS. The observed mass 
(2786.026 Da) of the active fraction matched to the calculated mass of the unmodified 
corepeptide with possible 1, 4 or 8 putative dehydrations (Table 16).  
 
 
 
Figure 13: HPLC chromatogram of the cell wash extract from B. pseudomycoides. The cell 
wash extract was applied to a Poros RP-HPLC column and eluted in a gradient of 20% to 
100% acetronitrile (containing 0.1% TFA). The active fraction was eluted after 4 min by 20 - 
30% acetronitrile. 
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Figure 14: HPLC chromatogram of the cell wash extract from B. pseudomycoides. The cell 
wash extract was applied to a C18 RP-HPLC column and eluted in a gradient of 20% to 100% 
acetronitrile (containing 0.1% TFA). The active fraction was eluted by 20 - 30% acetonitrile 
at around 10 min as indicated by the box. 
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Figure 15: MALDI TOF MS of the active cell wash extract from B. pseudomycoides after two 
consecutive HPLC runs showing the distinct mass of 2786.026 Da.  
 
3.5. Stability assay of the antimicrobial substance from B. pseudomycoides 
 For a further characterization of the antimicrobial compound, its stability against heat, pH and 
organic solvents, as well as resistance against proteases were determined. The antimicrobial 
activity of the cell wash extract was fully stable at 20 - 80 °C, even up to the observed period 
of 4 h. But at 100 °C, the cell wash extract was stable only up to 1 h and further incubation 
reduced its stability (Figure 16 A). Likewise, at low pH (3 - 5) the compound was stable even 
up to 4 h; however at moderate pH (6 - 8), it was stable only up to 1 h; and at very high pH (9 
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- 11), the activity was completely lost (Figure 16 B). Likewise, it was relatively stable against 
various organic solvents - ethanol, methanol, acetone, acetonitrile and isopropanol (Figure 16 
C). Finally, in the protease susceptibility test, the compound was sensitive to proteinase K and 
pronase E indicating that the substance might be a peptide, but resistant to trypsin (data not 
shown).  
 
 
 
 
 
 
Figure 16: Stability assays: A) Effect of heat treatment on the antimicrobial activity of the 
cell wash extract. B) Effect of pH on the antimicrobial activity of the cell wash extract. Bars at 
pH 2 represent the control. C) Effect of different organic solvents on the antimicrobial activity 
of the cell wash extract. Antimicrobial activity was observed against M. luteus by an agar well 
diffusion assay.  
A) 
B) 
C) 
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In order to verify the ability of the producer strain to excrete proteases during the 
antibiotic production, a protease production test was performed. In the test, the producer strain 
produced a protease in the culture supernatant (as observed on skim milk agar plates). 
Although, the culture supernatant exhibited the protease activity, the activity of the cell wash 
extract (against M. luteus) was not lost even after its incubation with the culture supernatant 
up to 2 h (Figure 17). This indicates that the compound was resistant against the proteases 
excreted by the producer.  
 
 
 
Figure 17: Antimicrobial activity of the isopropanol extract, the supernatant and the 
coincubation of isopropanol extract with the supernatant. The indicator strain used was M. 
luteus. 
 
3.6. SDS-PAGE analysis of the antimicrobial substance from B. pseudomycoides 
In an SDS-PAGE, the peptide bands could not be visualized (data not shown). But, when the 
polyacrylamide gel was placed onto an agar plate seeded with M. luteus, a zone of inhibition 
was observed. This observed inhibition zone might be due to the presence of the peptide in the 
SDS-PAGE. In addition, as inhibition zone was observed at the lower end of the gel, it could 
be speculated that the peptide is of low molecular weight (less than 10 kDa).  
 
 
3.7. Is the active substance encoded by the lantibiotic gene cluster? 
To verify the relation between the bioinformatically predicted lantibiotic gene cluster and the 
antimicrobial substance produced by B. pseudomycoides, the following experiments were 
conducted. Owing to its rhizoidal colony morophology, a knock out strategy for inactivation 
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of putative modification gene (pseM), and subsequent test of the mutant for its ability to 
produce the antimicrobial substance was difficult. Hence, as an alternate strategy, the putative 
structural (pseA) and modification (pseM) genes from the predicted gene cluster of B. 
pseudomycoides were heterologously expressed in E. coli and the clone was checked for its 
ability to produce an antimicrobial substance. 
 
 
3.7.1. Cloning of pseM in pET22b∆pelb 
The gene encoding the putative modification enzyme (PseM) of the lantibiotic gene cluster of 
B. pseudomycoides was introduced into the pET22b∆pelb vector to express a C-terminally 
His-tagged PseM. The complete sequence of pseM was amplified by PCR, using the PseMfor 
and PseMrev primer pair, and the genomic DNA of B. pseudomycoides DSM 12442 as a 
template. The resulting PCR fragment was 3223 bp long and lacked the terminal stop codon. 
This constructed expression vector was named pET22b∆pelb_lanM. 
 
3.7.2. Cloning of pseA in pUC19 and pET28b  
Using the genomic DNA isolated from B. pseudomycoides as a template and the PseAfor and 
PseArev primer pair, pseA was amplified by PCR. The resulting PCR fragment was 
subsequently digested by BamHI and HindIII, and was ligated into the corresponding 
restriction site of pUC19. In addition, to obtain the N-terminally His-tagged prepetide, pseA 
was cloned into the pET28b vector. The gene was amplified using the PseAforI and PseArevI 
primer pair. The resulting PCR fragment was 229 bp. It was subsequently digested by NdeI 
and XhoI and ligated into the corresponding restriction sites of pET28b. The resulting 
expression vector was named pET28b_lanA, and was confirmed by sequencing. Finally the 
constructed recombinant vectors were introduced into the expression strain E. coli BL21. 
 
3.8. Introduction of factor Xa cleavage sequence into precursor peptide PseA 
In order to investigate the biological activity of the peptides, the leader peptide must be 
removed. Thus, to facilitate the removal of leader sequence in vitro, an engineered factor Xa 
protease cleavage site was introduced into pseA. There were two possible cleavage sites in the 
PseA peptide viz. GA and GG. If ‘GG’ was chosen as a cleavage site, the calculated mass of 
the core peptide after cleavage would be much smaller than the observed mass of the active 
extract (i.e. 2786 Da) (Table 16). Additionally, if GG was the possible cleavage site, there 
would be a Cys residue within the leader sequence, which is unusual for lantibiotics. But if the 
GA motif was chosen for the cleavage (Figure 9 A), the calculated mass of the core peptide 
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would match the observed mass of the active extract with four dehydrations. In a first attempt, 
the GA motif was chosen to introduce the factor Xa protease cleavage site into pseA. The 
pET28b_lanA recombinant vector was used as a template to introduce the factor Xa 
recognition sequence by a mutagenesis approach. Immediately N-terminal to the putative GA 
cleavage site of the PseA peptide, the last four amino acid residues ‘VVGA’ were replaced 
with the factor Xa recognition sequence ‘IEGR’ (Figure 18) using the PseAXafor and 
PseAXarev primer pair. Finally, the N-terminal hexa-histidine lanAXa_pET28b construct was 
transformed into the expression strain E. coli BL21. 
 
 
 
Figure 18: Introduction of the factor Xa cleavage site into PseA. The four aa ‘VVGA’ were 
replaced by the factor Xa cleavage site ‘IEGR’ by site directed mutagenensis and are 
indicated by underline. 
 
PseA :  
IEGR GDCGGTCTWT KDCSICPSWSCWSWSC 
MNDKIIQYWNDPAKRSTLSAAELSKMPVNPAGDILAELSDADLDK VVGA GDCGGTCTWT KDCSICPSWSCWSWSC 
MNDKIIQYWNDPAKRSTLSAAELSKMPVNPAGDILAELSDADLDK  
PseAXa :  
  
6
7 
Table 16: Calculated molecular weights of PseA peptides depending on the dehydration states of the active peptide. Masses predicted to represent 
the mass of the active peptides as indicated by MALDI TOF MS are highlighted in grey. The possible cleavage sites (GA / GG) in aa- sequences are 
shown in bold letters. 
 
AA- Sequence 
 Number of putative dehydrations and corresponding molecular  weight (Da) 
0 1 2 3 4 5 6 7 8 
GAGDCGGTCTWTKDCSICPSWSCWSWSC 2987.10 2969.1 2951.1 2933.1 2915.1 2897.1 2879.1 2861.1 2843.1 
AGDCGGTCTWTKDCSICPSWSCWSWSC 2931.2 2913.2 2895.2 2877.2 2859.2 2841.2 2823.2 2805.2 2787.2 
GDCGGTCTWTKDCSICPSWSCWSWSC 2859.04 2841.04 2823.04 2805.04 2787.04 2768.04 2751.04 2733.04 2715.04 
DCGGTCTWTKDCSICPSWSCWSWSC 2803.1 2785.1 2767.1 2749.1 2731.1 2713.1 2695.1 2677.1 2659.1 
CGGTCTWTKDCSICPSWSCWSWSC 2688 2670 2652 2634 2616 2598 2580 2562 2544 
GGTCTWTKDCSICPSWSCWSWSC 2584.9 2566.9 2548.9 2530.9 2512.9 2494.9 2476.9 2458.9 2440.9 
GTCTWTKDCSICPSWSCWSWSC 2527.8 2509.8 2491.8 2473.8 2455.8 2437.8 2419.8 2401.8 2383.8 
TCTWTKDCSICPSWSCWSWSC 2470.8 2452.8 2434.8 2416.8 2398.8 2380.8 2362.8 2344.8 2326.8 
CTWTKDCSICPSWSCWSWSC 2369.7 2351.7 2333.7 2315.7 2297.7 2279.7 2261.7 2243.7   
TWTKDCSICPSWSCWSWSC 2266.5 2248.5 2230.5 2212.5 2194.5 2176.5 2158.5 2140.5   
WTKDCSICPSWSCWSWSC 2165.4 2147.4 2129.4 2111.4 2093.4 2075.4 2057.4     
TKDCSICPSWSCWSWSC 1979.2 1961.2 1943.2 1925.2 1907.2 1889.2 1871.2     
KDCSICPSWSCWSWSC 1878.1 1860.1 1842.1 1824.1 1806.1 1788.1       
DCSICPSWSCWSWSC 1749.9 1731.9 1713.9 1695.9 1677.9 1659.9       
CSICPSWSCWSWSC 1634.8 1616.8 1598.8 1580.8 1562.8 1544.8       
SICPSWSCWSWSC 1531.7 1513.7 1495.7 1477.7 1459.7 1441.7       
ICPSWSCWSWSC 1444.6 1426.6 1408.6 1390.6 1372.6         
CPSWSCWSWSC 1331.5 1313.5 1295.5 1277.5 1259.5         
PSWSCWSWSC 1228.3 1210.3 1192.3 1174.3 1156.3         
SWSCWSWSC 1131.2 1113.2 1095.2 1077.2 1059.2         
WSCWSWSC 1044.1 1026.1 1008.1 990.1           
SCWSWSC 857.9 839.9 821.9 803.9           
CWSWSC 770.8 752.8 734.8             
WSWSC 667.7 649.7 631.7             
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3.9. Heterologous expression and purification of PseM 
After overexpressing the pET22Bpelb_lanM recombinant vector in E. coli BL21, the purified 
His-tagged PseM was successfully obtained. The presence of PseM was verified in the SDS-
PAGE. Those eluates (lanes) that had a protein band with a MW equivalent to the calculated 
mass of His-tagged PseM (124 kDa) were confirmed to have the PseM (Figure 19).  
 
                          
 
Figure 19: SDS-PAGE analysis of His-tagged PseM purified by Ni-NTA affinity 
chromatography. Purified His-tagged PseM protein was analysed by SDS-PAGE (15%) and 
stained with Page Blue protein staining solution. Lane 1 = Prestained protein marker (kDa), 
Lane 2 = flowthrough, Lanes 3 - 5 = wash fractions and Lanes 6 - 13= eluates. The 124 kDa 
PseM protein was frequently observed in the wash fractions and in the eluates 7 - 8 (indicated 
inside the box). 
 
3.10. Heterologous expression and purification of the PseA and PseAXa peptides 
Heterologous expression of the recombinant vectors - pET28b_lanA and pET28b_lanAXa in 
E. coli BL21 was performed, followed by Ni-NTA purification (McClerren et al., 2006). 
However, the His-tagged PseA and the His-tagged PseAXa could not be purified under the 
previously established expression and purification conditions. Additional attempts to purify 
PseA and PseAXa from the inclusion bodies were also not successful. Based on these results, 
it was assumed that the recombinant PseA and PseAXa might be toxic to E. coli BL21. 
Therefore, pET28b_lanA and pET28b_lanAXa were transformed into E. coli C41 and E. coli 
130 
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35 
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C43 (which are optimized for overexpression of toxic proteins). However, overexpression of 
PseA and PseAXa in E. coli C41 or E. coli C43 strains was not successful either, indicating 
that the unmodified PseA / PseAXa might be unstable in E. coli. 
 
3.11. Cotransformation and coexpression 
Since PseA and PseAXa purification was not successful, a cotransformation and coexpression 
strategy was adopted. The chemocompetent E. coli BL21 and E. coli C43 were transformed 
with pET28b_lanAXa and pET22b∆pelb_lanM, or pET28b_lanA and pET22b∆pelb_lanM 
vectors. The transformed E. coli strains were grown and induced to coexpress PseA and PseM 
or PseAXa and PseM. Both the plasmids were stable after induction, as verified by the 
presence of full pET28b_lanAXa and pET22b∆pelb_lanM plasmids (Figure 20 A), or 
pET28b_lanA and pET22b∆pelb_lanM plasmids (data not shown) in the agarose gel 
electrophoresis. Growth curves of transformed E. coli BL21 containing PseA, PseAXa, 
PseA+PseM and PseAXa+PseM were compared. All the transformed bacteria grew well in 
the liquid media. However, the optical densities of the bacterial cultures harbouring a single 
expression of PseA or PseAXa had a relatively lower O.D. 600 (0.67) as compared to the 
coexpressed PseA+PseM or PseAXa+PseM (1.4) (Figure 20 B). This indicates that the single 
expression of PseA or PseAXa were toxic to the bacteria, while in the presence of PseM i.e. in 
PseA+PseM or PseAXa+PseM, the toxicity of of PseA or PseAXa was reduced.  
 
A)                   B) 
  
 
 
Figure 20: A) Agarose gel electrophoresis of plasmid preparations containing both the 
recombinant vectors pET22b∆pelb_PseM and pET28b_PseAXa as shown by the arrows. B) 
Growth rate of E. coli BL21 harbouring PseA, PseAXa, PseA+PseM and PseAXa+PseM after 
induction of protein expression.  
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3.12. Purification of modified PseA and PseAXa 
The His-tagged PseA and PseAXa were purified by Ni-NTA affinity chromatography 
according to McClerren et al. (2006). All the eluates were analysed by SDS-PAGE. 
Successful production of modified PseA and PseAXa was verified by the presence of protein 
bands of 10.20 kDa in SDS-PAGE (Figure 21), which matched the predicted mass of the 
peptide calculated from its aa sequence. The additional bands (approximately 24 kDa) 
observed in lanes 5 and 6 might correspond to the dimers of the peptide. The eluates 
containing PseA or PseAXa were dialysed using a 2,000 MWCO dialysis cassette. The 
peptide sample buffer was exchanged with 0.05% HCl for MALDI TOF MS. The 
concentrations of the peptides were measured using the Bradford assay. 
 
 
 
Figure 21: SDS-PAGE analysis of His-tagged PseAXa purified by Ni-NTA affinity 
chromatography. Purified His-tagged PseAXa protein was analysed by SDS-PAGE (20%) and 
stained with Page Blue protein staining solution. Lane 1 = Prestained protein marker (kDa), 
Lane 2 = flowthrough, Lanes 3 - 4 = wash fractions and Lanes 5 - 9 = eluates. A 10.2 kDa 
peptide that matched the calculated MW of PseAXa was observed in the eluates 5 - 7 as 
indicated inside the box. 
 
The peptide was further purified using HPLC. The peptide was loaded on a C4 column 
and the active fraction was eluted with 100% ACN with 0.1% TFA after 21 - 23 min (Figure 
22). All the fractions were analysed by MALDI TOF MS. The analysis showed a major mass 
signal at m/z 10203 and minor mass signals (m/z 10236, 10253 and 10271 which might 
represent the incompletely modified peptides with two-, one-fold dehydrated and unmodified 
peptide) (Figure 23). The observed molecular weight (10203 Da) of the peptide was 74 Da 
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smaller than the calculated MW of the ion of the unmodified propeptide (m/z 10277.4). This 
reduction in molecular weight of the peptide might be due to the loss of four water molecules 
during posttranslational modification indicating that the peptide obtained by coexpression was 
the modified product and that out of 8 Ser/Thr residues in putative core peptide; only 4 had 
been dehydrated during modification. Thus, 4 Ser/Thr escaped the dehydration step; a 
phenomenon that is not uncommon in lanthionine containing peptides. 
 
 
Figure 22: HPLC chromatogram of the modified PseAXa. The modified PseAXa was 
obtained in the fraction eluted by 100% acetronitrile with 0.1% TFA at 21 - 23 min.  
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Figure 23: MALDI TOF MS of the modified PseAXa peptide (10203.7 Da) produced by 
coexpression of PseAXa with PseM in E. coli. The minor signals (m/z 10236, 10253 and 
10271) might represent peptides with incomplete modification. 
 
The PseAXa protein sample buffer was exchanged for buffer containing 20 mM Tris-
HCl (pH 8), 100 mM NaCl and 2 mM CaCl2 through dialysis prior to digestion by factor Xa. 
Then the peptide was incubated with factor Xa protease at 4 °C overnight. The reaction was 
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stopped by 0.1% TFA. An aliquot of the reaction was purified using a ZipTipC18, and was 
analysed by MALDI TOF MS. The analysis revealed a mass of 2785.6 Da (Figure 24 A) that 
matched the calculated MW of the core peptide with four fold dehydration (Table 16, page 
67) and as well as minor mass signals representing traces of the one-, two- and three fold 
dehydrated core peptides were observed. MALDI TOF MS also revealed the three other 
masses (2171.3 Da, 3526.4 Da and 5679.8 Da), which might be attributed to the fragments of 
the leader peptide (Figure 24 A and Table 17). The mass of the core peptide was consistent 
with the mass obtained from the cell wash extract of B. pseudomycoides with four 
dehydrations. An attempt to separate the core peptide from the leader peptide fragments using 
HPLC was not successful so far.  
In addition, the modified prepeptide was incubated with trypsin for 4 h and yielded a 
mass signal at m/z 2785.7 (Figure 24 B), corresponding to the mass of the core peptide. 
Additionally, a mass signal was observed at m/z 2538.6, which corresponded to calculated 
mass of the N-terminal tryptic fragment (GSSHHHHHHSSGLVPRGSHMNDK) of the leader 
sequence.  
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Figure 24: MALDI TOF MS of PseAXa after digestion by (A) factor Xa and (B) trypsin. 
Inset: Amino acid sequence of PseA showing a possible cleavage site (↓) for trypsin. The 
peptide was not cleaved which indicates that a ring structure might prevent activity of the 
enzyme. 
Furthermore, the heterologously produced peptide showed antimicrobial activity after 
the proteolytic removal of the leader sequence from the modified lantibiotic precursor (Figure 
25). This heterologously produced active peptide was named pseudomycoicidin. 
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Figure 25: Detection of antimicrobial activity of the peptide after cleavage of the leader 
peptide by spot on the lawn method. Spot 1 = factor Xa cleavage buffer, spot 2 = peptide 
before removal of the leader, spot 3 = peptide after removal of the leader, inhibition zone is 
indicated by arrow, and spot 4 = not used.  
 
Table 17: The calculated masses of peptide fragments of PseAXa that could be generated 
(with predicted molecular weight before and after dehydration), when digested by factor Xa 
(after every Arg residue). Observed masses are indicated in bold (core peptide) or italics 
(leader sequences).  
 
PseAXa fragments 
 
Molecular weight (Da) with possible dehydrations 
-0 H2O -1 H2O -2 H2O -3 H2O -4 H2O 
GSSHHHHHHSSGLVPRGSHMNDKIIQYWNDPAKR
STLSAAELSKMPVNPAGDILAELSDADLDKIEGRG
DCGGTCTWTKDCSICPSWSCWSWSC 
10276.4 10258.4 10240.4 10222.4 10204.4 
GSSHHHHHHSSGLVPR 1768.8         
GSHMNDKIIQYWNDPAKRSTLSAAELSKMPVNPA
GDILAELSDADLDKIEGRGDCGGTCTWTKDCSICP
SWSCWSWSC 
8525.5 8507.5 8489.5 8471.5 8453.5 
GSSHHHHHHSSGLVPRGSHMNDKIIQYWNDPAKR 3924.2         
GSSHHHHHHSSGLVPRGSHMNDKIIQYWNDPAKR
STLSAAELSKMPVNPAGDILAELSDADLDKIEGR 
7430.2         
GDCGGTCTWTKDCSICPSWSCWSWSC 2859.04 2841.04 2823.04 2805.04 2787.04 
STLSAAELSKMPVNPAGDILAELSDADLDKIEGRG
DCGGTCTWTKDCSICPSWSCWSWSC 
6370.1 6352.1 6334.1 6316.1 6298.1 
STLSAAELSKMPVNPAGDILAELSDADLDKIEGR 3526.79         
GSHMNDKIIQYWNDPAKRSTLSAAELSKMPVNPA
GDILAELSDADLDKIEGR 
5683.3         
GSHMNDKIIQYWNDPAKR 2173.4         
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3.13. Determination of free Cys and free Dha residues in the peptide  
To determine the number of lanthionine rings in the peptide, the following experiments were 
performed. When a peptide contains a free Cys residue, IAA reacts with the Cys residue 
leading to an increase in its mass by 57 Da. This increase in the peptide mass ultimately 
proves the absence of a lanthionine ring (McClerren et al., 2006). In this study, the presence 
of free Cys was determined by alkylation with IAA together with and without the reducing 
agent TCEP. When the PseAXa peptide was treated with IAA in the presence of TCEP, its 
mass increase indicated the presence of two IAA adducts (approx. 114 Da). This increase in 
mass corresponded to the alkylation of two Cys in the core peptide (Figure 26). In contrast, in 
absence of TCEP, the IAA assay did not result in any increase in the mass of the peptide 
(Figure 26). This indicates that the two SH-groups might be tied up by a disulfide linkage. On 
the other hand, the other four Cys residues might be involved in the Lan or the MeLan ring 
formation. When the peptide was treated with TCEP, there was an increase in the mass of the 
peptide by 2 Da (10205 Da) (Figure 26). This increase in the peptide mass also indicated the 
presence of a disulfide bond in the peptide.  
Likewise, addition of βME will result in an increase of 79 Da if a free Dha residue is 
present. However, when the peptide was incubated with βME, a βME adduct was not detected 
(Figure 26). This indicates the absence of free Dha residues in the PseAXa peptide. However, 
the treatment with βME led to an addition of 2 Da in the mass of the peptide. Altogether, 
above results suggest the presence of four lanthionine rings and one disulfide linkage in the 
PseA peptide. Thus, the heterologously produced peptide was confirmed to be a modified 
lantibiotic. 
In addition to the lanthionine rings, the disulfide bond might also be essential for the 
activity of the peptide. To evaluate the importance of the disulfide bond in the peptide, the 
PseA peptide was incubated with TCEP. The breaking of disulfide link following TCEP 
treatment abolished the antibacterial activity of the peptide compared to control peptide 
without TCEP (Figure 27). This indicates that the disulfide bond is essential for the activity of 
the peptide. 
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Figure 26: MALDI TOF MS of (A) heterologously produced peptide (B) peptide after TCEP 
treatment (C) peptide after incubation with IAA in absence of TCEP (D) peptide after IAA 
treatment in presence of TCEP and (E) peptide after incubation with βME.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27: Activity assay of (A) PseAXa (B) PseAXa peptide treated with TCEP and (C) 
TCEP control, against M. luteus using the spot on the lawn method. 
A B 
C 
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3.14. Determination of the ring topology of the modified PseA  
To obtain the preliminary informations on the ring topology of the modified PseA, six 
PseAXa analogs were created. Those analogs were created by replacing single Cys by Ala 
residues as shown in Figure 28. Each PseAXa mutant was coexpressed along with PseM in E. 
coli C41 and was purified. The purified mutant peptides were named PseAXaC52A, 
PseAXaC56A, PseAxaC62A, PseAxaC65A, PseAXaC70A and PseAXaC75A.  
 
Figure 28: The aa sequences of PseAXa and its mutant peptides. The mutant peptides were 
constructed by replacing single Cys with Ala residue in the core peptide region of PseAXa. 
The replaced aa are highlighted. 
 
Mutant peptides were successfully purified by Ni-NTA chromatography as verified by 
the presence of a protein band of approximately 10.2 kDa in SDS-PAGE for each mutant 
(data not shown). After dialysis they were analysed by MALDI TOF MS. The analysis of the 
mutated peptides showed a mixture of prepeptides with different dehydration stages (Figure 
29).  
MALDI TOF MS of PseAXaC52A showed a main peak (10227 Da), which seemed to 
correspond to the one fold dehydrated mass (Figure 29 A). After incubation with TCEP, the 
fully modified peptide was observed as the main peak (10173 Da) (Figure 29 a, Annex XXII). 
The IAA assay showed that after incubation with TCEP, one IAA adduct was coupled to the 
peptide, indicating that PseAXaC52A had one free Cys residue (Annexes XX and XXI). 
When PseAXaC52A was incubated with trypsin, a weak signal with the mass of the core 
peptide (2755 Da) was retained. This indicates the presence of the thioether ring(s) that 
protected the PseAXaC52A from trypsin digestion at least in a small fraction. In addition, 
there were other mass signals observed for N-terminal leader fragment (m/z 2540) and 
fragments generated by trypsin self digest (m/z 1676, 2195). 
Leader Core 
1                    10                      20                       30                  40                     50                         60                    70         
PseAXa MNDKIIQYWNDPAKRSTLSAAELSKMPVNPAGDILAELSDADLDKIEGRGDCGGTCTWTKDCSICPSWSCWSWSC 
PseAXaC52A  MNDKIIQYWNDPAKRSTLSAAELSKMPVNPAGDILAELSDADLDKIEGRGDAGGTCTWTKDCSICPSWSCWSWSC 
PseAXaC56A  MNDKIIQYWNDPAKRSTLSAAELSKMPVNPAGDILAELSDADLDKIEGRGDCGGTATWTKDCSICPSWSCWSWSC 
 
PseAXaC62A  MNDKIIQYWNDPAKRSTLSAAELSKMPVNPAGDILAELSDADLDKIEGRGDCGGTCTWTKDASICPSWSCWSWSC 
 
PseAXaC65A  MNDKIIQYWNDPAKRSTLSAAELSKMPVNPAGDILAELSDADLDKIEGRGDCGGTCTWTKDCSIAPSWSCWSWSC 
PseAXaC70A  MNDKIIQYWNDPAKRSTLSAAELSKMPVNPAGDILAELSDADLDKIEGRGDCGGTCTWTKDCSICPSWSAWSWSC 
PseAXaC75A  MNDKIIQYWNDPAKRSTLSAAELSKMPVNPAGDILAELSDADLDKIEGRGDCGGTCTWTKDCSICPSWSCWSWSA 
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MALDI TOF of PseAXaC56A showed a main peak at 10225 Da that again resembled 
to a one fold dehydrated mass (Figure 29 B). After incubation of PseAXaC56A with TCEP, 
the main peak (10172 Da) indicating the four fold dehydrated stage was observed (Figure 29 
b). The IAA and βME assays predicted the presence of one free Cys residue and one free 
Dha/Dhb residue in PseXaC56A (Annexes XX, XXI and XXII). The mass of the core peptide 
(2756 Da) was retained after incubation with trypsin, indicating the presence of at least one 
thioether ring that protected the peptide from trypsin digestion (Figure 30 c). Additionally, 
mass signals for leader fragments (m/z 2178, 2398) and trypsin fragments (m/z 1112.5, 
1434.7, 3154.1) were observed in MALDI TOF MS of the digest. 
MALDI TOF MS of PseAXaC62A showed one main peak at 10225.6 Da that 
represented the one fold dehydrated mass (Figure 29 C). When the peptide was incubated with 
TCEP, a main peak with a mass at 10228 Da appeared that again corresponded to a one fold 
dehydrated state (Figure 29 c, Annex XXIII). When PseAXaC62A was incubated with 
trypsin, it was completely digested by trypsin as indicated by the absence of the core peptide 
signal in MALDI TOF MS (Figure 30 d). However, a mass signal for N-terminal leader 
fragment (m/z 1768) was observed. These imply that all the thioether rings spanning the 
trypsin cleavage site were not closed in PseAXaC62A. 
MALDI TOF MS of PseAXaC65A showed, a major peak at 10206.1 Da that matched 
to the two fold dehydrated mass (Figure 29 D). When incubated with TCEP, the peptide 
displayed one main peak at 10207 Da that fitted to the two fold dehydrated state (Figure 29 d, 
Annex XXIII). PseAXaC62A was completely digested by trypsin as the core peptide signal 
did not appear in MALDI TOF MS (Figure 30 e). However, a mass signal for N-terminal 
leader fragment (m/z 1768) was observed. These findings indicate that not all the thioether 
rings were closed in PseAXaC65A. 
MALDI TOF MS of PseAXaC70A showed a major signal at m/z 10190.2 and a minor 
signal at m/z 10412 Da (Figure 29 E). The major signal corresponded to three fold dehydrated 
mass. After TCEP addition, this peptide showed one main peak with mass of 10190 Da that 
resembled a three fold dehydrated stage. The other peak with the observed mass of 10494 Da 
(10190 + 304 Da) was indicative of a glutathione adduct (GSH) (Figure 29 e, Annex XXIII). 
The IAA and βME assays predicted the presence of two free Cys residues and absence of 
Dha/Dhb residues in PseAXaC70A (Annex XX, XXI and XXII). The mass of the core peptide 
(2773 Da) was retained even after incubation with trypsin (Figure 30 f). In addition, there was 
a mass signal for N-terminal fragment of the leader (m/z 2539.9) in MALDI TOF MS. These 
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results indicated that the PseAXaC70A might have three thioether rings and one disulfide 
link. 
MALDI TOF MS of PseAXaC75A showed one major peak of 10224.4 Da, that 
resembled to its one fold dehydrated state and the minor peaks at m/z 10174, 10190, 10207 
and 10241, that corresponded to four, three, two fold dehydrated states and unmodified state 
respectively (Figure 29 F). After incubation with TCEP, one major peak with a mass of 10174 
Da (4 fold dehydrated state) was observed. Additionally, another peak with a mass of 306 Da 
larger than the main peak; a representative of the glutathione adduct (expected increase mass 
=305.1Da), was observed. The IAA and βME assays of PseAXaC75A demonstrated the 
presence of one free Cys residue in it (Annex XXIII). The mass signal of PseAXaC75A core 
peptide was absent in MALDI TOF MS of the trypsin digest, explaining that the protease had 
cut the peptide. In addtion, several other mass signals of the leader fragment (m/z 1767) and 
the other fragments yielded by trypsin self digest (m/z 1432.5, 2161.4, 3151.1) were observed 
(Figure 30 g). Thus, these results suggest that the thioether rings that stabilize the cleavage 
site were not closed in this peptide and a disulfide bond was not formed as well. 
All the PseAXa mutants were inactive against M. luteus even after the removal of the 
leader by factor Xa (data not shown). The MALDI TOF MS of all the mutants after factor Xa 
digestion showed a mixture of different peaks, indicating the different dehydration states of 
the core peptide as well as the presence of adducts with some peptides (Figure 31).  
The core peptide of PseA has a few similarities to the known lantibiotics (see Figure 
37). Hence, the lanthionine bridging pattern can only be predicted by homology (see 
discussion) but clear cut experimental evidence will have to be obtained by further studies. 
This is due to the fact that all mutant peptides were not fully modified; rather they were 
mixture of peptides having different dehydration states. Tandem MS-MS resulted in an 
unsatisfactory fragmentation of PseAXa and its mutant analogs and only little results were 
obtained (Annex XVIII).  
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Figure 29: MALDI TOF MS of PseAXa mutant peptides (A-F) with its respective TCEP treated peptides (a-f). 
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Figure 30: MALDI TOF MS of PseAXa peptide (a) and its mutants (b-g) after treatment with 
trypsin. The mass of the core peptide is represented in bold letters.  
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 Figure 31: MALDI TOF MS of PseAXa (a) and its mutants (b-g) after cleavage by factor Xa. 
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3.15. Mode of action 
3.15.1. Growth of microorganisms in the presence of the antimicrobial substance 
In order to elucidate the effect of the antimicrobial substance from B. pseudomycoides on the 
growth of microorganisms, the following experiment was conducted. M. luteus and S. aureus 
SG511 were grown separately in MH broth. After 5 h (exponential phase) of incubation, the 
antimicrobial substance that had been partially purified from cell pellet was added to the 
cultures. This addition prevented further growth and reduced their optical density, indicating a 
lytic effect of the antimicrobial substance (Figure 32). 
 
 
Figure 32: Effect of the antimicrobial substance on the growing cells of M. luteus (■) and S. aureus 
(●) in MH broth. The bacterial batches treated with the antimicrobial substance after 5 h are 
indicated by a dashed line (···) while the untreated controls are indicated by a solid line (—).  
 
3.15.2. Minimum inhibition concentration (MIC) 
To determine the MIC of pseudomycoicidin, its inhibitory effect against the indicator strain 
M. luteus was tested. The concentration of the peptide was estimated by Bradford assay. Here, 
the heterologously produced pseudomycoicidin showed an MIC of 3 µM in the presence of 
Ca
2+
 (Figure 33).  
A – Medium control
B – Growth control
C – Bacteria + Pseudomycoicidin
D –Acetonitrile control
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Figure 33: Determination of the MIC of pseudomycoicidin against M. luteus in a microtiter 
plate. The peptide is pipetted in 2-fold dilution from left to right (row C1-C12, 12µM to 
0.005µM). 
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3.15.3. Reporter gene assay 
In order to investigate the binding ability of the antimicrobial substance purified from cell 
wash extract of B. pseudomycoides and heterologously produced pseudomycoicidin with lipid 
II, the following experiments were conducted. Both preparations were screened for their 
ability to induce the expression of LacZ promoter fusions of the detoxification systems LiaRS 
(TMB016), Psd RSA-AB (TMB299) and Yxdjk-LM (TMB588), in three different reporter 
strains viz. B. subtilis TMB016, B. subtilis TMB 299 and B. subtilis TMB 588. In this system, 
LacZ is expressed in response to the antibiotics that stimulate sensing and detoxification 
systems in Bacillus strains (Burkhard and Stein, 2008). PsdRSA-AB system is induced by 
lantibiotics like nisin and actagardine, whereas, LiaRS system is induced by cinnamycin. The 
substances were pipetted on a TSA plate containing X-gal seeded with the three different 
reporter strains. Although, all three Bacillus strains were affected by the antimicrobial 
substance purified from cell wash extract and the heterologously produced pseudomycoicidin, 
the absence of blue rings around the zones of inhibition of both preparations (Figure 34) 
indicated that both, the antimicrobial substance and the pseudomycoicidin, did not stimulate 
the detoxification systems of B. subtilis.  
 
             
 
Figure 34: Reporter gene assay: A) a partially purified antimicrobial substance from cell 
wash extract of B. pseudomycoides B) the heterologously produced pseudomycoicidin. Agar 
well diffusion method was used with B. subtilis TMB 299 seeded TSA plate containing X-gal. 
 
3.15.4. Lipid II interaction assay 
Additionally, a possible interaction of lipid II with pseudomycoicidin was also determined by 
TLC. Lipid II was incubated with pseudomycoicidin in estimated ratios of 1:1, 1:2 and 1:3 in 
the presence of Ca
2+
. Nisin and mersacidin were used as controls. The plates were stained 
A) B) 
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with phosphomolybdic acid stain. Nisin formed a complex at the origin with the lipid II. In 
contrast, both mersacidin and pseudomycoicidin did not retain lipid II at the origin. However, 
both peptides - mersacidin and pseudomycoicidin delayed the migration of lipid II compared 
to the lipid II control (Figure 35 A). Furthermore, the antibacterial activity of 
pseudomycoicidin seemed to be inhibited when lipid II was incubated with pseudomycoicidin 
(data not shown). However, MIC of pseudomycoicidin against M. luteus was not affected by 
the addition of lipid II in a molar ratio of 1:1 (data not shown) and 1:2 (Figure 35 B) in the 
presence of Ca
2+
. 
 
   
 
 
(1:2)
 
 
Figure 35: Lipid II interaction assay: A) TLC of reaction mixture of lipid II incubated with 
different peptides. B) MIC of the heterologously produced pseudomycoicidin in the presence 
of lipid II against M. luteus.  
A) 
B) 
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4. Discussion 
The identification and production of wide variety of antibiotics have revolutionized medical 
approaches. Unfortunately, the intensive use and misuse of clinical antibiotics have led to the 
emergence of resistant strains. For example, Staphylococcus aureus strains have been found 
to be resistant to methicillin; even vancomycin resistant enterococci (VRE) have now become 
quite common (Novak et al., 1999; Weigel et al., 2003). The constant increase in multi drug 
resistant microorganisms necessitates the need to investigate and develop new antibacterial 
compounds. Lantibiotics are considered as promising candidates for the future antibiotics. 
They are highly effective against diverse pathogenic bacteria (Fickers et al., 2012).  
The genus Bacillus (B. subtilis, B. polymyxa, B. brevis, B. licheniformis, B. circulans 
and B. cereus) is well known as a producer of polypeptide antibiotics such as bacitracin, 
gramicidin S, polymyxin, tyrocidine, etc (Mittenhuber et al., 1989; Morikawa et al., 1992; 
Perez et al., 1992; Drablos et al., 1999).  
The possibility that B. pseudomycoides DSM 12442 might also produce a lantibiotic 
was recognized during the database search for new lantibiotic gene clusters in different 
bacteria, when genomic data mining revealed a putative class II lantibiotic gene cluster.  
 
Putative lantibiotic gene cluster of B. pseudomycoides 
In silico analysis of B. pseudomycoides showed the presence of gene cluster that might encode 
a class II type single peptide lantibiotic. The gene cluster consists of one structural gene 
(pseA), a single modification gene (pseM), a transpoter gene (pseT) and the immunity genes 
(pseEFG). However, the gene cluster lacks the regulatory genes. The typical two component 
regulatory system (lanR, lanK) is present in the gene cluster of nisin (Kuipers et al., 1993) and 
class II lantibiotics like mersacidin (Altena et al., 2000) or cinnamycin (Widdick et al., 2003). 
Some lantibiotic gene clusters contain an extra regulatory gene such as mrsR1 in mersacidin 
(Guder et al., 2002) and cinR1 in cinnamycin (Widdick et al., 2003). Likewise, some 
lantibiotics contain orphan regulators in their gene cluster viz. MutR in mutacin II, EpiQ in 
epidermin, and LtnR in lacticin 3147 (Bierbaum et al., 2009; Li et al., 2012). Lantibiotics like 
Pep5 (Kaletta et al., 1989), lacticin 481(Piard et al., 1993), lactocin S (Mortvedt et al., 1991) 
and lanthipeptides like catenulipeptin (Wang et al., 2012) and venezuelin (Goto et al., 2010) 
do not have regulatory genes. 
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The gene cluster from B. pseudomycoides has a single bifunctional modification 
enzyme (PseM). PseM contains the conserved ‘CHG’, ‘GXXHGXXG’ and ‘WCXG’ domains 
that are generally present in LanM proteins (Paul et al., 2007). So far, several class II type 
lantibiotics - mersacidin (Chatterjee et al., 1992), lacticin 481 (Piard et al., 1993), nukacin 
ISK-1 (Sashihara et al., 2000), mutacin II (Novak et al., 1994), actagardine (Zimmerman et 
al., 1995), cinnamycin, etc (Marki et al., 1991) have been shown to have the bifunctional 
modification enzyme (LanM), performing both the dehydration and cyclization step 
(Chatterjee et al., 2005b).  
The PseA prepetide has 75 amino acids and two putative protease cleavage motifs 
(GA/GG) (Figure 9). Such a ‘GG’ or ‘GA’ cleavage motif is found in most of the class II 
lantibiotics (Sahl and Bierbaum, 1998). Interestingly, the amino acid sequence of the core 
peptide of PseA is different from the known lantibiotics. However, it possesses a classical 
lantibiotic leader (Figure 9) that shows similarities to the known lantibiotics e.g. mersacidin 
(Bierbaum et al., 1995). In similarity to all mersacidin-like lantibiotics (except duramycin), 
the core peptide possess a conseved motif (TxS/TxE/DC), which might be involved in binding 
of lipid II. The similarity of the PseA amino acid sequence to the known lantibiotics and the 
presence of the LanM modification enzyme suggest that it could be a novel class II lantibiotic.  
In addition, the core peptide has a unique amino acid sequences ‘SWSCWSWSC’ at the C-
terminal end (Figure 9). Such repetitive amino acid motifs have been described for TOMM 
like peptides. Here the S and C residues serve as precursors for thiazoles or oxazoles (Haft, 
2009; Melby et al., 2011). A similar “CWSC” motif is present in the class IIa bacteriocin 
thuricin 17, thuricin H and cerein MRX1 produced by B. thuringiensis (Chehimi et al., 2007; 
Abriouel et al., 2011; Haft, 2009). Sonorensin, a member of heterocycloanthracins, purified 
from Bacillus sonorensis MT93, contains five repeated SCWSC motifs (Chopra et al., 2014). 
Since the core peptide of PseA has a repetitive motif similar to TOMMs, the formation of 
thiazole or oxazole rings might have been possible in PseA. Additionally, possible thiazole 
and oxazole modification enzymes are encoded in the genome, however, not in the lantibiotic 
gene cluster. These unique features made it an attractive compound for investigations. The 
fate of ribosomally synthesized, posttranslationally modified peptides seems to be determined 
by the sequences of their leader peptides, which direct the prepeptides to their respective 
modification machineries (Oman and van der Donk, 2010). This has been demonstrated for 
some lantibiotics as well as microcin B17 and streptolysin S, which both contain thiazole and 
oxazole residues. The leader sequence of pseudomycoicidin shows high similarity to that of 
MrsA and ActA and therefore would direct the peptide to the LanM enzyme (Fig. 1).  
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PseA is rich in Trp residues. The Trp-rich peptides preferentially disrupt large 
unilammelar vesicles with a net negative charge following their insertion into interfacial 
region of phospholipid bilayer (Schibli et al., 2002). Such a mode of action has been already 
reported for Trp-rich antimicrobial peptides such as tritrpticin (Lawyer et al., 1996), 
indolicidin (Selsted et al., 1992), puroindoline (Haney et al., 2013), and the antibacterial 
fragments of lactoferrin and lactoferricine (Schibli et al., 2002; Chan et al, 2006). In contrast 
the Trp residues stabilise the conformation of pediocin-like bacteriocins (Fimlandet al., 2002).  
The PseA core peptide is anionic in nature having a net -1 charge. There are also few 
other existing lanthipeptides which exhibit a net -1 charge, such as duramycin C 
(Fredenhagen et al., 1990; Märki et al., 1991), variacin (Pridmore et al., 1996), Amfs (Ueda et 
al., 2002) and the labyrinthopeptins (Müller et al., 2010). In this study, the PseA peptide was 
identified by bioinformatic analysis, rather than by screening of producer strains. Similarly, 
several lantibiotics and lanthipeptides such as haloduracin (McClerren et al., 2006), 
lichenicidin (Begley et al., 2009; Dischinger et al., 2009), Bsa (Daly et al., 2010), venezuelin 
(Goto et al., 2010) and the prochlorosins (Li et al., 2010) were also identified by genomic data 
mining. 
Upstream of pseA, a short ORF having 71% identity to the PseA leader sequence is 
present. Since this sequence does not have start codon and cleavage motive, it is not clear that 
the sequence might encode a peptide. Its structural gene is encoded at the 5’ end of the contig 
00045 and the upstream sequences of the gene cluster are not yet clear. From the PubMed 
graphic assembly of the genome contigs, it seems that contig 00074 is adjacent to contig 
00045. However, attempts to fill the gap in this study using PCR and sequencing were 
unsuccessful.  
 
The antimicrobial substance from B. pseudomycoides 
The antimicrobial substance produced by B. pseudomycoides had a good antibacterial 
spectrum against wide range of Gram-positive bacteria including some MRSA strains and a 
few other human pathogens (Figure 12). However, Gram-negative bacteria and yeasts were 
not affected by the antimicrobial substance. A similar antimicrobial spectrum was shown for 
lichenicidin from B. licheniformis. Among indicator strains tested, lichenicidin inhibited many 
Gram-positive bacteria including MRSA strains but Gram-negative bacteria and yeasts were 
not inhibited (Dischinger et al., 2009) and this has been shown for all lantibiotics tested so far 
since they are not able to penetrate the outer membrane.  
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Ammonium sulphate precipitation, ion exchange columns and reverse phase 
chromatography were successfully used in the past to purify the peptides from bacteria such 
as streptin (Wescombe and Tagg, 2003), Pep 5 (Sahl and Brandis, 1981), epicidin 280 
(Heidrich et al., 1998), etc. However, in this study the attempts to purify the antimicrobial 
substance by means of (NH4)2SO4 precipitation, an anion exchange column, a cation 
exchange column and an XAD column were unsatisfactory. The active fraction either eluted 
in the flowthrough or the active fraction did not elute at all. There could be many possible 
reasons (single or in combination) for the problems encountered during the purification of 
antimicrobial substance, like, limited solubility, its high affinity to the column materials, its 
composition with multiple W and C residues which are prone to oxidation and / or hydrogen 
bonding.  
Many antimicrobial substances are produced as a defense of the producer strain and 
are secreted into the medium. But, contrastingly the antimicrobial substance of B. 
pseudomycoides was associated with the cell wall. Thus, the antimicrobial substance might be 
related to other functions such as morphogenesis or metabolism of the producer strain, rather 
than representing only a defense mechanism of the bacterium. There are a few other 
lantibiotics functioning as morphogenetic peptides, such as those from Streptomyces (Willey 
and van der Donk, 2007). A location of the peptide in the cell wall of the producer strain was 
also described for lichenicidin (Dischinger et al., 2009), haloduracin (Lawton et al., 2007) and 
lacticin (Cotter et al., 2006). For the lichenicidin peptide, the authors discussed that the 
peptides have a net positive charge, thus, the negatively charged capsule of the producer strain 
might have restricted the diffusion of the cationic peptides from the cell wall (Dischinger et 
al., 2009). Likewise, for the lacticin peptides, it was hypothesised that the LtnA2 peptide 
might adhere to the cell wall via the LtnA1 peptide (Cotter et al., 2006). 
The use of lantibiotic peptides in medicine is limited due to their susceptibility towards 
proteases, and in case of nisin low stability at physiological pH level (Breukink and de 
Kruijff, 2006). Thus, the stability of a peptide towards the proteases and physiological pH 
would be an advantage for its application. In this study, the antimicrobial substance produced 
by B. pseudomycoides was stable to heat and acidic pH (3 – 5) but was unstable at higher pH 
values. Similarly, though there is one possible cleavage site for trypsin (WTK ↓ DCS) the 
antimicrobial substance was resistant to trypsin. This indicates the presence of the ring 
structures in the peptide which protect it from the proteolytic cleavage by the enzyme. 
Likewise, the addition of pronase E and proteinase K inactivated the antimicrobial substance 
indicating that it has a proteinaceous nature. A similar result was observed for the activity 
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from isopropanol cell wash extract of B. licheniformis with proteases. It was resistant to 
trypsin and chymotrypsin, while sensitive to proteinase K and pronase E (Dischinger et al., 
2009). The extract from B. licheniformis was highly heat stable and moderately stable to 
ranges of pH (1.5 – 9). Likewise, a streptin produced by S. pyogenes was stable to high heat 
(100 °C) for 10 min and acidic pH (3), while it was sensitive to trypsin and moderately stable 
at alkaline pH (Wescombe and Tagg, 2003). Similarly, mutacin from S. mutans (Novak et al., 
1994) was also found to be sensitive to trypsin. 
Additionally, the antimicrobial substance from B. pseudomycoides was resistant to the 
protease produced by the producer itself since activity of the antimicrobial substance was 
retained, after incubation with supernantant containing protease. A similar result was shown 
for lichenicidin, where, the cell wash extract was active against S. aureus ATCC 33592 even 
after incubation with the supernatant containing protease (Dischinger et al., 2009). In contrast, 
subtilomycin a new lantibiotic from S. griseus was sensitive to the protease produced by the 
producer itself; however subtilomycin was resistant to proteinase K and chymotrypsin (Phelan 
et al., 2013). 
 
Heterologous expression of lantibiotic genes 
The production assays indeed confirmed the expression of an antimicrobially active 
substance by B. pseudomycoides, however, BLASTs identified three proteins with high 
similarity to the putative heterocycloanthracin biosynthesis genes described by Haft (2009) on 
contig00260 (acc. no. ACMX01000028) and comprise a protein carrying the conserved 
“ocin_THiF_like” domain (bpmyx0001_11050), a SagD/YcaO like cyclodehydratase 
(bpmyx0001_11040) and a MbcC like oxidoreductase (bpmyx0001_11030). A MbcC like 
oxidoreductase shows 71% similarity to SagB-type dehydrogenase domain of B. cereus 
(WP_016119836.1) and shows similarity to the part of SagB of S. pyogenes (acc. no. 
TIGR03605) that is responsible for the maturation of streptolysin S from ribosomally 
produced precursor peptide (Lee et al., 2008). In contrast to B. licheniformis 
ATCC14580/DSM13, no precursor peptide is encoded upstream of these genes, but 
bpmyx0001_22790 on contig00122 (acc. no. ACMX01000049) (MKMNEFQQE 
LQALSLNDYQSGNVMYWDQQNQYPYYYIEDDARRCGGCGRCGGFRCGGFRCGGFR
CFGCFGCFSCFGCGGCGGCSNCFDGFNGATWWVI) shows similarity to the 
heterocycloanthracin precursor genes described in (Haft, 2009). In consequence, it could not 
be excluded that the antibacterial activity in the cell wash extract might represent another 
substance. It is not unusual for Bacillus species to produce an array of different antibiotics, for 
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example B. amyloliquefaciens FZB42 harbours gene clusters that enable production of ten 
different antimicrobial substances (Chen et al., 2009; Scholz et al., 2011) and even B. subtilis 
168 is still able to excrete several antimicrobial compounds (Stein, 2005). Generally a knock 
out strategy is adopted to verify the role of a lantibiotic gene cluster in the production of an 
antimicrobially active substance. In this strategy, the modification enzyme LanM from the 
gene cluster is knocked out and subsequently the production of the antimicrobially active 
substance from the mutant is determined (Dischinger et al., 2009). However, the genetic 
manipulation of B. pseudomycoides was difficult because of its colony morphology (Figure 
10). Therefore a heterologous expression system was established. The heterologous 
expression of the lantibiotic modification enzyme PseM and its corresponding lantibiotic 
precursor PseA were tested separately, where the overexpression and purification of the PseM 
protein were successful. However, the overexpression of PseA alone was not successful. The 
PseA peptide may be unstable, thus it might have degraded during the harvest, lysis or even 
during the growth after induction. Thus, in vitro modification of PseA by PseM could not be 
performed. In contrast successful heterologous production and in vitro modification have been 
reported for other lantibiotics such as haloduracin, nisin and prochlorosin (McClerren et al., 
2006; Li et al., 2010). 
Besides in vitro modification assays, the heterologous expression of complete gene 
clusters were successfully performed for several lantibiotics in bacteria too, such as nisin and 
subtilin in B. subtilis (Yuksel et al., 2007), lacticin 3147 in Enterococcus faecalis (Ryan et al 
2001) and lichenicidin in E. coli (Caetano et al., 2011) and gallidermin by Lactococcus lactis 
(van Heel, 2013). In contrast, Nagao et al. (2011), Shi et al. (2011) and Okesli et al. (2011) 
described another novel methodology for conducting post translational modifications. This 
method generates lanthipeptides in the heterologous host E. coli yielding fully modified 
prepeptides by coexpression of His-tagged LanA with LanM. With this method, modified 
prepeptides can be obtained by one step purification. Following a similar strategy, the 
modified precursor peptide was produced in this study after coexpression of PseM and PseA 
in E. coli. The produced preptide was named pseudomycoicidin. The observed MW of the 
prepeptide was 74 Da less than the calculated MW of the unmodified prepeptide. This 
reduction in the mass could be attributed to the loss of four water molecules during 
maturation, indicating that the PseM dehydrated 4 serine or threonine residues in the core 
region of PseA and catalyzed the subsequent cyclization of cysteine thiols to form the 
thioether rings. Since there are eight Ser / Thr residues in the putative core peptide, only four 
of those residues were dehydrated, the remaining four residues escaped from dehydration. The 
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phenomenon of free hydroxyamino acid escaping from dehydration was also noted in some 
other lantibiotics such as nisin A, lacticin 481, haloduracin and some prochlorosins 
(Chatterjee et al., 2005a; Li et al., 2010).  
All lantibiotics, characterized so far, require the removal of the N-terminal leader 
sequence of the modified peptide to attain their activity (van der Meer et al., 1993). Since the 
sequence of the PseA contains two protease cleavage motifs viz. GA and GG, there are two 
possible cleavage sites in the peptide. MALDI TOF MS showed the active cell wash extract 
harbours a molecule with a mass of 2786 Da and that is consistent with a peptide mass if 
cleaved after GA cleavage site (Table 16, page 67). Therefore, the GA motif was chosen as 
the cleavage site. In plantaricin W (PlwAβ) (Holo et al., 2001) and haloduracin (HalA2) 
(McClerren et al., 2006), ‘Gly-Asp’ is present after putative double glycine cleavage site. In 
both cases, after cleavage of the prepetide at Gly-Gly processing site, an additional proteolysis 
occurs resulting in a removal of six N- terminal residues from the core peptide. Similarly, in 
cytolysin an additional cleavage by CylA was shown to be necessary for activity of cytolysin 
(Cox et al., 2005). Here, PseA also has ‘Gly-Asp’ after Gly-Gly cleavage site but the 
additional cleavage is not possible because Cys residue is present immediately after ‘GD’. 
Thus, to facilitate the in vitro cleavage of the N-terminal leader sequence, a factor Xa 
cleavage site was placed at ‘GA’ cleavage site of PseA. The core peptide obtained after 
cleavage of the leader sequence showed an antimicrobial activity against M. luteus (Figure 25, 
spot 3). This strategy of in vitro removal of leader after the in vivo modification of peptide is 
known as semi-in vitro biosynthesis (Lin et al., 2011). Bovicin HJ50 was produced in the 
same way by coexpressing BovA with BovM in E. coli followed by the removal of the leader 
peptide in vitro using BovT.  
Additionally, the PseAXa peptide cleaved by the factor Xa was analysed by MALDI 
TOF MS for the determination of the masses of the modified core and the leader peptide. The 
core peptide had a molecular mass of 2785 Da, which matched the calculated core peptide 
mass of 2787 Da with four dehydrations. This MW of the core peptide also agreed with the 
detected mass of 2786 Da for the active cell wash extract of B. pseudomycoides. The decrease 
in the mass of 2 Da between the observed and the calculated mass of the core peptide might 
be attributed to the formation of one disulfide bond in the peptide during modification. 
Likewise, there were 3 other mass signals observed in MALDI TOF MS viz. m/z 5679, 3526 
and 2171. These signals corresponded to the calculated masses of fragments of the leader 
peptide formed by the cleavage by factor Xa, which obviously processed the leader after 
every Arg ‘R’ residue. Such unspecific cleavage after Arg residues has been observed before 
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(Hall, I., Riggs, P., unpublished observations, c.f. https://www.neb.com/products/p8010-
factor-xa-protease).  
When the pseudomycoicidin was incubated with trypsin, although a trypsin cleavage 
site is present in the peptide, the cleavage products were not observed; rather the mass signal 
for the entire core peptide (m/z 2785) was still present after the digest (Figure 24 B). This 
indicates that the heterologously produced pseudomycoicidin is fully modified and that the 
lanthionine ring/s stabilized the peptide against the digest. Lantibiotics such as nisin, 
epidermin and Pep5 are elongated peptides and posses a hinge region. This hinge region is 
essential for pore formation but it is also susceptible to the activity of proteases like trypsin 
or chymotrypsin (Wilimowska-Pelc et al., 1976; Allgaier et al., 1986; Bierbaum et al., 1996). 
As shown for Pep 5, by introducing additional rings the hinge region can be stabilized and 
protected against the attack by such proteases (Bierbaum et al., 1996). Such a stability 
against proteases is an important property when considering for their application in different 
fields such as food industry, and human and veterinary medicine (Ryan et al., 2002). 
 
Presence of ring and disulfide linkage in PseAXa 
The cyclized and uncyclized peptides have identical masses, so they are indistinguishable by 
MALDI TOF MS (Paul et al., 2007). There are eight Ser/Thr residues and six Cys residues in 
the pseudomycoicidin prepeptide. Hence, it was possible that all Cys could be involved in 
ring formation. However, since pseudomycoicidin has four dehydrated amino acids, only four 
lanthionine rings were possible in this peptide. McClerren et al. (2006), Paul et al. (2007) and 
Goto et al. (2011) have performed chemical modifications with a thiol specific reagents (IAA 
or N-ethylmaleimide or p-hydroxymercuribenzoic acid) to determine the presence of free 
cysteines in the peptide. Similarly, in this study, the addition of IAA was performed to verify 
the presence of free Cys residues in the modified PseAXa. Individual Cys residues react with 
IAA to form an adduct which results in a mass shift of + 57 Da (McClerren et al., 2006). 
Thus, when the modified PseAXa was incubated with IAA in presence of the reducing agent 
TCEP, a product (10314 Da) with an increase in mass due to formation of two IAA adducts 
(~114 Da) was obtained. This indicates that there are two free Cys residues in the peptide 
which could react with IAA and that the remaining four Cys residues are involved in the 
formation of Lan/MeLan rings. However in absence of TCEP, there was no formation of 
adducts after treatment with IAA. Similarly the haloduracin α-peptide showed addition of two 
adducts after treatment with reductant, suggesting that the two free Cys residues are tied up in 
a disulfide linkage (McClerren et al., 2006). Thus, it may be speculated that the two free Cys 
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residues of PseAXa are involved in the formation of a disulfide linkage as similar to Halα, 
sublancin or Plwα (Paik et al., 1998; Holo et al., 2001; McClerren et al., 2006).  
Wang and van der Donk (2012) determined the location of free Dha residues in 
catenulipeptin by using βME. They found the presence of one extra dehydroalanine residue in 
addition to four Dha residues required for labionin formation. Likewise, the presence of 4 
rings in pseudomycoicidin was further confirmed by the βME assay. When the peptide was 
incubated with βME, the peptide did not form a βME adduct, demonstrating the absence of 
free Dha residues in the peptide and confirming that all four dehydrated amino acid residues 
are involved in Lan / MeLan formation.  
Likewise, when the pseudomycoicidin was treated with the reducing agents TCEP and 
βME, its mass was increased by 2 Da. This increase in the mass could be attributed to the 
reduction of a disulfide bond in the PseAXa. Most lantibiotics do not possess disulfide bridges 
(Bulaj et al., 2005). But the disulfide linkages are generally thought to enhance the stability of 
a protein, and sublancin 168 (Paik et al., 1998), Plwα (Holo et al. 2001), thermophilin1277 
(Kabuki et al. 2009), bovicin HJ50 (Xiao et al., 2004), and Halα (McClerren et al., 2006) are 
lantibiotics that contain disulfide linkages. When PseAXa was incubated with TCEP, the 
antimicrobial activity of the peptide was completely lost (Figure 27), showing the importance 
of the disulfide bond for its activity. Similarly, the disulfide bridge was indispensable for full 
antimicrobial activity of bovicin HJ50 (Lin et al., 2011). In contrast, the reduced haloduracin 
peptides exhibited activity against the indicator strain (McClerren et al., 2006). 
 
Prediction of ring topology in PseA 
Although the peptide has four Lan / MeLan rings and additional one disulfide bond, the 
pattern of rings is still unknown. The ring topology of some lanthionine-containing peptides 
has been determined by the spectrometric analysis of LanA analogs (Caetano et al., 2011; 
Goto et al., 2011; Garg et al., 2012). The analogs are prepared by replacing Cys with Ala 
residues in the peptide, followed by a spectrometric analysis using MALDI TOF and tandem 
mass spectrometry. For some of these peptides, the topology determined by tandem MS 
studies was confirmed by NMR spectroscopy (Shenkarev et al., 2010). In this work, to gain 
insight into the topology of the lanthionine rings in pseudomycoicidin, six PseAXa analogs 
were constructed by replacing the single Cys with Ala residues at different positions in the 
peptide. The constructs were designed to disrupt only one ring at a time. Subsequently, each 
mutant peptide was subjected to MALDI TOF MS and tandem MS-MS after coexpression and 
purification. The MALDI TOF MS showed that the mutant peptides were a mixture of fully 
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and partially modified peptides. Before addition of TCEP none of the mutants showed a single 
peak (Figure 29) (with four fold dehydration) as shown by the wild type peptide. Hence, all 
Cys residues seem to be essential for full modification of PseAXa. Since the modification of 
lantibiotics is thought to be completed before the secretion through the membrane (Wescombe 
and Tagg, 2003), it is possible that such incompletely modified forms of peptide are present in 
the cell lysates as used here. For example, incompletely dehydrated forms of Pep5 were found 
in lysates of the producer cell, while the fully dehydrated form was only detected in the 
culture supernatant (Sahl et al., 1991). Similarly, the cell wash extract from B. 
pseudomycoides also exhibited incompletely dehydrated forms of peptide in MALDI TOF 
MS.  
The mechanisms by which the LanM enzymes carry out the dehydration and 
cyclization reactions are little known (Lee et al., 2009). Studies conducted in vitro on the 
bifunctional lacticin 481 and haloduracin synthetase provided the first clues into the 
mechanism of dehydration (Xie et al., 2004; Chatterjee et al., 2005a; Miller et al., 2006; 
McClerren et al., 2006). In nisin and lacticin 481, dehydration takes place independently from 
the cyclization activity (Li et al., 2006; Paul et al., 2008). Likewise, Chatterjee et al. (2006) 
showed that the dehydration activity of LctM is not coupled to the cyclization activity. In 
contrast to our expectations, the replacement of Cys residues in the PseAXa prepeptide, not 
only prevented the ring formation but also interfered with the dehydration step. These 
findings show that, with PseM, the dehydration and cyclization reactions of PseAXa might 
occur simultaneously. A similar result was observed by Lee et al. (2009) when they tested the 
dehydration and cyclization of HalA2 by HalM2. However, with lacticin 481, removal of one 
or more rings by mutation of Cys residues did not affect the dehydration of Ser / Thr residues 
(Chatterjee et al., 2006). Additionally, in PseAXa, when the N-terminal Cys and the C-
terminal Cys had been replaced by Ala, four fold dehydrated peptides were observed. In 
contrast, the replacement of the more centrally located Cys residues by Ala resulted in one to 
three fold dehydrated peptides, and in the case of Cys 56 a free Dha or Dhb residue was 
observed. The modification by PseM was disturbed by the removal of Cys residues, indicating 
that the substrate specificity of PseM is much narrower in contrast to that of NisB 
(Majchrzykiewicz et al., 2010) or LctM (Patton et al., 2008). This was also confirmed when a 
trial to co-express another lantibiotic structural gene from Caldicellulosiruptor bescii 
(Kataeva et al., 2009) fused to the pseudomycoicidin leader along with PseM in E. coli, did 
not result in modification of the core peptide.  
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All PseA mutants were inactive after the removal of the leader suggesting that all the 
thioether rings and the disulfide link are essential for its antimicrobial activity. In contrast, not 
all rings were essential for the bioactivity of haloduracin as shown by the mutation studies of 
Halα and Halβ (Cooper et al., 2008). Chen et al. (1998) showed that the two of the mutacin II 
variants (C15A and C26A), constructed by replacing Cys with Ala failed to exhibit 
antimicrobial activity; however one of the variant (C27A) was able to retain some residual 
antimicrobial activity.  
Similarly, some mutants of PseAXa - PseAXaC52A, PseAXaC56A and PseAXaC70A 
were resistant against trypsin (Figure 30). This shows that the ring(s) that protected the trypsin 
cleavage site are present in all of these three mutant peptides. However, the other mutant 
peptides viz. PseAXaC62A, PseAXaC65A and PseAXaC75A were completely digested by 
trypsin, showing the absence of ring(s) that could have protected them from cleavage in these 
peptides.  
The analysis of the MALDI TOF MS and MS-MS fragmentation data from the mutant 
peptides was difficult because i) several internal fragments were produced during MS-MS and 
ii) many mutant peptides were not fully modified showing different dehydration patterns.  
The subsequent analyses of PseAXaC52A and PseAXaC75A showed formation of one 
IAA adduct and the absence of βME adducts, indicating the presence of one free Cys in each 
peptide. From these data, it could be predicted that the Cys residues at positions 52 and 75 
might be involved in the disulfide bonding. Such a head-to-tail disulfide bond was observed 
also in the S-linked glycopeptide sublancin 168 (Paik et al., 1998; Oman et al., 2011). 
Furthermore, this indicated that the Cys residues at positions 56, 62, 65 and 70 might be 
involved in Lan/MeLan ring formation. The lanthionine bridging pattern of mersacidin 
(Figure 36) is conserved in other lantibiotics of this family, such as lichenicidin (Rey et al., 
2004), actagardine (Zimmermann et al., 1995), haloduracin (McClerren et al., 2006), 
plantaricin W α (Holo et al., 2001) and michiganin A (Holtsmark et al., 2006). In these 
lantibiotics, ring C of mersacidin is conserved and is considered to be involved in binding to 
lipid II (Zimmermann and Jung, 1997; Appleyard et al., 2009). PseA also has the conserved 
lipid II binding motif. Thus, PseA might also contain the conserved double ring system 
involving Thr 57 – Cys 62 and Thr 59 – Cys 65 (Figure 37). Likewise, following back-to-
front rule of cyclisation, MeLan ring involving Thr 55 – Cys 56 might also be formed. 
Additionally, there might be a ring structure between Ser 63 – Cys 70, since a mass indicating 
fragmentation between Pro 66 and Ser 67 was observed in the MS-MS of PseAXaC70A 
(Annex XIX). The bridging pattern proposed here is also confirmed by the trypsin digests, as 
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the mutant peptides PseAXaC62A, PseAXaC65A and PseAXaC75A were completely 
digested by trypsin. In contrast the mutant peptides PseAXaC52A, PseAXaC56A and 
PseAXaC70A were resistant to the tryptic digest. 
MrsA           CTFTLPGGGGVCTLTSECIC
ActA                 SSGWVCTLTIECGTVICAC
PseA                GDCGGTCTWTKDCSICPSWSCWSWSC
SalA                 GNGVVLTLTHECNLATWTKKLKC
NukA               KKKSGVIPTVSHDCHMNSFQFVFTCCS
Licα TITLSTCAILSKPLGNNGYLCTVTKECMPSCN
Halα CAWYNISCRLGNKGAYCTLTVECMPSCN
 
 
Figure 36: Amino acid sequence alignment of MrsA (Bierbaum et al., 1995), ActA 
(Zimmermann et al., 1995), PseA, SalA (Wescombe et al., 2006), NukA (Sashihara et al., 
2000), Licα (Dischinger et al., 2009) and Halα (McClerren et al., 2006). The conserved lipid 
II binding motif is given in bold letters. The thioether ring pattern represents that of MrsA in 
which the conserved double ring pattern is presented by a solid line. Underline indicates the 
trypsin cleavage site in PseA. 
 
Based on the experimental data and on the structure of mersacidin, the predicted structure for 
pseudomycoicidin is presented in Figure 37.  
G D C G G T C T W T K D C S I C P S W S C W S W S C
S S
 
 
Figure 37: A possible bridging pattern in pseudomycoicidin. Solid lines show the possible 
thioether ring pattern. Disulfide bridge is indicated by ‘---S-S---‘. 
 
The class II lantibiotics, such as mersacidin (Chatterjee et al., 1992), actagardine 
(Zimmermann et al., 1995), cinnamycin and duramycin (Fredenhagen et al., 1990; Märki et 
al., 1991), are highly globular peptides with over lapping rings. Here, pseudomycoicidin also 
seems to be a globular peptide because of the disulfide bridge and overlapping rings. 
However, lacticin 481 and related peptides are globular with a linear N-terminus (Dufor et al., 
2006). The class I lantibiotics – nisin (Gross and Morell, 1971), epidermin (Allgaier et al., 
1986), Pep5 (Kaletta et al., 1989), etc. are elongated peptides. Furthermore, for confirmation 
 98 
 
of the structure of pseudomycoicidin, mutant peptides could be created by replacing Ala in 
place of Ser or Thr residues and could determine the residues which have been dehydrated. 
Moreover, the complete elucidation and determination of the ring topology requires further 
structural confirmation by NMR spectroscopy.  
 
Mode of action 
Lantibiotics kill bacterial cells either by pore formation or by inhibition of the cell wall 
biosynthesis or by a combination of both mechanisms (Breukink et al., 1999). Lantibiotics 
like nisin and other structurally related lantibiotics (gallidermin, epidermin) use lipid II as a 
docking molecule to form a pore (Brötz et al., 1998b; Breukink et al., 1999; Wiedemann et 
al., 2001), whereas mersacidin like-peptides inhibit the transglycosylation step of cell wall 
biosynthesis, thereby blocking the precursor from incorporation into the cell wall (Brötz et al., 
1997). In silico analysis highlighted the sequence TxS/TxDC as a putative lipid II interaction 
site. The lipid II binding motif of pseudomycoicidin resembles to that of mersacidin. 
Therefore, it was assumed that the interaction of PseA with lipid II would be similar to that of 
mersacidin. Furthermore, the lipid II binding lantibiotics e.g. nisin, epidermin, subtilin, 
mersacidin, lacticin 481, and haloduracin possess an ABC transport protein LanFEG (Brötz et 
al., 1997; Breukink et al., 1999; Hsu et al., 2003; Bonelli et al., 2006; Oman and van der 
Donk, 2009). Since the pseudomycoicidin gene cluster also encodes a putative LanFEG 
transporter that might play a role in immunity, the ability of pseudomycoicidin to bind lipid II 
was tested.  
In order to evaluate the lipid II interaction ability of a lantibiotic, different experiments 
were performed in the past. Burkhard and Stein (2008) and Starón et al. (2011) established an 
assay for identification of peptide antibiotics that interfere with the lipid II cycle. They 
constructed four B. subtilis biosensors that can sense the induction of detoxification systems 
(LiaRS, PsdRS-AB, Yxdjk-LM and BceRS-AB) by different lipid II interfering peptide 
antibiotics. These indicator strains can sense bacitracin, vancomycin and lantibiotics like 
mersacidin, actagardine, gallidermin, duramycin, subtilin and nisin. Nisin and actagardine can 
induce PsdRS-AB expression. Likewise, the BceRS-AB system is induced by mersacidin and 
actagardine. However, in this study, pseudomycoicidin did not show induction of any of the 
biosensors.  
Additionally, Brötz et al. (1998a) showed the antagonization of the activity of 
mersacidin by purified lipid II and a strong inhibition of nukacin ISK-I activity in the 
presence of lipid I and lipid II (Islam et al., 2012). However, the MIC of pseudomycoicidin 
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was not affected by the addition of lipid II. The estimated molar concentrations (2:1 and 1:1) 
of lipid II over pseudomycoicidin did not affect the MIC, indicating that the amount of lipid II 
added was not sufficient for competing with the cell bound target for available 
pseudomycoicidin. Furthermore, it was presumed that the affinity of pseudomycoicidin for the 
purified lipid II in solution might be weaker than for the membrane bound lipid II. The N-
terminal part of PseA harbours the conserved mersacidin-like lipid II binding motif 
(CTxT/SxE/DC) and the C-terminal part contains three Trp residues and another Trp is in the 
N-terminus. Thus, in contrast to mersacidin, it can be speculated that PseA might exhibit its 
mode of action by inserting and integrating into the membrane and as well as by binding to 
the lipid II. 
In TLC, lipid II showed different migration patterns after incubation with 
pseudomycoicidin, nisin and mersacidin.  The nisin-lipid II complex was retained at the 
origin, while lipid II that had been incubated with the pseudomycoicidin and mersacidin 
migrated more slowly compared to free lipid II. This finding indicates that there might be a 
weak interaction between lipid II and the peptides (pseudomycoicidin and mersacidin). 
Wiedemann et al. (2006) observed that nisin and plantaricin C form a stable complex with 
lipid II and remain at the origin, whereas lipid II showed migration in the TLC system after 
incubation with mersacidin. The authors predicted that the presence of a highly positively 
charged N terminus may have facilitated the strong interaction of plantaricin C with lipid II. 
The binding of pseudomycoicidin to lipid II can be tentatively attributed to the same binding 
motif found in mersacidin. The binding motif in pseudomycoicidin differs from that of 
mersacidin in only one amino acid (Asp ‘D’ instead of Glu ‘E’), and an exchange of Asp 13 
for Glu in nukacin ISK-1 yielded a higher activity (Islam et al., 2009). Therefore, the 
molecular interaction between PseA and lipid II might differ from that between the 
mersacidin and lipid II. This difference in the interaction pattern between the peptide and lipid 
II might have led to the slight retardation of lipid II incubated with pseudomycoicidin and 
mersacidin. So far, there is only little evidence for an interaction of pseudomycoicidin and 
lipid II, i.e. the retardation in thin layer chromatography. To confirm the importance of 
TxS/TxDC motif in pseudomycoicidin, a mutant could be made by replacing D by E residue 
and test for higher activity. Moreover, it would be interesting to monitor microscopically the 
influence of pseudomycoicidin on cell wall integrity of bacteria. Wenzel et al. (2012) 
investigated the influence of lantibiotics such as nisin, mersacidin, gallidermin on cell wall 
integrity of B. subtilis using fluorescent microscopy. Therefore, further experiments are 
required to elucidate the full understanding of the mode of action of pseudomycoicidin.  
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5. Summary and Conclusions 
 
Lantibiotics are antibiotic peptides produced by Gram-positive bacteria. They are ribosomally 
synthesized and posttranslationally modified. The presence of thioether amino acids 
lanthionine and methyllanthionine is the characteristic feature of the lantibiotics. 
Posttranslational modification includes- a. dehydration of Ser or Thr residues, b. formation of 
thioether linkages between dehydro amino acids and Cys residues and c. proteolytic removal 
of the leader. All the genes involved in the biosynthesis of lantibiotics such as the structural 
(lanA), modification (lan BC/M/lab KC/lanP/lanL), regulation (lanR, lank), export (lanT/P) 
and immunity (lanI/EFG/H) genes are normally organized in a gene cluster. 
In this work, genomic data mining was performed to identify a new lantibiotic gene 
cluster by blasting the biosynthetic enzyme MrsM. The database search found a putative class 
II type of lantibiotic gene cluster in Bacillus pseudomycoides DSM 12442.  
B. pseudomycoides produced an antimicrobially active substance in the cell wash 
extract. The extract was active against many Gram-positive bacteria but not against Gram-
negative bacteria and yeast. Moreover, the substance exerted a lytic effect on the bacterial 
cells as for example the sensitive indicator strains Micrococcus luteus and Staphylococcus 
aureus SG511. Although the antimicrobial substance was partially purified by RP HPLC, its 
complete purification failed so far. The antimicrobial substance had a mass of 2786.0 Da, 
which corresponds to the calculated mass of the LanA core peptide with four fold 
dehydration. It was relatively stable to heat, acidic pH and organic solvents. Likewise, it was 
resistant to enzymes like trypsin while sensitive to pronase E and proteinase K. In addition, it 
was also resistant against the proteases excreted by the producer strain itself. 
Secondly, to test whether the antimicrobial activity in the cell wash extract was 
associated with the putative lantibiotic gene cluster, heterologous expression of the structural 
(PseA) and the modification enzyme (PseM) was attempted in E. coli. To this end, PseA and 
PseM were successfully cloned as N-terminally His-tagged PseA and C-terminally His-tagged 
PseM respectively. A factor Xa cleavage site was introduced into the precursor peptide by site 
directed mutagenesis for in vitro leader processing. Purified PseM was successfully obtained 
by overexpression. The modified PseAXa was obtained by coexpression of PseAXa with 
PseM. In addition, after in vitro cleavage of the leader, the peptide exhibited activity against 
M. luteus. In MALDI TOF MS analyses, the peptide had a mass of 2785 Da, which was 
equivalent to its calculated mass with four fold dehydration. The peptide thus produced was 
named pseudomycoicidin. 
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Chemical modification assays with IAA, TCEP and βME demonstrated the presence 
of four thioether rings and an additional disulfide linkage in pseudomycoicidin. Similarly, 
MALDI TOF MS of the trypsin digested peptide did not lead to loss of the signal for the core 
peptide. As the peptide was not cleaved by trypsin, it was confirmed that the cleavage site was 
protected by thioether rings. 
For the prediction of the ring pattern in pseudomycoicidin, six PseAXa mutant analogs 
were created by replacing single Cys with Ala residues. After coexpression with PseM, all the 
mutant peptides were partially modified and showed mixtures of different dehydration states. 
This result shows that the removal of Cys residues is unfavourable for modification and that it 
affected not only the cyclization process but also the dehydration step. Here, the bridging 
patterns of these peptides could not be elucidated. Therefore, the structural prediction of the 
ring pattern of pseudomycoicidin will need additional NMR data. 
To gain a first insight on the mode of action of pseudomycoicidin, the interaction of 
peptide with the lipid II was studied. When the peptide was tested for its ability to induce the 
lacZ promoters in the Bacillus reporter strains, positive induction was not observed. 
Additionally, the MIC of the peptide was not affected by the addition of lipid II. After thin 
layer chromatography of a mixture of the peptide and lipid II, the peptide-lipid II complex 
was not retained at the origin, however the lipid II band seemed to be retarded. Although, the 
lipid II binding motif (CTxS/TxDC) is present in the peptide, the interaction with lipid II was 
not confirmed so far by first experiments thus further experiments are required to determine 
the mode of action of the peptide in detail. 
In conclusion, genomic data mining identified a new class II lantibiotic gene cluster in 
B. pseudomycoides. The strain produces an antimicrobially active compound with a mass of 
2786 Da that is active against Gram-positive bacteria. This antimicrobial substance is fairly 
stable to heat, acidic pH and organic solvents, and is resistant to trypsin. The coexpression of 
the structural and modification gene, pseA and pseM from the gene cluster produced a 
modified prepeptide. After in vitro cleavage of the leader, the peptide was active and had a 
molecular mass of 2785 Da with four thioether rings and one disulfide ring. All the four 
thioether rings and disulfide linkage were indispensable for the activity of the peptide. Thus, 
the production of antimicrobially active peptide by coexpression of PseA with PseM indicates 
that the active substance in cell wash extract is indeed a lantibiotic. This antimicrobial peptide 
is a class II lantibiotic and was named “pseudomycoicidin”.  
 
 
 102 
 
6. References  
Abriouel H, Franz CMAP, Omar NB, Gálvez A (2011) Diversity and applications of 
Bacillus bacteriocins. FEMS Microbiol Rev. 35 (1): 201–232.  
Allgaier H, Jung G, Werner RG, Schneider U, Zähner H (1986) Epidermin: sequencing of 
a heterodetic tetracyclic 21-peptide amide antibiotic. Eur J Biochem. 160 (1): 9–22. 
Altena K, Guder A, Cramer C, Bierbaum G (2000) Biosynthesis of the lantibiotic 
mersacidin: organization of a type B lantibiotic gene cluster. Appl Environ Microbiol. 
66 (6): 2565–2571. 
Appleyard AN, Choi S, Read DM, Lightfoot A, Boakes S, Hoffmann A, Chopra I,  
Bierbaum G, Rudd BAM, Dawson MJ, Cortes J (2009) Dissecting structural and 
functional diversity of the lantibiotic mersacidin. Chem Biol. 16 (5–3): 490–498. 
Aranha C, Gupta S, Reddy KV (2004) Contraceptive efficacy of antimicrobial peptide 
Nisin: in vitro and in vivo studies. Contraception. 69 (4): 333–338. 
Arguelles Arias A, Ongena M, Devreese B, Terrak M, Joris B, Fickers P 
(2013) Characterization of amylolysin, a novel lantibiotic from Bacillus 
amyloliquefaciens GA1. PLoS ONE. 8 (12): e83037.  
Arnison PG, Bibb MJ, Bierbaum G, Bowers AA, Bugni TS, Bulaj G, Camarero JA, 
Campopiano DJ, Challis GL, Clardy J, Cotter PD, Craik DJ, Dawson M, Dittmann 
E, Donadio S, Dorrestein PC, Entian KD, Fischbach MA, Garavelli JS, Goransson 
U, Gruber CW, Haft DH, Hemscheidt TK, Hertweck C, Hill C, Horswill AR, 
Jaspars M, Kelly WL, Klinman JP, Kuipers OP, Link AJ, Liu W, Marahiel MA, 
Mitchell DA, Moll GN, Moore BS, Muller R, Nair SK, Nes IF, Norris GE, Olivera 
BM, Onaka H, Patchett ML, Piel J, Reaney MJ, Rebuffat S, Ross RP, Sahl H-G, 
Schmidt EW, Selsted ME, Severinov K, Shen B, Sivonen K, Smith L, Stein T, 
Süssmuth RD, Tagg JR, Tang GL, Truman AW, Vederas JC, Walsh CT, Walton 
JD, Wenzel SC, Willey JM, van der Donk WA (2012) Ribosomally synthesized and 
post-translationally modified peptide natural products: overview and recommendations 
for a universal nomenclature. Nat Prod Rep. 30 (1): 108–160. 
Asaduzzaman SM, Al-Mahin A, Bashar T, Noor R (2010) Lantibiotics: a candidate for 
future generation of antibiotics. S J Microbiol. 1 (1): 1–12. 
 103 
 
Asaduzzaman SM, Sonomoto K (2009) Lantibiotics: diverse activities and unique modes of 
action. J Biosci Bioeng. 107 (5): 475– 487. 
Bagley MC, Dale JW, Merritt EA, Xiong X (2005) Thiopeptide antibiotics. Chem Rev. 105 
(2): 685–714.  
Banks DJ, Porcella SF, Barbian KD, Beres SB, Philips LE, Voyich JM, DeLeo FR, 
Martin JM, Somerville GA, Musser JM (2004) Progress toward characterization of 
the group A Streptococcus metagenome: complete genome sequence of a macrolide–
resistant serotype M6 strain. J Infect Dis. 190 (4): 727–738. 
Bauer R, Chikindas ML, Dicks LM (2005) Purification, partial amino acid sequence and 
mode of action of pediocin PD–1, a bacteriocin produced by Pediococcus damnosus 
NCFB 1832. Int J Food Microbiol. 101 (1): 17–27. 
Begley M, Cotter PD, Hill C, Ross RP (2009) Identification of a novel two–peptide 
lantibiotic, lichenicidin, following rational genome mining for LanM proteins. Appl 
Environ Microbiol. 75 (17): 5451–5460. 
Bierbaum G, Brötz H, Koller K P, Sahl H-G (1995) Cloning, sequencing and production of 
the lantibiotic mersacidin. FEMS Microbiol Lett. 127 (1–2): 121–126.  
Bierbaum G, Gotz F, Peschel A, Kupke T, van de Kamp M, Sahl H-G (1996) The 
biosynthesis of the lantibiotics epidermin, gallidermin, Pep5 and epilancin K7. A Van 
Leeuw. 69 (2): 119–127.  
Bierbaum G, Sahl H-G (1987) Autolytic system of Staphylococcus simulans 22: influence of 
cationic peptides on activity of N–acetylmuramoyl–L–alanine amidase. J Bacteriol. 169 
(12): 5452–5458. 
Bierbaum G, Sahl H-G (2009) Lantibiotics: mode of action, biosynthesis and 
bioengineering. Curr Pharm Biotechnol. 10 (13): 2–18. 
Bierbaum G, Sahl H-G (2014) The search for new anti–infective drugs: untapped resources 
and strategies. Int J Med Microbiol. 304 (1): 1–2. 
Birri DJ, Brede DA, Nes IF (2012) Salivaricin D, a novel intrinsically trypsin–resistant 
lantibiotic from Streptococcus salivarius 5M6c isolated from a healthy infant. Appl 
Environ Microbiol.  78 (2): 402–410. 
 104 
 
Blight MA, Holland IB (1990) Structure and function of haemolysin B, P–glycoprotein and 
other members of a novel family of membrane translocators. Mol Microbiol. 4 (6): 873–
880.  
Blom J, Rueckert C, Niu B, Wang Q, Borriss R (2012) The complete genome of Bacillus 
amyloliquefaciens subsp. Plantarum CAU B946 contains a gene cluster for 
nonribosomal synthesis of iturin A. J Bacteriol. 194 (7): 1845–1846.  
Boakes S, Appleyard AN, Cortes J, Dawson MJ (2010) Organization of the biosynthetic 
genes encoding deoxyactagardine B (DAB), a new lantibiotic produced by Actinoplanes 
liguriae NCIMB41362. J Antibiot (Tokyo). 63 (7): 351–358. 
Boakes S, Cortes J, Appleyard AN, Rudd BA, Dawson MJ (2009) Organization of the 
genes encoding the biosynthesis of actagardine and engineering of a variant generation 
system. Mol Microbiol. 72 (5): 1126–1136. 
Bonelli RR, Schneider T, Sahl H-G, Wiedemann I (2006) Insights into in vivo activities of 
lantibiotics from gallidermin and epidermin mode of action studies. Antimicrob Agents 
Chemother. 50 (4): 1449–1457. 
Booth MC, Bogie CP, Sahl H-G, Siezen RJ, Hatter KL, Gilmore MS (1996) Structural 
analysis and proteolytic activation of Enterococcus faecalis cytolysin, a novel 
lantibiotic. Mol Microbiol. 21 (6): 1175–1184. 
Bouhss A, Al Dabbagh B, Vincent M, Odaert B, Aumont-Nicaise M, Bressolier P (2009) 
Specific interactions of clausin, a new lantibiotic, with lipid precursors of the bacterial 
cell wall. Biophys J. 97 (5): 1390–1397. 
Breukink E, de Kruijff B (2006) Lipid II as a target for antibiotics. Nat Rev Drug Discov. 5 
(4): 321–332. 
Breukink E, van Husden HE, Vollmerhaus PJ, Swiezewska E, Brunner L, Walker S, 
Heck AJ, de Kruiff B (2003) Lipid II is an intrnsic component of the pore induced by 
nisin in bacterial membranes. J Biol Chem. 278 (22): 19898–19903. 
Breukink E, Wiedemann I, van Kraaij C, Kuipers OP, Sahl H-G, de Kruijff B (1999) 
Use of the cell wall precursor lipid II by a pore-forming peptide antibiotic. Science. 286 
(5448): 2361–2364.  
Broadbent JR, Chou YC, Gillies K, Kondo JK (1989) Nisin inhibits several gram-positive, 
mastitis-causing pathogens. J Dairy Sci. 72 (12): 3342–3345. 
 105 
 
Brötz H, Bierbaum G, Leopold K, Reynolds PE, Sahl H-G (1998a) The lantibiotic 
mersacidin inhibits peptidoglycan synthesis by targeting lipid II. Antimicrob Agents 
Chemother. 42 (1):154–160. 
Brötz H, Bierbaum G, Reynolds, PE, Sahl H-G (1997) The lantibiotic mersacidin inhibits 
peptidoglycan biosynthesis at the level of transglycosylation. Eur J Biochem. 246 (1): 
193–199. 
Brötz H, Josten M, Wiedemann I, Schneider U, Götz F, Bierbaum G, Sahl H-G (1998b) 
Role of lipid-bound peptidoglycan precursors in the formation of pores by nisin, 
epidermin and other lantibiotics. Mol Microbiol. 30 (2): 317–327. 
Brown WLC, Acker MG, Clardy J, Walsh CT, Fischbach MA (2009) Thirteen 
posttranslational modifications convert a 14-residue peptide into the antibiotic thiocillin. 
Proc Natl Acad Sci USA. 106 (8): 2549–2553. 
Bulaj G (2005) Formation of disulfide bonds in proteins and peptides. Biotechnol Adv. 23 
(1): 87-92. 
Burkard M, Stein T (2008) Microtiter plate bioassay to monitor the interference of 
antibiotics with the lipid II cycle essential for peptidoglycan biosynthesis. J Microbiol 
Methods. 75 (1): 70–74. 
Caetano T, Krawczyk JM, Mösker E, Süssmuth RD, Mendo S (2011) Heterologous 
expression, biosynthesis, and mutagenesis of type II lantibiotics from Bacillus 
licheniformis in Escherichia coli. Chem Biol. 18 (1): 90 – 100.  
Castiglione F, Lazzarini A, Carrona l, Corti E, Ciciliato I, Gastaldo L, Candiani P, Losi 
D, Marinelli F, Selva E, Parenti F (2008) Determining the structure and mode of 
action of microbisporin, a potent lantibiotic active against multiresistant pathogens. 
Chem Biol. 15 (1): 22–31. 
Castiglione F, Lazzarini A, Carrona l, Corti E, Ciciliato I, Gastaldo L, Candiani P, Losi 
D, Marinelli F, Selva E (2007) A novel lantiboitic acting on bacterial cell wall 
synthesis produced by the uncommen actinimycete Planomonospora sp. Biochemistry. 
46 (20): 5884–5895. 
Chan DI, Prenner EJ, Vogel HJ (2006) Tryptophan- and arginine- rich antimicrobial 
peptides: structures and mechanisms of action. Biochim Biophys Acta. 1758 (9): 1184–
1202. 
 106 
 
Chandrapati S, O’Sullivan DJ (1999) Nisin independent induction of the nisA promoter in 
Lactococcus lactis during growth in lactose or galactose. FEMS Microbiol Lett. 170 (1): 
191–198. 
Chandrapati S, O’Sullivan DJ (2002) Characterization of the promoter regions involved in 
galactose- and nisin- mediated induction of the nisA gene in Lactococcus lactis ATCC 
11454. Mol Microbiol. 46 (2): 467–477. 
Chatterjee C, Miller LM, Leung YL, Xie L, Yi M, Kelleher NL, van der Donk WA 
(2005a) Lacticin 481 synthetase phosphorylates its substrate during lantibiotic 
production. J Am Chem Soc. 127 (44): 15332–15333.  
Chatterjee C, Patton GC, Cooper L, Paul M, van der Donk WA (2006) Engineering 
dehydro amino acids and thioethers into peptides using lacticin 481 synthetase. 
Chembiol. 13 (10): 1109–1117. 
Chatterjee C, Paul M, Xie L, van der Donk WA (2005b) Biosynthesis and mode of action 
of lantibiotics. Chem Rev. 105 (2): 633–684. 
Chatterjee S, Lad SJ, Phansalkar MS, Rupp RH, Ganguli BN, Fehlhaber HW, Kogler H 
(1992) Mersacidin, a new antibiotic from Bacillus: fermentation, isolation, purification, 
and chemical characterization. J Antibiot. (Tokyo). 45 (6): 832–838. 
Chehimi S, Delalande F, Sablé S, Hajlaoui MR, van Dorsselaer A, Limam F, Pons AM 
(2007) Purification and partial amino acid sequence of thuricin S, a new anti-Listeria 
bacteriocin from Bacillus thuringiensis. Can J Microbiol. 53 (2): 284–290. 
Chen L, Tai PC (1987) Effects of antibiotics and other inhibitors on ATP dependent protein 
translocation into membrane vesicles. J Bacteriol. 169 (6): 2373–2379. 
Chen P, Novak J, Kirk M, Barnes S, Qi F, Caufield PW (1998) Structure-activity study of 
the lantibiotic mutacin II from Streptococcus mutans T8 by a gene replacement 
strategy. Appl Environ Microbiol. 64 (7): 2335–2340. 
Chen XH, Koumoutsi A, Scholz R, Schneider K, Vater J, Sussmuth R, Piel J, Borriss R. 
10-3-2009. Genome analysis of Bacillus amyloliquefaciens FZB42 reveals its potential 
for biocontrol of plant pathogens. J Biotechnol. 140 (1-2): 27-37. 
Chopra L, Singh G, Choudhary V, Sahoo DK (2014) Sonorensin: an antimicrobial peptide, 
belonging to the heterocycloanthracin subfamily of bacteriocins, from a new marine 
isolate, Bacillus sonorensis MT93. Appl Environ Microbiol. 80 (10): 2981–2990. 
 107 
 
Choung SY, Kobayashi T, Inoue J, Takemoto K, Ishitsuka H, Inoue K (1988) Hemolytic 
activity of a cyclic peptide Ro09-0198 isolated from Streptoverticillium. Biochim 
Biophys Acta. 940 (2): 171–179. 
Claesen J, Bibb M (2010) Genome mining and genetic analysis of cypemycin biosynthesis 
reveal an unusual class of posttranslationally modified peptides. Proc Natl Acad Sci 
USA. 107 (37): 16297–16302. 
Coburn PS, Pillar CM, Jett BD, Haas W, Gilmore MS (2004) Enterococcus faecalis senses 
target cells and in response expresses cytolysin. Science. 306 (5705): 2270–2272. 
Cooper LE, McClerren AL, Chary A, van der Donk WA (2008) Structure-activity 
relationship studies of the two-component lantibiotic haloduracin. Chem Biol. 15 (10): 
1035–1045. 
Cotter PD, Deegan LH, Lawton EM, Draper LA, O’Connor PM, Hill C, Ross RP (2006) 
Complete alanine scanning of the two-component lantibiotic lacticin 3147: generating a 
blueprint for rational drug design. Mol Microbiol. 62 (3): 735–747. 
Cotter PD, Hill C, Ross RP (2005) Bacterial lantibiotics: strategies to improve therapeutic 
potential. Curr Protein Pept Sci. 6 (1): 61–75. 
Cox CR, Coburn PS, Gilmore MS (2005) Enterococcal cytolysin: a novel two component 
peptide system that serves as a bacterial defense against eukaryotic and prokaryotic 
cells. Curr Protein Pept Sci. 6 (1): 77–84. 
Crowther GS, Baines SD, Todhunter SL, Freeman J, Chilton CH, Wilcox MH (2013) 
Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of 
Clostridium difficile infection. J Antimicrob Chemother. 68 (1): 168–176. 
Dabard J, Bridonneau C, Phillipe C, Anglade P, Molle D, Nardi M, Ladiré M, Girardin 
H, Marcille F, Gomez A, Fons M (2001) Ruminococcin A, a new lantibiotic produced 
by a Ruminococcus gnavus strain isolated from human feces. Appl Environ Microbiol. 
67 (9): 4111–4118. 
Daly KM, Upton M, Sandiford SK, Draper LA, Wescombe PA, Jack RW, O'Connor 
PM, Rossney A, Götz F, Hill C, Cotter PD, Ross RP, Tagg JR (2010) Production of 
the Bsa lantibiotic by community-acquired Staphylococcus aureus strains. J Bacteriol. 
192 (4): 1131–1142. 
Davies J (2011) How to discover new antibiotics: harvesting the parvome. Curr Opin Chem 
Biol. 15 (1): 5–10. 
 108 
 
de Kwaadsteniet M, Doeschate K, Dicks LM (2008) Characterization of the structural gene 
encoding nisin F, a new lantibiotic produced by a Lactococcus lactis subsp. lactis isolate 
from freshwater catfish (Clarias gariepinus). Appl Environ Microbiol. 74 (2): 547–549. 
de Vos WM, Kuipers OP, van der Meer JR, Siezen RJ (1995) Maturation pathway of nisin 
and other lantibiotics: posttranslationally modified antimicrobial peptides exported by 
gram-positive bacteria. Mol Biol. 17 (3): 427–437.  
Deegan L, Hill C, Ross P, Sahl H-G (2006) The mode of action of the lantibiotic lacticin 
3147 - a complex mechanism involving specific interaction of two peptides and the cell 
wall precursor lipid II. Mol Microbiol. 61 (2): 285–296.  
Delves-Broughton J (1990) Nisin and its uses as a food preservative. Food Technol. 44 (3): 
100–117. 
Dierksen KP, Moore CJ, Inglis M, Wescombe PA, Tagg JR (2007) The effect of ingestion 
of milk supplemented with salivaricin A-producing Streptococcus salivarius on the 
bacteriocin-like inhibitory activity of streptococcal populations on the tongue. FEMS 
Microbiol Ecol. 59 (3): 584–591. 
Dischinger J, Basi Chipalu S, Bierbaum G (2014) Lantibiotics: promising candidates for 
future applications in health care. Int J Med Microbial. 304 (1): 51–62. 
Dischinger J, Josten M, Szekat C, Sahl H-G, Bierbaum G (2009) Production of the novel 
two-peptide lantibiotic lichenicidin by Bacillus licheniformis DSM 13. PLoS ONE. 4 
(8): e6788.  
Drablos F, Nicholson DG, Ronning M (1999) EXAFS study of zinc coordination in 
bacitracin A. Biochim Biophys Acta. 1431 (2): 433–442. 
Draper LA, Grainger K, Deegan LH, Cotter PD, Hill C, Ross RP (2009) Cross-immunity 
and immune mimicry as mechanisms of resistance to the lantibiotic lacticin 3147. Mol 
Microbiol. 71 (4): 1043–1054. 
Dufour A, Hindré T, Haras D, Le Pennec JP (2007) The biology of lantibiotics from the 
lacticin 481 group is coming of age. FEMS Microbiol Rev. 31 (2): 134–167. 
Ekkelenkamp MB, Hanssen M, Danny Hsu ST, de Jong A, Milatovic D, Verhoef J, van 
Nuland NA (2005) Isolation and structural characterization of epilancin 15X, a novel 
lantibiotic from a clinical strain of Staphylococcus epidermidis. FEBS Lett. 579 (9): 
1917–1922. 
 109 
 
Emma JS, Andrew R Hesketh, Mervyn JB (2013) Cloning and analysis of the 
planosporicin lantibiotic biosynthetic gene cluster of Planomonospora alba. J Bacteriol. 
195 (10): 2309–2321. 
Felnagle EA, Jackson EE, Chan YA, Podevels AM, Berti AD, McMahon MD, Thomas 
MG (2008) Nonribosomal peptide synthetases involved in the production of medically 
relevant natural products. Mol Pharm. 5 (2): 191–211.  
Fickers P (2012) Antibiotic compounds from Bacillus: Why are they so amazing? Am J 
Biochem Biotech. 8 (1): 40–46. 
Fimland G, Eijsink VG, Nissen-Meyer J (2002) Mutational analysis of the role of 
tryptophan residues in an antimicrobial peptides. Biochemistry. 41 (30): 9508–9515. 
Fleming A (2001) On the antibacterial action of cultures of a penicillium, with special 
reference to their use in the isolation of B. influenzae. 1929. Bull World Health Organ. 
79 (8): 780–790. 
Fontana MB, de Bastos Mdo C, Brandelli A (2006) Bacteriocins Pep5 and epidermin 
inhibit Staphylococcus epidermidis adhesion to catheters. Curr Microbiol. 52 (5): 350–
353. 
Foulston LC, Bibb MJ (2010) Microbisporicin gene cluster reveals unusual features of 
lantibiotic biosynthesis in actinomycetes. Proc Natl Acad Sci USA. 107: 13461–13466. 
Fredenhagen A, Fendrich G, Marki F, Marki W, Gruner J, Raschdorf F, Peter HH 
(1990) Duramycins B and C, two new lanthionine containing antibiotics as inhibitors of 
phospholipase A2. Structural revision of duramycin and cinnamycin. J Antibiot 
(Tokyo). 43 (11): 1403–1412. 
Fuchs SW, Jaskolla TW, Bochmann S, Kotter P, Wichelhaus T, Karas M, Stein T, 
Entian KD (2011) Entianin, a novel subtilin-like lantibiotic from Bacillus subtilis 
subsp. spizizenii DSM 15029T with high antimicrobial activity. Appl Environ 
Microbiol. 77 (5): 1698–1707. 
Furmanek B, Kaczorowski T, Bugalski R, Bielawski K, Bohdanowicz J, Podhajska AJ 
(1999) Identification, characterization and purification of the lantibiotic staphylococcin 
T, a natural gallidermin variant. J Appl Microbiol. 87 (6): 856–866. 
Garg N, Salazar-Ocampo LMA, van der Donk WA (2013) In vitro activity of the nisin 
dehydratase NisB. Proc Natl Acad Sci USA. 110 (18): 7258–7263.  
 110 
 
Garg N, Tang W, Goto Y, Nair SK, van der Donk WA (2012) Lantibiotics from 
Geobacillus thermodenitrificans. Proc Natl Acad Sci USA. 109 (14): 5241–5246.  
Georgalaki M, Papadimitriou K, Anastasiou R, Pot B, van Driessche G, Devreese 
B, Tsakalidou E (2013) Macedovicin, the second food-grade lantibiotic produced by 
Streptococcus macedonicus ACA-DC 198. Food Microbiol. 33 (1): 124–130.  
Georgalaki MD, van Den Berghe E, Kritikos D, Devreese B, van Beeumen J, 
Kalantzopoulos G, de Vuyst L, Tsakalidou E (2002) Macedocin, a food-grade 
lantibiotic produced by Streptococcus macedonicus ACA-DC 198. Appl Environ 
Microbiol. 68 (12): 5891–5903. 
Ghiselli R, Giacometti A, Cirioni O (2004) RNAIII-inhibiting peptide and/or nisin inhibit 
experimental vascular graft infection with methicillin-susceptible and methicillin 
resistant Staphylococcus epidermis. Eur J Vasc Endovasc Surg. 27 (6): 603–607. 
Gonzalez B, Arca P, Mayo B, Suarez JE (1994) Detection, purification, and partial 
characterization of plantaricin C, a bacteriocin produced by a Lactobacillus plantarum 
strain of dairy origin. Appl Enviro Microbiol. 60 (6): 2158–2163. 
Goto Y, Li B, Claesen J, Shi Y, Bibb MJ, van der Donk WA (2010) Discovery of unique 
lanthionine synthetases reveals new mechanistic and evolutionary insights. PLoS Biol. 8 
(3): e1000339.  
Goto Y, Okesli A, van der Donk WA (2011) Mechanistic studies of Ser/Thr dehydration 
catalyzed by a member of the LanL lanthionine synthetase family. Biochemistry. 50 (5): 
891–898. 
Grasemann H, Stehling F, Brunar H, Widmann R, Laliberte TW, Molina L, Doring G, 
Ratjen F (2007) Inhalation of Moli1901 in patients with cystic fibrosis. Chest. 131 
(5):1461–1466. 
Gross E, Kiltz HH, Craig LC (1973) Subtilin, II: the amino acid composition of subtilin. 
Hoppe Seylers Z Physiol Chem. 354 (7): 799–801. 
Gross E, Morell JL (1971) The structure of nisin. J Am Chem Soc. 93 (18): 4634–4635. 
Guder A, Schmitter T, Wiedemann I, Sahl H-G, Bierbaum G (2002) Role of the single 
regulator MrsR1 and the two-component system MrsR2/K2 in the regulation of 
mersacidin production and immunity. Appl Environ Microbiol. 68 (1): 106–113. 
 111 
 
Haft DH (2009) A strain variable bacteriocin in Bacillus anthracis and Bacillus cereus with 
repeated Cys-Xaa-Xaa motifs. Biol Direct. 4: 15. 
Haft DH, Basu MK, Mitchell DA (2010) Expansion of ribosomally produced natural 
products: a nitrile hydratase- and Nif11-related precursor family. BMC Biology. 8: 70. 
Hancock RE, Chapple DS (1999) Peptide antibiotics. Antimicrob Agents Chemother. 43 (6): 
1317–1323. 
Haney EF, Petersen AP, Lau CK, Jing W, Storey DG, Vogel HJ (2013) Mechanism of 
action of puroindoline derived tryptophan-rich antimicrobial peptides. Biochim Biophys 
Acta. 1828 (8): 1802–1813. 
Hao K, He P, Blom J, Rueckert C, Mao Z, Wu Y, He Y, Borriss R (2012) The genome of 
plant growth-promoting Bacillus amyloliquefaciens subsp. plantarum strain YAU 
B9601-Y2 contains a gene cluster for mersacidin synthesis. J Bacteriol. 194 (12): 3264–
3265. 
Hasper HE, de Kruijff, B, Breukink E (2004) Assembly and stability of nisin-lipid II pores. 
Biochemistry. 43 (36): 11567–11575.  
Hasper HE, Kramer NE, Smith JL, Hillman JD, Zachariah C, Kuipers OP, de Kruijff 
B, Breukink E (2006) An alternative bactericidal mechanism of action for lantibiotic 
peptides that target lipid II. Science. 313 (5793): 1636–1637. 
He Z, Kisla D, Zhang L, Yuan C, Green-Church KB, Yousef AE (2007) Isolation and 
identification of a Paenibacillus polymyxa strain that coproduces a novel lantibiotic and 
polymyxin. Appl Environ Microbiol. 73 (1): 168–178. 
Heidrich C, Pag U, Josten M, Metzger J, Jack RW, Bierbaum G, Jung G, Sahl H-G 
(1998) Isolation, characterization, and heterologous expression of the novel lantibiotic 
epicidin 280 and analysis of its biosynthetic gene cluster. Appl Environ Microbiol. 64 
(9): 3140–3146. 
Hillman JD, Novak J, Sagura E, Gutierrez JA, Brooks TA, Crowley PJ, Hess M, Azizi 
A, Leung K, Cvitkovitch D, Bleiweis AS (1998) Genetic and biochemical analysis of 
mutacin 1140, a lantibiotic from Streptococcus mutans. Infect Immun. 66 (6): 2743–
2749.  
Hindre T, Le Pennec JP, Haras D, Dufour A (2004) Regulation of lantibiotic lacticin 481 
production at the transcriptional level by acid pH. FEMS Microbiol Lett. 231 (2): 291–
298. 
 112 
 
Holo H, Jeknic Z, Daeschel M, Stevanovic S, Nes IF (2001) Plantaricin W from 
Lactobacillus plantarum belongs to a new family of two-peptide lantibiotics. 
Microbiology. 147 (P3): 643–651. 
Holtsmark I, Mantzilas D, Eijsink VG, Brurberg MB (2006) Purification, characterization, 
and gene sequence of michiganin A, an actagardine-like lantibiotic produced by the 
tomato pathogen Clavibacter michiganensis subsp. michiganensis. Appl Environ 
Microbiol. 72 (9): 5814–5821. 
Hosoda K, Ohya M, Kohno T, Maeda T, Endo S, Wakamatsu K (1996) Structure 
determination of an immunopotentiator peptide, cinnamycin, complexed with 
lysophosphatidylethanolamine by 1H-NMR1. J Biochem (Tokyo). 119 (2): 226–30. 
Hsu STD, Breukink E, Bierbaum G, Sahl H-G, de Kruijff B, Kaptein R, van Nuland NA, 
Bonvin AM (2003) NMR study of mersacidin and lipid II interaction in 
dodecylphosphocholine micelles. Conformational changes are a key to antimicrobial 
activity. J Biol Chem. 278 (15): 13110–13117. 
Hsu STD, Breukink E, Kaptein R (2006) Structural motifs of Lipid II-binding lantibiotics 
as a blueprint for novel antibiotics. Anti-Infect Agents Med Chem. 5 (3): 245–254. 
Hsu STD, Breukink E, Tischenko E, Lutters MA, de Kruijff B, Kaptein R, Bonvin AM, 
van Nuland NA (2004) The nisin-lipid II complex reveals a pyrophosphate cage that 
provides a blueprint for novel antibiotics. Nat Struct Mol Biol. 11 (10): 963–967.  
Hurst A (1981) Nisin. Adv Appl Microbiol. 27: 85–123. 
Hyink O, Balakrishnan M, Tagg JR (2005) Streptococcus rattus strain BHT produces both 
a class I two-component lantibiotic and a class II bacteriocin. FEMS Microbiol Lett. 252 
(2): 235–241. 
Hynes WL, Friend VL, Ferretti JJ (1994) Duplication of the lantibiotic structural gene in 
M-type 49 group A Streptococcus strains producing streptococcin A-M49.  Appl 
Environ Microbiol. 60 (11): 4207–4209. 
Ingram L (1969) Synthesis of the antibiotic nisin: formation of lanthionine and P-methyl-
lanthionine. Biochim Biophys Acta. 184 (1): 216–219. 
Ingram L (1970) A ribosomal mechanism for synthesis of peptides related to nisin. Biochim 
Biophys Acta. 224 (1): 263–265. 
 113 
 
Islam MR, Nishie M,  Nagao J, Zendo T, Keller S,  Nakayama J, Kohda D, Sahl H-G, 
Sonomoto K (2012) Ring A of nukacin ISK-1: a lipid II-binding motif for type-A(II) 
lantibiotic. J Am Chem Soc. 134 (8): 3686–3690. 
Islam MR, Shioya K, Nagao J, Nishie M, Jikuya H, Zendo T, Nakayama J, Sonomoto K 
(2009) Evaluation of essential and variable residues of nukacin ISK-1by NNK scanning. 
Mol Microbiol. 72 (6): 1438-1447.  
Israil AM, Jack RW, Jung G, Sahl H-G (1996) Isolation of a new epidermin variant from 
two strains of Staphylococcus epidermidis frequency of lantibiotic production in 
coagulase-negative staphylococci. Zentralbl Bakteriol. 284 (2–3): 285–296. 
Iwamoto K, Hayakawa T, Murate M, Makino A, Ito K, Fujisawa T, Kobayashi T (2007) 
Curvature-dependent recognition of ethanolamine phospholipids by duramycin and 
cinnamycin. Biophys J. 93 (5): 1608–1619.  
Jabes D, Brunati C, Candiani G, Riva S, Romano G, Donadio S (2011) Efficacy of the 
new lantibiotic NAI-107 in experimental infections induced by multidrug-resistant 
Gram-positive pathogens. Antimicrob Agents Chemother. 55 (4): 1671–1676. 
Jack R, Benz R, Tagg J, Sahl H-G (1994) The mode of action of SA-FF22, lantibiotic 
isolated from Streptococcus pyogens strain FF22. Eur J Biochem. 219 (1–2): 699–705. 
Jack RW, Tagg JR, Ray B (1995) Bacteriocins of gram –positive bacteria. Microbiol Rev. 
59 (2): 171–200. 
Jung G (1991) Lantibiotics: a survey. Nisin and novel lantibiotics. Proc. 1
st
 Int. Workshop on 
Lantibiotics, (Jung, G.; Sahl, H-G., eds) ESCOM, Leiden. pages 1–34. 
Kabuki T, Uenishi H, Watanabe M, Seto Y, Nakajima H (2007) Characterization of a 
bacteriocin, thermophilin 1277, produced by Streptococcus thermophilus SBT1277. J 
Appl Microbiol. 102 (4): 971–980. 
Kaletta C, Entian KD, Jung G (1991) Prepeptide sequence of cinnamycin (Ro 09-0198): the 
first structural gene of a duramycin type lantibiotic. Eur J Biochem. 199 (2): 411–15. 
Kaletta C, Entian KD, Kellner R, Jung G, Reis M, Sahl H-G (1989) Pep5, a new 
lantibiotic: structural gene isolation and prepeptide sequence. Arch Microbiol. 152 (1): 
16–19. 
Kalmokoff ML, Lu D, Whitford MF, Teather RM (1999) Evidence for production of a 
new lantibiotic (butyrivibriocin OR79A) by the ruminal anaerobe Butyrivibrio 
 114 
 
fibrisolvens OR79: characterization of the structural gene encoding butyrivibriocin 
OR79A. Appl Enviro Microbiol. 65 (5): 2128–2135. 
Karaya K, Shimizu T, Taketo A (2001) New gene cluster for lantibiotic streptin possibly 
involved in streptolysin S formation. J Biochem. 129 (5): 769–775. 
Kataeva IA, Yang SJ, Dam P, Poole FL, Yin Y, Zhou F, Chou WC, Xu Y, Goodwin L, 
Sims DR, Detter JC, Hauser LJ, Westpheling J, Adams MW (2009) Genome 
sequence of the anaerobic, thermophilic, and cellulolytic bacterium "Anaerocellum 
thermophilum" DSM 6725. J Bacteriol. 191 (11): 3760-3761. 
Kellner R, Jung G, Horner T, Zahner H, Schnell N, Entian KD, Götz F (1988) 
Gallidermin: a new lanthionine-containing polypeptide antibiotic. Eur J Biochem. 177 
(1): 53–59. 
Kellner R, Jung G, Josten M, Kaletta C, Entian KD, Sahl H-G (1989) Pep5: structure 
elucidation of a large lantibiotic. Angew Chem. 101 (5): 618–621. 
Kelly WL, Pan L, Li C (2009) Thiostrepton biosynthesis: prototype for a new family of 
bacteriocins. J Am Chem Soc. 131 (12): 4327–4334. 
Kido Y, Hamakado T, Yoshida T, Anno M, Motoki Y, Wakamiya T, Shiba T (1983) 
Isolation and characterization of ancovenin, a new inhibitor of angiotensin I converting 
enzyme, produced by actinomycetes. J Antibiot (Tokyo). 36 (10): 1295–1299. 
Kies S, Vuong C, Hille M, Peschel A, Meyer C, Götz F, Otto M (2003) Control of 
antimicrobial peptide synthesis by the agr quorum sensing system in Staphylococcus 
epidermidis: activity of the lantibiotic epidermin is regulated at the level of precursor 
peptide processing. Peptides. 24 (3): 329–338. 
Klaenhammer TR (1993) Genetics of bacteriocins produced by lactic acid bacteria. FEMS 
Microbiol Rev. 12 (1–3): 39–86. 
Klein C, Entian KD (1994) Genes involved in self protection against the lantibiotic subtilin 
produced by Bacillus subtilis ATCC 6633. Appl Environ Microbiol. 60 (8): 2793–2801. 
Kluskens LD, Kuipers A, Rink R, de Boef E, Fekken S, Driessen AJ, Kuipers OP, Moll 
GN (2005) Post-translational modification of therapeutic peptides by NisB, the 
dehydratase of the lantibiotic nisin. Biochemistry. 44 (38): 12827–12834. 
Knerr PJ, van der Donk WA (2012) Discovery, biosynthesis, and engineering of 
lantipeptides. Ann Rev Biochem. 81: 479–505. 
 115 
 
Kodani S, Hudson ME, Durrant MC, Buttner MJ, Nodwell JR, Willey JM (2004) The 
SapB morphogen is a lantibiotic-like peptide derived from the product of the 
developmental gene ramS in Streptomyces coelicolor. Proc Natl Acad Sci USA. 101: 
11448–11453. 
Kodani S, Lodato MA, Durrant MC, Picart F, Willey JM (2005) SapT, a lanthionine- 
containing peptide involved in aerial hyphae formation in the Streptomycetes. Mol 
Microbiol. 58 (5): 1368–1380.  
Komiyama K, Otoguro K, Segawa T, Shiomi K, Yang H, Takahashi Y, Hayashi M, 
Otani T, Omura S (1993) A new antibiotic, cypemycin. Taxonomy, fermentation, 
isolation and biological characteristics. J Antibiot (Tokyo). 46 (11): 1666–1671. 
Kordel M, Benz R, Sahl H-G (1988) Mode of action of staphylococcin-like peptide Pep5-
voltage dependent depolarization of bacterial and artificial membranes. J Bacteriol. 170 
(1): 84–88. 
Krätzschmar J, Krause M, Marahiel MA (1989) Gramicidin S biosynthesis operon 
containing the structural genes grsA and grsB has an open reading frame encoding a 
protein homologous to fatty acid thioesterases. J Bacteriol. 171 (10): 5422–5429. 
Krawczyk B, Völler GH, Völler J, Ensle P, Süssmuth RD (2012) Curvopeptin: a new 
lanthionine-containing class III lantibiotic and its co-substrate promiscuous synthetase. 
Chembiochem.  13 (14): 2065–2071. 
Kuipers OP, Beerthuyzen MM, Siezen RJ, de Vos WM (1993) Characterization of the 
nisin gene cluster nisABTCIPR of Lactococcus lactis. Requirement of expression of the 
nisA and nisI genes for development of immunity. Eur J Biochem. 216 (1): 281–291. 
Kupke T, Götz F (1996) Post-translational modifications of lantibiotics. A Van Leeuw. 69 
(2): 139–150. 
Lawton EM, Cotter PD, Hill C, Ross RP (2007) Identification of a novel twopeptide 
lantibiotic, haloduracin, produced by the alkaliphile Bacillus halodurans C-125. FEMS 
Microbiol Lett 267: 64–71. 
Lawton EM, Ross RP, Hill C, Cotter PD (2007) Two-peptide lantibiotics: a medical 
perspective. Mini Rev Med Chem. 7 (12): 1236–1247. 
Lawyer C, Pai S, Watabe M, Borgia P, Mashimo T, Eagleton L, Watabe K (1996) 
Antimicrobial activity of a 13 amino acid tryptophan-rich peptide derived from putative 
 116 
 
porcine precursor protein of a novel family of antibacterial peptides. FEBS Lett 390 (1): 
95-98. 
Lee JH, Li X, O’Sullivan (2011) Transcription analysis of a lantibiotic gene cluster from 
Bifidobacterium longum DJO10A. Appl Environ Microbiol. 77 (17): 5879–5887. 
Lee MV, Ihnken LAF, You YO, McClerren AL, van der Donk WA, Kelleher NL (2009) 
Distributive and directional behaviour of lantibiotic synthetases revealed by high 
resolution tandem mass spectrometry. J Am Chem Soc. 131 (34):12258–12264. 
Lee SW, Mitchell DA, Markley AL, Hensler ME, Gonzalez D, Wohlrab A, Dorrestein 
PC, Nizet V, Dixon JE (2008) Discovery of a widely distributed toxin biosynthetic 
gene cluster. Proc Natl Acad Sci USA. 105 (15): 5879–5884. 
Levengood MR, Patton GC, Van der Donk WA (2007) The leader peptide is not required 
for post-translational modification by lacticin 481 synthetase. J Am Chem Soc. 129 (34): 
10314–10315. 
Li B, Sher D, Kelly L, Shi Y, Huang K, Knerr PJ, Joewono I, Rusch D, Chisholm SW, 
van der Donk WA (2010) Catalytic promiscuity in the biosynthesis of the cyclic 
peptide secondary metabolites in planktonic marine cyanobacteria. Proc Natl Acad Sci 
USA. 107 (23): 10430–10435. 
Li B, Yu JPJ, Brunzelle JS, Moll GN, van der Donk WA, Nair SK (2006) Structure and 
mechanism of the lantibiotic cyclase involved in nisin biosynthesis. Science. 311 
(5766): 1464–1467.  
Li J, Girard G, Florea BI, Geurink PP, Li N, van der Marel GA, Overhand 
M, Overkleeft HS, van Wezel GP (2012) Identification and isolation of lantibiotics 
from culture: a bioorthogonal chemistry approach. Org Biomol Chem. 10 (43): 8677–
8683. 
Li YM, Milne JC, Madison LL, Kolter R, Walsh CT (1996) From peptide precursors to 
oxazole and thiazole-containing peptide antibiotics: microcin B17 synthase. Science. 
274 (5290): 1188–1193. 
Liao R, Duan L, Lei C, Pan H, Ding Y, Zhang Q, Chen D, Shen B, Yu Y, Liu W (2009) 
Thiopeptide biosynthesis featuring ribosomally synthesized precursor peptides and 
conserved posttranslational modifications. Chem Biol. 16 (2): 141–147. 
Limbert M, Isert D, Klesel N, Markus A, Seibert G, Chatterjee S, Chatterjee DK, Jani R 
H, Ganguli BN (1991) Chemotherapeutic properties of mersacidin in vitro and in vivo, 
 117 
 
in: G. Jung, HG Sahl (Eds.), Nisin and novel lantibiotics, ESCOM, Leiden, The 
Netherlands. 448–456. 
Lin Y, Teng K, Huan L, Zhong J (2011) Dissection of the bridging pattern of bovicin HJ50, 
a lantibiotic containing a characteristic disulfide bridge. Microbiol Res. 166 (3): 146 –
154. 
Linett PE, Strominger JL (1973) Additional antibiotic inhibitors of peptidoglycan synthesis. 
Antimicrob Agents Chemother. 4 (3): 231– 236. 
Liu W, Hansen JN (1992) Enhancement of the chemical and antimicrobial properties of 
subtilin by site-directed mutagenesis. J Biol Chem. 267 (35): 25078–85. 
Livermore DM (2004) The need for new antibiotics. Clin Microbiol Infect. 10 (4):1-9. 
Maffioli SI, Potenza D, Vasile F, de Matteo M, Sosio M, Marsiglia B, Rizzo V, Scolastico 
C, Donadio S (2009) Structure revision of the lantibiotic 97518. J Nat Prod. 72 (4): 
605–607. 
Majchrzykiewicz JA, Lubelski J, Moll GN, Kuipers A, Bijlsma JJ, Kuipers OP, Rink R 
(2010) Production of a class II two-component lantibiotic of Streptococcus pneumoniae 
using the class I nisin synthetic machinery and leader sequence. Antimicrob Agents 
Chemother. 54 (4): 1498–1505. 
Märki F, Hanni E, Fredenhagen A, van Oostrum J (1991) Mode of action of the 
lanthionine-containing peptide antibiotics duramycin, duramycin B and C, and 
cinnamycin as indirect inhibitors of phospholipase A2. Biochem Pharmacol. 42 (10): 
2027. 
Marsh AJ, O’Sullivan O, Ross RP, Cotter PD, Hill C (2010) In silico analysis highlights 
the frequency and diversity of type 1 lantibiotic gene clusters in genome sequenced 
bacteria. BMC Genomics. 11: 679 
Mathews RG, Goulding CW (1997) Enzyme catalyzed methyl tranfers to thiols: the role of 
zinc. Curr Opin Chem Biol. 1 (3): 332–339. 
McAuliffe O, Hill C, Ross RP (1999) Inhibition of Listeria monocytogenes in cottage cheese 
manufactured with a lacticin 3147-producing starter culture. J Appl Microbiol. 86 (2): 
251–256. 
 118 
 
McAuliffe O, Hill C, Ross RP (2000) Identification and overexpression of ltnI, a novel gene 
which confers immunity to the two-component lantibiotic, lacticin 3147. 
Microbiology.146 (P 1): 129–138. 
McAuliffe O, O’Keeffe T, Hill C, Ross RP (2001) Regulation of immunity to the two-
component lantibiotic, lacticin 3147, by the transcriptional repressor LtnR. Mol 
Microbiol. 39 (4): 982–993. 
McClerren AL, Cooper LE, Quan C, Thomas PM, Kelleher NL, van der Donk WA 
(2006) Discovery and in vitro biosynthesis of haloduracin, a new two-component 
lantibiotic. Proc Natl Acad Sci USA. 103: 17243–17248.  
Meindl K, Schmiederer T, Schneider K, Reicke A, Butz D, Keller S, Gühring H, Vértesy 
L, Wink J, Hoffmann H, Brönstrup M, Sheldrick GM, Süssmuth RD (2010) 
Labyrinthopeptins: a new class of carbacyclic lantibiotics. Angew Chem Int. 49 (6): 
1151–1154. 
Melby JO, Nard NJ, Mitchell DA (2011) Thiazole/oxazole-modified microcins: complex 
natural products from ribosomal templates. Curr Opin Chem Biol. 15 (3): 369–378. 
Meyer C, Bierbaum G, Heidrich C, Reis M, Süling J, Iglesias-Wind MI, Kempter C, 
Molitor E, Sahl H-G (1995) Nucleotide sequence of the lantibiotic Pep5 biosynthetic 
gene cluster and functional analysis of PepP and PepC. Eur J Biochem. 232 (2): 478–
489. 
Miller LM, Chatterjee C, van der Donk WA, Kelleher NL (2006) The dehydration activity 
of lacticin 481 synthetase is highly processive. J Am Chem Soc. 128 (5): 1420–1421.  
Miroux B, Walker JE (1996) Over-production of proteins in Escherichia coli: mutant hosts 
that allow synthesis of some membrane proteins and globular proteins at high levels. J 
Mol Biol. 260 (3): 289–298. 
Mitchell DA, Lee SW, Pence MA, Markley AL, Limm JD, Nizet V, Dixon JE (2009) 
Structural and functional dissection of the heterocyclic peptide cytotoxin streptolysin S. 
J Biol Chem. 284 (19): 13004–13012. 
Mittenhuber G, Weckermann R, and Marahiel MA (1989) Gene cluster containing the 
genes for tyrocidine synthetases 1 and 2 from Bacillus brevis: evidence for an operon. J. 
Bacteriol. 171: 4881–1887. 
Moll GN, Konings WN, Driessen AJM (1999) Bacteriocins: mechanism of membrane 
insertion and pore formation. Ant Van Leeuw. 76 (1–4): 185–198. 
 119 
 
Morgan SM, O'Connor PM, Cotter PD, Ross RP, Hill C (2005) Sequential actions of the 
two component peptides of the lantibiotic lacticin 3147 explain its antimicrobial activity 
at nanomolar concentrations. Antimicrob Agents Chemother. 49 (7): 2606–2611. 
Morikawa N, Hagiwara K, Nakajima T (1992) Brevinin-1 and -2, unique antimicrobial 
peptides from the skin of the frog, Rana brevipoda porsa. Biochem Biophys Res 
Commun. 189 (1):184–190. 
Morris RP, Leeds JA, Naegeli HU, Oberer L, Memmet K, Weber E, LaMarche MJ, 
Parker CN, Burrer N, Esterow S, Hein AE, Schmitt EK, Krastel P (2009) 
Ribosomally synthesized thiopeptide antibiotics targeting elongation factor Tu. J Am 
Chem Soc. 131 (16): 5946–5955. 
Morrison DA (1977) Transformation in Escherichia coli: cryogenic preservation of 
competent cells. J Bacteriol. 132 (1): 349–351. 
Mortvedt CI, Nes IF (1990) Plasmid-associated bacteriocin production by Lactococcus sake 
strain. J Gen Microbiol. 136 (8): 1601–1607. 
Mortvedt CI, Nissen-Meyer J, Sletten K, Nes IF (1991) Purification and amino acid 
sequence of lactocin S, a bacteriocin produced by Lactobacillus sake L45. Appl Environ 
Microbiol. 57 (6): 1829–1834.  
Mota-Meira M, Lacroix C, LaPointe G, Lavoie MC (1997) Purification and structure of 
mutacin B-Ny266: a new lantibiotic produced by Streptococcus mutans. FEBS Lett. 410 
(2-3): 275–279. 
Mulders JW, Boerrigter IJ, Rollema HS, Siezen RJ, de Vos WM (1991) Identification and 
characterization of the lantibiotic nisin Z, a natural nisin variant. Eur J Biochem. 201 
(3): 581–584. 
Müller WM, Ensle P, Krawczyk B, Süssmuth RD (2011) Leader peptide-directed 
processing of labyrinthopeptin A2 precursor peptide by the modifying enzyme LabKC. 
Biochemistry. 50 (39): 8362–8373.  
Müller WM, Schmiederer T, Ensle P, Süssmuth RD (2010) In vitro biosynthesis of the 
prepeptide of type-III lantibiotic labyrinthopeptin A2 including formation of a C-C bond 
as a post-translational modification. Angew Chem Int Ed Engl. 49 (13): 2436–2440. 
Nagao J, Morinaga Y, Islam MR, Asaduzzaman SM, Aso Y, Nakayama J, Sonomoto K 
(2009) Mapping and identification of the region and secondary structure required for the 
maturation of the nukacin ISK-1 prepeptide. Peptides. 30 (8): 1412–1420. 
 120 
 
Nagao J, Shioya K, Harada Y, Okuda K, Zendo T, Nakayama J, Sonomoto K (2011) 
Engineering unusual amino acids into peptides using lantibiotic synthetase. Methods 
Mol Biol. 705: 225-236. 
Nakagawa I, Kurokawa K, Yamashita A, Nakata M, Tomiyasu Y, Okahashi N, 
Kawabata S, Yamazaki K, Shiba T, Yasunaga T, Hayashi H, Hattori M, Hamada S 
(2003) Genome sequence of an M3 strain of Streptococcus pyogenes reveals a large-
scale genomic rearrangement in invasive strains and new insights into phage evolution. 
Genome Res. 13 (6A): 1042–1055. 
Nakamura LK (1998) Bacillus pseudomycoides sp. nov. Int J Syst Bacteriol. 48 (P 3): 1031–
1035. 
Nakamura S, Racker E (1984) Inhibitory effect of duramycin on partial reactions catalyzed 
by (Na+, K+)-adenosinetriphosphatase from dog kidney. Biochemistry. 23 (2): 385–389. 
Nascimento JS, Ceotto H, Nascimento SB, Giambiagi-Demarval M, Santos KR, Bastos 
MC (2006) Bacteriocins as alternative agents for control of multiresistant 
staphylococcal strains. Lett Appl Microbiol. 42 (3): 215–221. 
Navaratna MA, Sahl H-G, Tagg JR (1998) Two-component anti-Staphylococcus aureus 
lantibiotic activity produced by Staphylococcus aureus C55. Appl Environ Microbiol. 
64 (12): 4803–4808. 
Navarro J, Chabot J, Sherrill K, Aneja R, Zahler SA, Racker E (1985) Interaction of 
duramycin with artificial and natural membranes. Biochemistry. 24 (17): 4645–4650. 
Nes IF, Diep DB, Havarstein LS, Brurberg MB, Eijsink V, Holo H (1996) Biosynthesis of 
bacteriocins in lactic acid bacteria. A Van Leeuw. 70 (2–4): 113–128. 
Newman DJ, Cragg GM (2007) Natural products as sources of new drugs over the last 25 
years. J Nat Prod. 70 (3): 461–477. 
Nishie M, Sasaki M, Nagao J, Zendo T, Nakayama J, Sonomoto K (2011) lantibiotic 
transporter requires cooperative functioning of the peptidase domain and ATP binding 
domain. J Biol Chem. 286 (13): 11163–11169. 
Novak J, Caufield PW, Miller EJ (1994) Isolation and biochemical characterization of a 
novel lantibiotic mutacin from Streptococcus mutans. J Bacteriol. 176 (14): 4316–4320. 
O’Sullivan DJ, Lee JH (2011) Lantibiotics and uses there of. US Patent No: 7,960,505. 
 121 
 
Okeley NM, Paul M, Stasser JP, Blackburn N, van der Donk WA (2003) SpaC and NisC, 
the cyclases involved in subtilin and nisin biosynthesis, are zinc proteins. Biochemistry. 
42 (46): 13613–13624. 
Ökesli A, Cooper LE, Fogle EJ, van der Donk WA (2011) Nine post-translational 
modifications during the biosynthesis of cinnamycin. J Am Chem Soc. 133 (34): 13753–
13760. 
Okuda K, Aso Y, Nakayama J, Sonomoto K (2008) Cooperative transport between 
NukFEG and NukH in immunity against the lantibiotic nukacin ISK-1 produced by 
Staphylococcus warneri ISK-1. J Bacteriol. 190 (1): 356–362. 
Oliynyk I, Varelogianni G, Roomans GM, Johannesson M (2010) Effect of duramycin on 
chloride transport and intracellular calcium concentration in cystic fibrosis and non-
cystic fibrosis epithelia. Apmis. 118 (12): 982–990. 
Oman TJ, Boettcher JM, Wang H, Okalibe XN, van der Donk WA (2011) Sublancin is 
not a lantibiotic but an S-linked glycopeptide. Nat Chem Biol. 7 (2): 78–80.  
Oman TJ, van der Donk WA (2009) Insights into the mode of action of the two -peptide 
lantibiotic haloduracin. ACS Chem Biol. 4 (10): 865–874. 
Oman TJ, van der Donk WA (2010) Follow the leader: the use of leader peptides to guide 
natural product biosynthesis. Nat Chem Biol. 6 (1): 9–18. 
Onaka H, Nakaho M, Hayashi K, Igarashi Y, Furumai T (2005) Cloning and 
characterization of the goadsporin biosynthetic gene cluster from Streptomyces sp. TP-
A0584. Microbiology. 151 (P 12): 3923–3933. 
Paik SH, Chakicherla A, Hansen JN (1998) Identification and characterization of the 
structural and transporter genes for, and the chemical and biological properties of, 
sublancin 168, a novel lantibiotic produced by Bacillus subtilis 168. J Biol Chem. 273 
(36): 23134–23142. 
Papadelli M, Karsioti A, Anastasiou R, Georgalaki M, Tsakalidou E (2007) 
Characterization of the gene cluster involved in the biosynthesis of macedocin, the 
lantibiotic produced by Streptococcus macedonicus. FEMS Microbiol Lett. 272 (1): 75–
82. 
Patton GC, Paul M, Cooper LE, Chatterjee C, van der Donk WA (2008) The importance 
of the leader sequence for directing lanthionine formation in lacticin 481. Biochemistry. 
47 (28): 7342–7351. 
 122 
 
Paul M, Patton GC, van der Donk WA (2007) Mutants of the zinc ligands of lacticin 481 
synthetase retain dehydration activity but have impaired cyclization activity. 
Biochemistry. 46 (21): 6268–6276. 
Perez C, Suarez C, Castro GR (1992) Production of antimicrobials by Bacillus subtilis MIR 
15. J. Biotechnol. 26 (2–3): 331–336. 
Peschel A, Götz F (1996) Analysis of the Staphylococcus epidermidis genes epi F,-E and –G 
involved in epidermin immunity. J Bacteriol. 178 (2): 531–536. 
Peschel A, Schnell N, Hille M, Entian KD, Götz F (1997) Secretion of the lantibiotic 
epidermin and gallidermin: sequence analysis of the genes gdmT and gdmH, their 
influence on the epidermin production and their regulation by EpiQ. Mol Gen Genet. 
254 (3): 312–318. 
Phelan RW, Barret M, Cotter PD, O'Connor PM, Chen R, Morrissey JP, Dobson ADW, 
O'Gara F, Barbosa TM (2013) Subtilomycin: A New Lantibiotic from Bacillus subtilis 
Strain MMA7 Isolated from the Marine Sponge Haliclona simulans. Mar Drugs. 11(6): 
1878–1898.  
Piard JC, Kuipers OP, Rollema HS, Desmazeaud MJ, de Vos WM (1993) Structure, 
organization, and expression of the lct gene for lacticin 481, a novel lantibiotic produced 
by Lactococcus lactis. J Biol Chem. 268 (22): 16361–16368. 
Pidot SJ, Coyne S, Kloss F, Hertweck C (2014). Antibiotics from neglected bacterial 
sources. Int J Med Microbiol. 304 (1): 14–22. 
Plat A, Kluskens LD, Kuipers A, Rink R, Moll GN (2011) Requirements of the engineered 
leader peptide of nisin for inducing modification, export, and cleavage. Appl Environ 
Microbiol. 77 (2): 604–611. 
Pridmore D, Rekhif N, Pittet AC, Suri B, Mollet B (1996) Variacin, a new lanthionine-
containing bacteriocin produced by Micrococcus varians: comparison to lacticin 481 of 
Lactococcus lactis. Appl Environ Microbiol. 62 (5): 1799–1802. 
Qi F, Chen P, Caufield PW (1999) Purification of mutacin III from group III Streptococcus 
mutans UA787 and genetic analyses of mutacin III biosynthesis genes. Appl Environ 
Microbiol. 65 (9): 3880–3887.  
Qi F, Chen P, Caufield PW (2000) Purification and biochemical characterization of mutacin 
I from the group I strain of Streptococcus mutans, CH43, and genetic analysis of 
mutacin I biosynthesis genes. Appl Environ Microbiol. 66 (8): 3221–3229. 
 123 
 
Ramseier HR (1960) Die wirkung von nisin auf Clostridium butyricum. Arch Mikrobiol. 37 
(1): 57–94. 
Reisinger P, Seidel H, Tschesche H, Hammes WP (1980) The effect of nisin on murein 
synthesis. Arch Microbiol. 127 (3): 187–193. 
Rey MW, Ramaiya P, Nelson BA, Brody-Karpin SD, Zaretsky EJ, Tang M, Lopez de 
Leon A, Xiang H, Gusti V, Clausen IG, Olsen PB, Rasmussen MD, Andersen JT, 
Jørgensen PL, Larsen TS, Sorokin A, Bolotin A, Lapidus A, Galleron N, Ehrlich 
SD, Berka RM (2004) Complete genome sequence of the industrial bacterium Bacillus 
licheniformis and comparisons with closely related Bacillus species. Genome Biol. 5 
(10): R77. 
Rink R, Kuipers A, de Boef E, Leenhouts KJ, Driessen AJ, Moll GN, Kuipers OP (2005) 
Lantibiotic structures as guidelines for the design of peptides that can be modified by 
lantibiotic enzymes. Biochemistry. 44 (24): 8873–8882. 
Robson CL, Wescombe PA, Klesse NA, Tagg JR (2007) Isolation and partial 
characterization of the Streptococcus mutans type AII lantibiotic mutacin K8. 
Microbiology. 153 (5): 1631–1641. 
Rodriguez E, Arques JL, Gaya P, Nunez M, Medina M (2001) Control of Listeria 
monocytogenes by bacteriocins and monitoring of bacteriocin-producing lactic acid 
bacteria by colony hybridization in semi-hard raw milk cheese. J Dairy Res. 68 (1): 
131–137. 
Rogers LA, Whittier EO (1928) Limiting factors in the lactic fermentation. J Bacteriol. 16 
(4): 211–229. 
Rollema HS, Kuipers OP, Both P, de Vos WM, Siezen RJ (1995) Improvement of 
solubility and stability of the antimicrobial peptide nisin by protein engineering. Appl 
Environ Microbiol. 61 (8): 2873– 78. 
Roy RS, Gehring AM, Milne JC, Belshaw PJ, Walsh CT (1999) Thiazole and oxazole 
peptides: biosynthesis and molecular machinery. Nat Prod Rep. 16 (2): 249–263. 
Rubin RJ, Harrington CA, Poon A, Dietrich K, Greene JA, Moiduddin A (1999) The 
economic impact of Staphylococcus aureus infection in New York City hospitals. 
Emerg Infect Dis 5 (1): 9–17. 
 124 
 
Ryan MP, Hill C, Ross RP (2002) Exploitation of lantibiotic peptides for food and medical 
uses. In: Peptide antibiotics - discovery, mode of action and applications. Edited by C. J. 
Dutton MA. Haxell H A I, McArthur RG, Wax Marcel Dekker, New York, 193–242.  
Ryan MP, Jack RW, Josten M, Sahl H-G, Jung G, Ross RP, Hill C (1999) Extensive post-
translational modification, including serine to D-alanine conversion, in the two-
component lantibiotic, lacticin 3147. J Biol Chem. 274 (53): 37544–37550. 
Ryan MP, McAuliffe O, Ross RP, Hill C (2001) Heterologous expression of lacticin 3147 in 
Enterococcus faecalis: comparison of biological activity with cytolysin. Lett Appl 
Microbiol. 32 (2):71–77. 
Ryan MP, Rea MC, Hill C, Ross RP (1996) An application in cheddar cheese manufacture 
for a strain of Lactococcus lactis producing a novel broad-spectrum bacteriocin, lacticin 
3147. Appl Environ Microbiol. 62 (2): 612–619. 
Sahl H-G, Bierbaum G (1998) Lantibiotics: biosynthesis and biological activities of 
uniquely modified peptides from gram-positive bacteria. Annu Rev Microbiol. 52: 41–
79. 
Sahl H-G, Brandis H (1981) Production, purification and chemical properties of an 
antistaphylococcal agent produced by Staphylococcus epidermidis. J Gen Microbiol. 
127 (2): 377–384. 
Sahl H-G, Reis M, Eschbach M, Szekat C, Beck-Sickinger AG, Metzger J, Stefanovic S, 
Jung G (1991) Isolation of Pep5 prepeptides in different stages of modification, p. 332-
346. In G. Jung and H.-G. Sahl (ed.), Nisin and novel lantibiotics. Escom Publishers, 
Leiden, The Netherlands. 
Sanger F, Nicklen S, Coulson AR (1977) DNA sequencing with chain-terminating 
inhibitors. Proc Natl Acad Sci USA. 74 (12): 5463–5467. 
Sashihara T, Kimura H, Higuchi T, Adachi A, Matsusaki H, Sonomoto K, Ishizaki A 
(2000) A novel lantibiotic, nukacin ISK-1, of Staphylococcus warneri ISK-1: cloning of 
the structural gene and identification of the structure. Biosci Biotechnol Biochem. 64 
(11): 2420–2428. 
Sass P, Bierbaum G (2007) Lytic activity of recombinant bacteriophage phi11 and phi12 
endolysins on whole cells and biofilms of Staphylococcus aureus. Appl Environ 
Microbiol. 73 (1): 347–352. 
 125 
 
Sass P, Bierbaum G (2009) Native graS mutation supports the susceptibility of 
Staphylococcus aureus strain SG511 to antimicrobial peptides. Int J Med Microbiol. 299 
(5): 313–322. 
Sawa N, Wilaipun P, Kinoshita S, Zendo T, Leelawatcharamas V, Nakayama J, 
Sonomoto K (2012) Isolation and characterization of enterocin W, a novel two-peptide 
lantibiotic produced by Enterococcus faecalis NKR-4-1. Appl Environ Microbiol. 78 
(3): 900–903. 
Schibli DJ, Epand RF, Vogel HJ, Epand RM (2002) Tryptophan rich antimicrobial 
peptides; comparative properties and membrane interaction. Biochem Cell Biol. 80 (5): 
667–677. 
Schleifer KH, Fischer U (2002) Description of a new species of the genus Staphylococcus: 
Staphylococcus carnosus. Int J Sys Bacteriol. 32 (2): 153–156. 
Schnell N, Engelke G, Augustin J, Rosenstein R, Ungermann V, Götz F, Entian KD 
(1992) Analysis of genes involved in the biosynthesis of the lantibiotic epidermin. Eur J 
Biochem. 204 (1): 57–68.  
Schnell N, Entian KD, Schneider U, Götz F, Zähner H, Kellner R, Jung G (1988) 
Prepeptide sequence of epidermin, a ribosomally synthesized antibiotic with four 
sulphide-rings. Nature. 333 (6170): 276–278. 
Scholz R, Molohon KJ, Nachtigall J, Vater J, Markley AL, Süssmuth RD, Mitchell DA, 
Borriss R (2011) Plantazolicin, a novel microcin B 17/ streptolysin S-like natural 
product from Bacillus amyloliquefaciens FZB42. J Bacteriol. 193 (1): 215–224. 
Selsted ME, Novotny MJ, Morris WL, Tang YQ, Smith W, Cullor JS (1992) Indolicidin, 
a novel bactericidal tridecapeptide amide from neutrophils. J Biol Chem. 267 (7): 4292–
4295. 
Shenkarev ZO, Finkina EI, Nurmukhamedova EK, Balandin SV, Mineev KS, 
Nadezhdin KD, Yakimenko ZA, Tagaev AA, Temirov YV, Arseniev AS, 
Ovchinnikova TV (2010) Isolation, structure elucidation, and synergistic antibacterial 
activity of a novel two-component lantibiotic lichenicidin from Bacillus licheniformis 
VK21. Biochemistry. 49 (30): 6462–6472. 
Shi Y, Yang X, Garg N, van der Donk WA (2011) Production of lantipeptides in 
Escherichia coli. J Am Chem Soc. 133 (8): 2338–2341. 
 126 
 
Siezen RJ, Kuipers OP, de Vos WM (1996) Comparison of lantibiotic gene clusters and 
encoded proteins. A Van Leeuw. 69 (2): 171–184. 
Simone M, Monciardini P, Gaspari E, Donadio S, Maffioli SI (2013) Isolation and 
characterization of NAI-802, a new lantibiotic produced by two different Actinoplanes 
strains. J Antibiot. 66 (2): 73–78. 
Sivonen K, Leikoski N, Fewer DP, Jokela J (2010) Cyanobactins-ribosomal cyclic peptides 
produced by cyanobacteria. Appl Microbiol Biotechnol. 86 (5): 1213–1225. 
Skaugen M, Nes IF (1994) Transposition in Lactobacillus sake and its abolition of lactocin S 
production by insertion of IS1163, a new member of the IS3 family. Appl Environ 
Microbiol. 60 (8): 2818–2825. 
Staron A, Finkeisen DE, Mascher T (2011) Peptide antibiotic sensing and detoxification 
modules of Bacillus subtilis. Antimicrob Agents Chemother. 55 (2): 515–525. 
Stein T (2005) Bacillus subtilis antibiotics: structures, syntheses and specific functions. Mol 
Microbiol. 56 (4): 845–857.  
Stein T, Borchert S, Conrad B, Feesche J, Hofemeister B, Hofemeister J, Entian KD 
(2002) Two different lantibiotic-like peptides originate from the ericin gene cluster of 
Bacillus subtilis A1/3. J Bacteriol. 184 (6): 1703–1711. 
Stein T, Heinzmann S, Solovieva I, Entian KD (2003) Function of Lactococcus lactis nisin 
immunity genes nisI and nisFEG after coordinated expression in the surrogate host 
Bacillus subtilis. J Biol Chem. 278 (1): 89–94. 
Stoffels G, Nissen-Meyer J, Gudmundsdottir A, Sletten K, Holo H, Nes IF (1992) 
Purification and characterization of a new bacteriocin isolated from a Carnobacterium 
sp. Appl Environ Microbiol. 58 (5): 1417–1422. 
Stone DK, Xie XS, Racker E (1984) Inhibition of clathrin-coated vesicle acidification by 
duramycin. J Biol Chem. 259 (5): 2701–2703. 
Studier FW, Moffatt BA (1986) Use of bacteriophage T7 RNA polymerase to direct 
selective high-level expression of cloned genes. J Mol Biol. 189 (1): 113–130. 
Szekat C, Jack RW, Skutlarek D, Färber H, Bierbaum G (2003) Construction of an 
expression system for site-directed mutagenesis of the lantibiotic mersacidin. Appl 
Environ Microbiol. 69 (7): 3777–3783. 
 127 
 
Takami H, Nakasone K, Takaki Y, Maeno G, Sasaki R, Mansui N, Fuji F, Hirama C, 
Nakaramura Y, Oqasawara N, Kuhara S, Horikoshi K (2000) Complete genome 
sequence of the alkaliphilic bacterium Bacillus halodurans and genomic sequence 
comparison with Bacillus subtilis. Nucleic Acids Res. 28 (21): 4317–4331. 
Teng Y, Zhao W, Qian C, Li O, Zhu L, Wu X (2012) Gene cluster analysis for the 
biosynthesis of elgicins, novel lantibiotics produced by Paenibacillus elgii B69. BMC 
Microbiol. 12: 45. 
Thompson RL, Wright AJ (1998) General principles of antimicrobial therapy. Mayo Clin 
Proc. 73 (10): 995-1006. 
Toogood PL (1993) Model studies of lantibiotic biogenesis. Tetrahedron Lett. 34 (49): 7833–
7836. 
Ueda K, Oinuma K, Ikeda G, Hosono K, Ohnishi Y, Horinouchi S, Beppu T (2002) 
AmfS, an extracellular peptidic morphogen in Streptomyces griseus. J Bacteriol. 184 
(5): 1488–1492. 
van de Kamp M, Horstink LM, van den Hooven HW, Konings RNH, Hilbers CW, Frey 
A, Sahl H-G, Metzger JW, van de Ven FJ (1995) Sequence analysis by NMR 
spectroscopy of the peptide lantibiotic epilancin K7 from Staphylococcus epidermidis 
K7. Eur J Biochem. 227 (3): 757–71. 
van der Meer JR, Polman J, Beerthuyzen MM, Siezen RJ, Kuipers OP, de Vos WM 
(1993) Characterization of the Lactococcus lactis nisin A operon genes nisP, encoding a 
subtilisin-like serine protease involved in precursor processing, and nisR, encoding a 
regulatory protein involved in nisin biosynthesis. J Bacteriol. 175 (9): 2578–2588. 
van Heel AJ, Mu D, Montalban-Lopez M, Hendriks D, Kuipers OP (2013) Designing and 
producing modified, new-to-nature peptides with antimicrobial activity by use of a 
combination of various lantibiotic modification enzymes. ACS Synth Biol. 19 (2):397–
404. 
van Heusden HE, de Kruijff B, Breukink E (2002) Lipid II induces a transmembrane 
orientation of the pore-forming peptide lantibiotic nisin. Biochemistry. 41 (40): 12171–
12178.  
van Kraaij C, de Vos WM, Siezen RJ, Kuipers OP (1999) Lantibiotics: biosynthesis, mode 
of action and applications. Nat Prod Rep. 16 (5): 575–587. 
 128 
 
Vertesy L, Aretz W, Bonnefoy A, Ehlers E, Kurz M, Markus A, Schiell M, Vogel M, 
Wink J, Kogler H (1999) Ala(0)-actagardine, a new lantibiotic from cultures of 
Actinoplanes liguriae ATCC 31048. J Antibiot (Tokyo). 52 (8): 730–741. 
Völler GH, Krawczyk JM, Pesic A, Krawczyk B, Nachtigall J, Süssmuth RD (2012) 
Characterization of new class III lantibiotics—erythreapeptin, avermipeptin and 
griseopeptin from Saccharopolyspora erythraea, Streptomyces avermitilis and 
Streptomyces griseus demonstrates stepwise N-terminal leader processing. Chem Bio 
Chem. 13 (8): 1174–1183. 
Wang H, van der Donk WA (2012) Biosynthesis of the class III lantipeptide catenulipeptin. 
ACS Chem Biol. 7 (9): 1529–1535.  
Wang J, Ma H, Ge X, Zhang J, Teng K, Sun Z, Zhong J (2014) Bovicin HJ50-Like 
Lantibiotics, a Novel Subgroup of Lantibiotics Featured by an Indispensable Disulfide 
Bridge. PLoS ONE 9 (5): e97121. 
Waschkau B, Waldeck J, Wieland S, Eichstadt R, Meinhardt F (2008) Generation of 
readily transformable Bacillus licheniformis mutants. Appl Microbiol Biotechnol 78 (1): 
181–188. 
Weigel LM, Clewell DB, Gill SR, Clark NC, McDougal LK, Flannagen SE, Kolonay JF, 
Shetty J, Killgore GE, Tenover FC (2003) Genetic analysis of a high-level 
vancomycin resistant isolate of Staphylococcus aureus. Science. 302 (5650): 1569–
1571. 
Wenzel M, Kohl B, Münch D, Raatschen N, Albada HB, Hamoen L, Metzler-Nolte N, 
Sahl H-G, Bandow JE (2012) Proteomic response of Bacillus subtilis to lantibiotics 
reflects differences in interaction with the cytoplasmic membrane. Antimicrob Agents 
Chemother. 56 (11): 5749–5757. 
Wescombe PA, Burton JP, Cadieux PA, Klesse NA, Hyink O, Heng NC, Chilcott CN, 
Reid G, Tagg JR (2006) Megaplasmids encode differing combinations of lantibiotics in 
Streptococcus salivarius. A Van Leeuw. 90 (3): 269–280.  
Wescombe PA, Tagg JR (2003) Purification and characterization of streptin, a type A1 
lantibiotic produced by Streptococcus pyogenes. Appl Environ Microbiol. 69 (5): 2737–
2747. 
 129 
 
Wescombe PA, Upton M, Renault P, Wirawan RE, Power D, Burton JP, Chilcott CN, 
Tagg JR (2011) Salivaricin 9, a new lantibiotic produced by Streptococcus salivarius. 
Microbiology. 157 (5): 1290–1299. 
Widdick DA, Dodd HM, Barraille P, White J, Stein TH, Chater KF, Gasson MJ, Bibb 
MJ (2003) Cloning and engineering of the cinnamycin biosynthetic gene cluster from 
Streptomyces cinnamoneus cinnamoneus DSM 40005. Proc Natl Acad Sci USA. 100 
(7): 4316–4321. 
Wiedemann I, Benz R, Sahl H-G (2004) Lipid II-mediated pore formation by the peptide 
antibiotic nisin: a black lipid membrane study. J Bacteriol. 186 (10): 3259–3261.  
Wiedemann I, Böttiger T, Bonelli RR, Schneider T, Sahl H-G, Martinez B (2006) Lipid II 
based antimicrobial activity of the lantibiotic palntaricin C. Appl Environ Microbiol. 72 
(4): 2809–2814. 
Wiedemann I, Böttiger T, Bonelli RR, Wiese A, Hagge SO, Gutsmann T, Seydel U, 
Deegan L, Hill C, Ross P, Sahl H-G (2006) The mode of action of the lantibiotic 
lacticin 3147- a complex mechanism involving specific interaction of two peptides and 
the cell wall precursor lipid II. Mol Microbial. 61 (2): 285–296. 
Wiedemann I, Breukink E, van Kraaij C, Kuipers OP, Bierbaum G, de Kruijff B, Sahl 
H-G (2001) Specific binding of nisin to the peptidoglycan precursor lipid II combines 
pore formation and inhibition of cell wall biosynthesis for potent antibiotic activity. J 
Biol Chem. 276 (3): 1772–1779.  
Wilaipun P, Zendo T, Okuda K, Nakayama J, Sonomoto K (2008) Identification of the 
nukacin KQU-131, a new type-A (II) lantibiotic produced by Staphylococcus hominis 
KQU-131 isolated from Thai fermented fish product (Pla-ra). Biosci Biotechnol 
Biochem. 72 (8): 2232–2235. 
Wilimowska-Pelc A, Olichwier Z, Malicka-Blaszkiewicz M, Mejbaum-Katzenellenbogen 
W (1976) The use of gel-filtration for the isolation of pure nisin from commercial 
products. Acta Microbiol Pol A. 8 (1): 71–77. 
Willey JM, van der Donk WA (2007) Lantibiotics: peptides of diverse structure and 
function. Annu Rev Microbiol. 61: 477–501.  
Wirawan RE, Klesse NA, Jack RW, Tagg JR (2006) Molecular and genetic 
characterization of a novel nisin variant produced by Streptococcus uberis. Appl 
Environ Microbiol. 72 (2): 1148–1156. 
 130 
 
Xiao H, Chen X, Chen M, Tang S, Zhao X, Huan L (2004) Bovicin HJ50, a novel 
lantibiotic produced by Streptococcus bovis HJ50. Microbiology. 150 (1): 103–108. 
Xie L, Miller LM, Chatterjee C, Averin O, Kelleher NL, van der Donk WA (2004) 
Lacticin 481: in vitro reconstitution of lantibiotic synthetase activity. Science. 303 
(5658): 679–681. 
Xie L, van der Donk WA (2004) Post-translational modifications during lantibiotic 
biosynthesis. Curr Opin Chem Biol. 8 (5): 498–507. 
Xie XS, Stone DK, Racker E (1983) Determinants of clathrin-coated vesicle acidification. J 
Biol Chem. 258 (24): 14834–14838. 
Xiulan Li, Daniel J, O’Sullivan DJ (2012) Contribution of the actinobacteria to the growing 
diversity of lantibiotics. Biotechnol Lett. 34 (12): 2133–2145. 
Yanisch-Perron C, Vieira J, Messing J (1985) Improved M13 phage cloning vectors and 
host strains: nucleotide sequences of the M13mp18 and pUC19 vectors.  Gene. 33 (1): 
103–119. 
Yonezawa H, Kuramitsu HK (2005) Genetic analysis of a unique bacteriocin, Smb, 
produced by Streptococcus mutans GS5. Antimicrob Agents Chemother. 49 (2): 541–
548. 
Yu Y, Duan L, Zhang Q, Liao R, Ding Y, Pan H, Wendt-Pienkowski E, Tang G, Shen B, 
Liu W (2009) Nosiheptide biosynthesis featuring a unique indole side ring formation on 
the characteristic thiopeptide framework. ACS Chem Biol. 4 (10): 855–864. 
Yuksel S, Hansen JN (2007) Transfer of nisin gene cluster from Lactococcus lactis ATCC 
11454 into the chromosome of Bacillus subtilis 168. Appl Microbiol Biotechnol. 74 (3): 
640–649. 
Zendo T, Fukao M, Ueda K, Higuchi T, Nakayama J, Sonomoto K (2003) Identification 
of the lantibiotic nisin Q, a new natural nisin variant produced by Lactococcus lactis 61-
14 isolated from a river in Japan. Biosci Biotechnol Biochem. 67 (7): 1616–1619. 
Zhu Y, Gieselman MD, Zhou H, Averin O, van der Donk WA (2003) Biomimetic studies 
on the mechanism of stereoselective lanthionine formation. Org Biomol Chem. 1 (19): 
3304–3315.  
Zimmermann N, Freund S, Fredenhagen A, Jung G (1993) Solution structures of the 
lantibiotics duramycin B and C. Eur J Biochem. 216 (2): 419–428 
 131 
 
Zimmermann N, Jung G (1997) The three-dimensional solution structure of the lantibiotic 
murein-biosynthesis-inhibitor actagardine determined by NMR. Em J Biochem. 246 (3): 
809–819. 
Zimmermann N, Metzge JW, Jung G (1995) The tetracyclic lantibiotic actagardine 1H-
NMR and 13C-NMR assignments and revised primary structure. Eur J Biochem. 228 
(3): 786–797. 
Zwick ME, Joseph SJ, Didelot X, Chen PE, Bishop-Lilly KA, Stewart AC, Willner K, 
Nolan N, Lentz S, Thomason MK, Sozhamannan S, Mateczun AJ, Du L, Read TD 
(2012) Genomic characterization of the Bacillus cereus sensu lato species: backdrop to 
the evolution of Bacillus anthracis. Genome Res. 22 (8): 1512–1524. 
 132 
 
 7. Annexes 
Annex I: Physical map of expression vector pET28a (Novagen/Merck chemicals). Plasmids 
confer resistance against kanamycin (Kan). His-tag coding sequences are located next to the 
mcs and allow cloning of N- or C-terminal His-tagged proteins. 
 
 
Annex II: Gene sequence of respective inserts and vectors 
 
A) PseA sequence having 229 bp 
ATGAATGATAAAATTATCCAATACTGGAACGATCCAGCTAAACGTTCTACTCTTTCAGCAGCAGAACTTAGCAAGAT
GCCAGTAAATCCTGCAGGAGATATTCTTGCAGAGCTTTCAGACGCTGATCTGGATAAAGTAGTGGGTGCTGGTGATT
GCGGTGGTACTTGTACATGGACAAAAGATTGCTCAATTTGTCCATCATGGTCTTGTTGGAGCTGGTCTTGCTAA 
 
B) PseAXa sequence having 229 bp. The replaced bases for factor Xa are highlighted. 
ATGAATGATAAAATTATCCAATACTGGAACGATCCAGCTAAACGTTCTACTCTTTCAGCAGCAGAACTTAGCAAGAT
GCCAGTAAATCCTGCAGGAGATATTCTTGCAGAGCTTTCAGACGCTGATCTGGATAAAATAGAGGGTCGTGGTGATT
GCGGTGGTACTTGTACATGGACAAAAGATTGCTCAATTTGTCCATCATGGTCTTGTTGGAGCTGGTCTTGCTAA 
 
C) pET28b sequence with the insert PseAXa (represented by lowercase letters) 
TGGCGAATGGGACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACAC
TTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAA
GCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTAGGG
TGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATA
GTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTCGGTCTATTCTTTTGATTTATAAGGGATTTTGCCG
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ATTTCGGCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAATTTTAACAAAATATTAACGTTTAC
AATTTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGT
ATCCGCTCATGAATTAATTCTTAGAAAAACTCATCGAGCATCAAATGAAACTGCAATTTATTCATATCAGGATTATC
AATACCATATTTTTGAAAAAGCCGTTTCTGTAATGAAGGAGAAAACTCACCGAGGCAGTTCCATAGGATGGCAAGAT
CCTGGTATCGGTCTGCGATTCCGACTCGTCCAACATCAATACAACCTATTAATTTCCCCTCGTCAAAAATAAGGTTA
TCAAGTGAGAAATCACCATGAGTGACGACTGAATCCGGTGAGAATGGCAAAAGTTTATGCATTTCTTTCCAGACTTG
TTCAACAGGCCAGCCATTACGCTCGTCATCAAAATCACTCGCATCAACCAAACCGTTATTCATTCGTGATTGCGCCT
GAGCGAGACGAAATACGCGATCGCTGTTAAAAGGACAATTACAAACAGGAATCGAATGCAACCGGCGCAGGAACACT
GCCAGCGCATCAACAATATTTTCACCTGAATCAGGATATTCTTCTAATACCTGGAATGCTGTTTTCCCGGGGATCGC
AGTGGTGAGTAACCATGCATCATCAGGAGTACGGATAAAATGCTTGATGGTCGGAAGAGGCATAAATTCCGTCAGCC
AGTTTAGTCTGACCATCTCATCTGTAACATCATTGGCAACGCTACCTTTGCCATGTTTCAGAAACAACTCTGGCGCA
TCGGGCTTCCCATACAATCGATAGATTGTCGCACCTGATTGCCCGACATTATCGCGAGCCCATTTATACCCATATAA
ATCAGCATCCATGTTGGAATTTAATCGCGGCCTAGAGCAAGACGTTTCCCGTTGAATATGGCTCATAACACCCCTTG
TATTACTGTTTATGTAAGCAGACAGTTTTATTGTTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGC
GTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAA
AAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTC
AGCAGAGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACC
GCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGG
ACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAG
CGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGC
GGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATC
TTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTA
TGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGC
GTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCG
AGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCTGATGCGGTATTTTCTCCTTACGCATCTGTGCGGTATT
TCACACCGCATATATGGTGCACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAGTATACACTCCGCTAT
CGCTACGTGACTGGGTCATGGCTGCGCCCCGACACCCGCCAACACCCGCTGACGCGCCCTGACGGGCTTGTCTGCTC
CCGGCATCCGCTTACAGACAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTCAGAGGTTTTCACCGTCATCACCGAA
ACGCGCGAGGCAGCTGCGGTAAAGCTCATCAGCGTGGTCGTGAAGCGATTCACAGATGTCTGCCTGTTCATCCGCGT
CCAGCTCGTTGAGTTTCTCCAGAAGCGTTAATGTCTGGCTTCTGATAAAGCGGGCCATGTTAAGGGCGGTTTTTTCC
TGTTTGGTCACTGATGCCTCCGTGTAAGGGGGATTTCTGTTCATGGGGGTAATGATACCGATGAAACGAGAGAGGAT
GCTCACGATACGGGTTACTGATGATGAACATGCCCGGTTACTGGAACGTTGTGAGGGTAAACAACTGGCGGTATGGA
TGCGGCGGGACCAGAGAAAAATCACTCAGGGTCAATGCCAGCGCTTCGTTAATACAGATGTAGGTGTTCCACAGGGT
AGCCAGCAGCATCCTGCGATGCAGATCCGGAACATAATGGTGCAGGGCGCTGACTTCCGCGTTTCCAGACTTTACGA
AACACGGAAACCGAAGACCATTCATGTTGTTGCTCAGGTCGCAGACGTTTTGCAGCAGCAGTCGCTTCACGTTCGCT
CGCGTATCGGTGATTCATTCTGCTAACCAGTAAGGCAACCCCGCCAGCCTAGCCGGGTCCTCAACGACAGGAGCACG
ATCATGCGCACCCGTGGGGCCGCCATGCCGGCGATAATGGCCTGCTTCTCGCCGAAACGTTTGGTGGCGGGACCAGT
GACGAAGGCTTGAGCGAGGGCGTGCAAGATTCCGAATACCGCAAGCGACAGGCCGATCATCGTCGCGCTCCAGCGAA
AGCGGTCCTCGCCGAAAATGACCCAGAGCGCTGCCGGCACCTGTCCTACGAGTTGCATGATAAAGAAGACAGTCATA
AGTGCGGCGACGATAGTCATGCCCCGCGCCCACCGGAAGGAGCTGACTGGGTTGAAGGCTCTCAAGGGCATCGGTCG
AGATCCCGGTGCCTAATGAGTGAGCTAACTTACATTAATTGCGTTGCGCTCACTGCCCGCTTTCCAGTCGGGAAACC
TGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGGGCGCCAGGGTGGTTTT
TCTTTTCACCAGTGAGACGGGCAACAGCTGATTGCCCTTCACCGCCTGGCCCTGAGAGAGTTGCAGCAAGCGGTCCA
CGCTGGTTTGCCCCAGCAGGCGAAAATCCTGTTTGATGGTGGTTAACGGCGGGATATAACATGAGCTGTCTTCGGTA
TCGTCGTATCCCACTACCGAGATATCCGCACCAACGCGCAGCCCGGACTCGGTAATGGCGCGCATTGCGCCCAGCGC
CATCTGATCGTTGGCAACCAGCATCGCAGTGGGAACGATGCCCTCATTCAGCATTTGCATGGTTTGTTGAAAACCGG
ACATGGCACTCCAGTCGCCTTCCCGTTCCGCTATCGGCTGAATTTGATTGCGAGTGAGATATTTATGCCAGCCAGCC
AGACGCAGACGCGCCGAGACAGAACTTAATGGGCCCGCTAACAGCGCGATTTGCTGGTGACCCAATGCGACCAGATG
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CTCCACGCCCAGTCGCGTACCGTCTTCATGGGAGAAAATAATACTGTTGATGGGTGTCTGGTCAGAGACATCAAGAA
ATAACGCCGGAACATTAGTGCAGGCAGCTTCCACAGCAATGGCATCCTGGTCATCCAGCGGATAGTTAATGATCAGC
CCACTGACGCGTTGCGCGAGAAGATTGTGCACCGCCGCTTTACAGGCTTCGACGCCGCTTCGTTCTACCATCGACAC
CACCACGCTGGCACCCAGTTGATCGGCGCGAGATTTAATCGCCGCGACAATTTGCGACGGCGCGTGCAGGGCCAGAC
TGGAGGTGGCAACGCCAATCAGCAACGACTGTTTGCCCGCCAGTTGTTGTGCCACGCGGTTGGGAATGTAATTCAGC
TCCGCCATCGCCGCTTCCACTTTTTCCCGCGTTTTCGCAGAAACGTGGCTGGCCTGGTTCACCACGCGGGAAACGGT
CTGATAAGAGACACCGGCATACTCTGCGACATCGTATAACGTTACTGGTTTCACATTCACCACCCTGAATTGACTCT
CTTCCGGGCGCTATCATGCCATACCGCGAAAGGTTTTGCGCCATTCGATGGTGTCCGGGATCTCGACGCTCTCCCTT
ATGCGACTCCTGCATTAGGAAGCAGCCCAGTAGTAGGTTGAGGCCGTTGAGCACCGCCGCCGCAAGGAATGGTGCAT
GCAAGGAGATGGCGCCCAACAGTCCCCCGGCCACGGGGCCTGCCACCATACCCACGCCGAAACAAGCGCTCATGAGC
CCGAAGTGGCGAGCCCGATCTTCCCCATCGGTGATGTCGGCGATATAGGCGCCAGCAACCGCACCTGTGGCGCCGGT
GATGCCGGCCACGATGCGTCCGGCGTAGAGGATCGAGATCTCGATCCCGCGAAATTAATACGACTCACTATAGGGGA
ATTGTGAGCGGATAACAATTCCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAGATATACCATGGGCAGCAGC
CATCATCATCATCATCACAGCAGCGGCCTGGTGCCGCGCGGCAGCCATATGaatgataaaattatccaatactggaa
cgatccagctaaacgttctactctttcagcagcagaacttagcaagatgccagtaaatcctgcaggagatattcttg
cagagctttcagacgctgatctggataaaatagagggtcgtggtgattgcggtggtacttgtacatggacaaaagat
tgctcaatttgtccatcatggtcttgttggagctggtcttgctaaCTCGAGCACCACCACCACCACCACTGAGATCC
GGCTGCTAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGG
CCTCTAAACGGGTCTTGAGGGGTTTTTTGCTGAAAGGAGGAACTATATCCGGAT 
 
Annex III: Amino acid sequence of N terminally His-tagged PseA and PseAXa having 10.2 
kDa. Additional amino acids are represented by bold letters and replaced aa are underlined.  
 
A) PseA 
 
GSSHHHHHHSSGLVPRGSHMNDKIIQYWNDPAKRSTLSAAELSKMPVNPAGDILAELSDADLDKVVGAGDCGGTCTW
TKDCSICPSWSCWSWSC 
 
B) PseAXa 
 
GSSHHHHHHSSGLVPRGSHMNDKIIQYWNDPAKRSTLSAAELSKMPVNPAGDILAELSDADLDKIEGRGDCGGTCTW
TKDCSICPSWSCWSWSC 
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Annex IV: Physical map of expression vectors pET22b Δpelb (Novagen/Merck chemicals). 
Plasmids confer resistance against ampicillin (Ap). His-tag coding sequences are located next 
to the mcs and allow cloning of N- or C-terminal His-tagged proteins. 
 
 
 
Annex V: Amino acid sequence of C terminally His-tagged PseM having 123.4 kDa. 
Additional amino acids are given in bold letter. 
 
MGMLANQALKKAFFIEERVQKSTTSNLAQEMQPDDYSNLRISNWIDGMGNNEDLFLKNLHLHNIEHKDLHKIMISNN
YDSDSSAEWLSIIGELERFNYQEPELPRILQKIIALNPNEPIAFFNFLLPFLKIGVERIEKAISLSEKKHGISLSKE
KVLFQLVRNLAETLSKVSFRTLTLELNIARLKELLVGETPQERYKYFSYTLLTDKNYLAQLYKQYPVLVRILSRKTI
RWADNFAEIYDHLLHDKKAIEQHFFNSTPITVIEDIKTNISDSHNGGKGVVIIKFNDDMNLVYKPRSLKIDEQFQQL
LCWFNELKEKKLRLLPITLLDRDTYGWSEFIEHKECSAEQEVKNFYRRMGYYLALLYSINAIDFHNENLIASGEYPM
LIDLETLFNQDAVQSTESVTAQEVALKTLSQSVLATNILPVFTLYNKIEGRGLNISGMANGEEQIYPSKVPVIQSNN
TDEQKVERGYMKIPASSNYPTLNGKQVSVTMYVDDMMAGFKEAYDLLTKNKDCLKNEISRFKNTRVRQILRATNRYG
NLLAISYHPDYLRDGLDREMLLGKLWLDTEMQPELTQVLLAEKADLLEGDIPYFTTEPGQPHIYDSQGRCYENYYKT
SSLAKTLDKIERLGPKDYEEQLQIIKLSMLALESSPSDKKSNYIPSVPDNQIDRDSFLEEAKRVADYLISRSIQGTN
NGKEDVSWIGTRLTDNAESLWRIAPLGNDLYDGISGIALFFGYLYKYTRDSKYRVYIQKCLPPIKESLQELLAYPKY
ASLGAFTGVLSNIYTLNHLTKILDEPSLMEEVKKVMPKLIESIPYMQEVDIIDGSAGSLIVCLDLYKQTGDEIFLEA
SKKFGEHILQKAIPQATGIGWKISVSEDALPGFSHGTSGIVWALHELYQLTGEQMLYDALKQGLAYERSLYMEEKRN
WALPSAAELPQLPCAWCHGAAGVVLSRLLLKKAGYSDSLIDIEIRVGLETIIKEGFGRDHSLCHGDTGNSAVLLLAS
KVLKEDLWKQYSYAVGEHVLDEIQQGGWKSGLPQYLETYGAMVGISGVGLGLLKLYDINGVPSITHLESITALKLEH
HHHHH. 
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Annex VI:  Sequence of pET22b∆pelB with insert pseM (represented by lowercase letters). 
 
TGGCGAATGGGACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACAC
TTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAA
GCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTAGGG
TGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATA
GTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTCGGTCTATTCTTTTGATTTATAAGGGATTTTGCCG
ATTTCGGCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAATTTTAACAAAATATTAACGTTTAC
AATTTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGT
ATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTC
CGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAA
AGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTT
TTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGAC
GCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAA
GCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACT
TACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTT
GATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAAC
AACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGG
ATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAG
CGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGG
GAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGT
CAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATC
CTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGAT
CAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGG
TGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAAT
ACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCT
AATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGG
ATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTG
AGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGG
CAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTC
GCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCG
GCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGA
TAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCG
AGGAAGCGGAAGAGCGCCTGATGCGGTATTTTCTCCTTACGCATCTGTGCGGTATTTCACACCGCATATATGGTGCA
CTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAGTATACACTCCGCTATCGCTACGTGACTGGGTCATGG
CTGCGCCCCGACACCCGCCAACACCCGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCGGCATCCGCTTACAGACAA
GCTGTGACCGTCTCCGGGAGCTGCATGTGTCAGAGGTTTTCACCGTCATCACCGAAACGCGCGAGGCAGCTGCGGTA
AAGCTCATCAGCGTGGTCGTGAAGCGATTCACAGATGTCTGCCTGTTCATCCGCGTCCAGCTCGTTGAGTTTCTCCA
GAAGCGTTAATGTCTGGCTTCTGATAAAGCGGGCCATGTTAAGGGCGGTTTTTTCCTGTTTGGTCACTGATGCCTCC
GTGTAAGGGGGATTTCTGTTCATGGGGGTAATGATACCGATGAAACGAGAGAGGATGCTCACGATACGGGTTACTGA
TGATGAACATGCCCGGTTACTGGAACGTTGTGAGGGTAAACAACTGGCGGTATGGATGCGGCGGGACCAGAGAAAAA
TCACTCAGGGTCAATGCCAGCGCTTCGTTAATACAGATGTAGGTGTTCCACAGGGTAGCCAGCAGCATCCTGCGATG
CAGATCCGGAACATAATGGTGCAGGGCGCTGACTTCCGCGTTTCCAGACTTTACGAAACACGGAAACCGAAGACCAT
TCATGTTGTTGCTCAGGTCGCAGACGTTTTGCAGCAGCAGTCGCTTCACGTTCGCTCGCGTATCGGTGATTCATTCT
GCTAACCAGTAAGGCAACCCCGCCAGCCTAGCCGGGTCCTCAACGACAGGAGCACGATCATGCGCACCCGTGGGGCC
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GCCATGCCGGCGATAATGGCCTGCTTCTCGCCGAAACGTTTGGTGGCGGGACCAGTGACGAAGGCTTGAGCGAGGGC
GTGCAAGATTCCGAATACCGCAAGCGACAGGCCGATCATCGTCGCGCTCCAGCGAAAGCGGTCCTCGCCGAAAATGA
CCCAGAGCGCTGCCGGCACCTGTCCTACGAGTTGCATGATAAAGAAGACAGTCATAAGTGCGGCGACGATAGTCATG
CCCCGCGCCCACCGGAAGGAGCTGACTGGGTTGAAGGCTCTCAAGGGCATCGGTCGAGATCCCGGTGCCTAATGAGT
GAGCTAACTTACATTAATTGCGTTGCGCTCACTGCCCGCTTTCCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAAT
GAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGGGCGCCAGGGTGGTTTTTCTTTTCACCAGTGAGACGGG
CAACAGCTGATTGCCCTTCACCGCCTGGCCCTGAGAGAGTTGCAGCAAGCGGTCCACGCTGGTTTGCCCCAGCAGGC
GAAAATCCTGTTTGATGGTGGTTAACGGCGGGATATAACATGAGCTGTCTTCGGTATCGTCGTATCCCACTACCGAG
ATATCCGCACCAACGCGCAGCCCGGACTCGGTAATGGCGCGCATTGCGCCCAGCGCCATCTGATCGTTGGCAACCAG
CATCGCAGTGGGAACGATGCCCTCATTCAGCATTTGCATGGTTTGTTGAAAACCGGACATGGCACTCCAGTCGCCTT
CCCGTTCCGCTATCGGCTGAATTTGATTGCGAGTGAGATATTTATGCCAGCCAGCCAGACGCAGACGCGCCGAGACA
GAACTTAATGGGCCCGCTAACAGCGCGATTTGCTGGTGACCCAATGCGACCAGATGCTCCACGCCCAGTCGCGTACC
GTCTTCATGGGAGAAAATAATACTGTTGATGGGTGTCTGGTCAGAGACATCAAGAAATAACGCCGGAACATTAGTGC
AGGCAGCTTCCACAGCAATGGCATCCTGGTCATCCAGCGGATAGTTAATGATCAGCCCACTGACGCGTTGCGCGAGA
AGATTGTGCACCGCCGCTTTACAGGCTTCGACGCCGCTTCGTTCTACCATCGACACCACCACGCTGGCACCCAGTTG
ATCGGCGCGAGATTTAATCGCCGCGACAATTTGCGACGGCGCGTGCAGGGCCAGACTGGAGGTGGCAACGCCAATCA
GCAACGACTGTTTGCCCGCCAGTTGTTGTGCCACGCGGTTGGGAATGTAATTCAGCTCCGCCATCGCCGCTTCCACT
TTTTCCCGCGTTTTCGCAGAAACGTGGCTGGCCTGGTTCACCACGCGGGAAACGGTCTGATAAGAGACACCGGCATA
CTCTGCGACATCGTATAACGTTACTGGTTTCACATTCACCACCCTGAATTGACTCTCTTCCGGGCGCTATCATGCCA
TACCGCGAAAGGTTTTGCGCCATTCGATGGTGTCCGGGATCTCGACGCTCTCCCTTATGCGACTCCTGCATTAGGAA
GCAGCCCAGTAGTAGGTTGAGGCCGTTGAGCACCGCCGCCGCAAGGAATGGTGCATGCAAGGAGATGGCGCCCAACA
GTCCCCCGGCCACGGGGCCTGCCACCATACCCACGCCGAAACAAGCGCTCATGAGCCCGAAGTGGCGAGCCCGATCT
TCCCCATCGGTGATGTCGGCGATATAGGCGCCAGCAACCGCACCTGTGGCGCCGGTGATGCCGGCCACGATGCGTCC
GGCGTAGAGGATCGAGATCTCGATCCCGCGAAATTAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTC
CCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAGATATACATACCATGGGGatgcttgcaaatcaagccttaaa
aaaggcatttttcatagaagaaagggtccaaaagagcacaactagtaatctcgctcaagaaatgcagcctgatgact
attccaatctccggattagcaactggatagacgggatgggcaacaacgaagatctctttttaaaaaacttacattta
cataatatagaacacaaggatttacataaaataatgataagtaataactatgattccgattccagcgctgaatggct
ttctattattggtgaattagaaagatttaattatcaggaaccagaattgccacgcattctccaaaaaataattgctc
taaatccaaatgagccaattgctttttttaattttttactcccctttttaaaaatcggggttgagagaatagaaaaa
gcaatctcattatctgaaaaaaaacatggtatctcattatcaaaagaaaaggtacttttccagcttgtgcgtaattt
ggctgaaacactcagcaaagtgagcttccgaactctaactttggaattgaatatagcaagattaaaagagcttcttg
tcggagaaacacctcaagagcgttataaatatttttcctatacacttttaaccgataaaaattacttagcacaactt
tataagcaataccctgtcttagtaagaattctttcaagaaagacaattagatgggcagataattttgcagaaattta
cgatcatcttctgcatgataagaaagcaatcgaacagcatttctttaatagtactcctataacagtcatcgaggata
taaaaacgaacatctccgattcgcacaatggcgggaaaggagtagttatcataaagttcaacgatgacatgaaccta
gtgtataagccaaggtctttaaaaatcgatgaacaatttcaacagcttttgtgctggtttaacgaattaaaagagaa
aaaactgagacttctccctatcactctactagatagggatacatacggctggagtgagtttatagaacataaagaat
gctcagccgaacaggaagtaaaaaacttttatcgtagaatgggatattatttggcacttttatattctatcaatgct
attgattttcacaacgagaacctgattgccagcggcgaatatccaatgctaattgatctagagaccctttttaatca
agatgccgtacagtcaaccgaatcagttactgctcaagaagtagcacttaaaacactaagtcaatctgttttggcta
ccaatatcctaccagttttcacattatacaataaaattgagggacgaggcctcaacataagtggtatggctaatggt
gaggaacagatttatccttccaaagtaccggttattcagtcgaataacacagatgaacaaaaagtagagcgtggata
catgaaaattcctgccagctcaaattatccaacattaaatggtaaacaggtaagtgtcactatgtatgtagatgaca
tgatggcagggttcaaggaagcttatgatttgttaaccaagaacaaagattgcctaaaaaatgagattagccgattt
aaaaatacaagggtaaggcagatattgcgggccactaacagatatggtaaccttctcgctatcagctatcacccgga
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ctatttacgggatggcctagacagagagatgcttttagggaaattatggcttgatacagaaatgcaaccagaattaa
cgcaggttcttctcgcggaaaaagcagacttattggaaggagacattccgtattttacaacagaaccagggcaaccc
catatctacgatagccagggacgttgctatgaaaactactataaaacaagtagcttggcaaaaacactcgacaaaat
agagaggctcggtccaaaagattatgaggaacagctacaaattattaagctttcaatgctggcacttgaatcatctc
catcagataaaaaatcaaactacatcccttccgttccggataaccaaatagatcgagattcgttcttagaagaagca
aaaagagtagcggattacctgatatccaggtctatacaaggaacaaataatggaaaagaggatgtctcttggatcgg
gacccgccttactgacaatgcagagagcctttggagaattgctcctctagggaatgatttatatgatggaataagcg
gtattgctctattttttggttatttatataaatatactagagattcgaagtatagggtctatatacaaaaatgttta
cctcctataaaagaatctcttcaggagctattagcttaccctaagtatgcttcattaggtgcttttactggcgtatt
atctaatatttatacgcttaaccacctaacaaaaatattagatgaaccttccttaatggaagaagtaaaaaaagtga
tgccaaagcttattgaatctattccatatatgcaggaagtggatattatagacggttcagctggctcacttattgtc
tgtttagacctttacaaacagacaggagatgaaatcttcttggaagcatcaaagaaattcggggaacatattcttca
aaaagctatacctcaagctacaggaattggctggaaaatatctgtctccgaagatgcattgcctggtttctctcatg
gaacctctggcattgtttgggccttgcatgaactttatcaacttaccggagagcaaatgttatatgatgccctcaaa
caaggattagcctatgagcgaagtctgtacatggaagaaaaaagaaattgggcccttccaagcgccgctgagctacc
tcaactcccttgtgcttggtgtcatggagcagcgggtgtagttttatcccgcctgctattgaaaaaggcaggttact
ccgattcgcttattgacattgaaatcagagtcggtttagagaccattataaaagaaggattcggtagagaccattcc
ctttgtcatggagatacaggaaattcagctgtactgttgctggcaagtaaagtacttaaagaggatctttggaaaca
gtacagctatgcagtaggggaacatgtattggatgaaattcagcaaggtggttggaaaagcggtctccctcagtacc
tagaaacatatggtgcaatggtaggcatttcaggcgtcggtttagggctacttaagctttatgatataaacggcgtt
ccttcaataactcacttggagtctataacagcactaaaaCTCGAGCACCACCACCACCACCACTGAGATCCGGCTGC
TAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTA
AACGGGTCTTGAGGGGTTTTTTGCTGAAAGGAGGAACTATATCCGGAT 
 
Annex VII: Column materials for protein purification 
Column Material 
Anion exchange  Hi Trap Q, 5 ml 
Cation exchange Hi Trap SP, 5 ml 
XAD Serdolit PAD I 
Affinity chromatography Ni-NTA 
 
Annex VIII: Buffers used for anion exchange chromatography 
Solutions Ingredients 
Start buffer 
 
20 mm N-Methylpeperazine pH 4.75 
Elution buffer Start buffer + 1 M NaCl (1:10) 
 
Annex IX: Buffer for cation exchange chromatography 
Solutions Ingredients 
Start buffer 
 
10 mM citric acid pH 3 
Elution buffer / Regeneration buffer 10 mM citric acid , 1 M NaCl, 1:10 ratio of citric acid to NaCl 
 139 
 
Annex X: Solvents for XAD column chromatography 
 
Isopropanol (100 %),  
Methanol (50 %, 60 %, 70 %, 100 %) 
Acetonitrile (25 %, 30 %, 45 %, 100 %)  
 
Annex XI: Buffers and solutions for agarose gel electrophoresis 
Solution Ingredients 
50X TAE Buffer 
 
121.14  g Tris Base , 9.31  g EDTA-Na, 27 ml Acetic acid (100 %), D/W up 
to 500 ml  
DNA loading buffer 
 
0.05 ml 0.05 % Bromophenol blue, 0.5 ml 0.1 % SDS, 41.015 mg 5 mM 
Na_Acetate, 25 mg 25 % sucrose, D/W up to 100 ml 
 
Annex XII: Buffers and solutions for SDS gel electrophoresis 
 
1. Separating Gel 
Stock solutions Final concentration 
  10 % 15 % 20 % 
40 % Acrylamid/Bisacrylamid (37.5:1) 2.25 ml 3.3756 ml 4.5 ml 
Solution A:2M Tris, pH 8.5 2.25 ml 2.25 ml 2.25 ml 
Solution D: 1M Tris + 0.8 %SDS 0 0 0 
D/W 3.126 ml 2.109 ml 0.984 ml 
20 % SDS 0.06 ml 0.06 ml 0.06 ml 
APS 1.2 ml 1.2 ml 1.2 ml 
Temed 0.006 ml 0.006 ml 0.006 ml 
 
2. Stacking Gel 
Stock solutions 5 % acrylamide concentration 
40 % Acrylamid/Bisacrylamid (37.5:1) 0.5 ml 
Solution A:2M Tris, pH 8.5 0 
Solution D: 1M Tris + 0.8 %SDS 0.6 ml 
Distilled water (D/W) 3.09 ml 
20 % SDS 0 
APS 0.8 ml 
Temed 0.01 ml 
 
3. Running buffer: 10 X Tris-Glycine-buffer (pH 8.5), 25 mM Tris, 192 mM Glycine, 0.1 % 
SDS 
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Annex XIII: Solutions used in Coomassie staining 
Solutions Ingredients 
Staining solution (100 ml) 
 
0.25 % (w/v) coomassie brilliant blue R250, 45 % Methanol, 10 % 
Glacial acetic acid   
Destaining solution (1 L) 45 % Methanol, 10 % Glacial acetic acid 
 
Annex XIV: Solutions for silver staining (Heukeschoven and Dernick; 1998) 
Solutions Ingredients 
Fixing solution (1L) 400 ml Ethanol, 100 ml Glacial acetic acid, 500 ml D/W 
Sensitizing solution 
 
75 ml Ethanol, 17 g Na- acetate.3H2O, 1.3 ml 25 % Glutaraldehyde (add 
fresh), 0.5 g sodium thiosuphate.5H2O, D/W up to 250 ml 
Silver nitrate solution 
 
0.125 g silver nitrate, 25 µl Formaldehyde (add fresh), D/W up to 125 ml 
Developing solution 
 
4.125 g sodium carbonate, 12.5 µl Formaldehyde, D/W  up to 125 ml 
Stop solution 14.6 g EDTA-Na.2H2O, D/W up to 1000 ml 
Preservation solution 100 ml Glycerol, D/W up to 1000 ml 
 
Annex XV: Buffers for protein purification from inclusion bodies 
Solution Ingredients 
Buffer A 
 
50 mM Tris-HCl pH 8, 5 mM EDTA, 10 mM NaCl, D/W up to 200 ml 
 
 
Buffer B 
 
20 mM Na2HPO4, pH 7.2, 20 mM NaCl, 5 mM EDTA, 25 % sucrose, D/W up to 200 ml 
 
Annex XVI: Preparation of NZY broth 
Medium Components/composition 
NZY
+
 medium 10 g of NZ amine (casein hydrolysate) 
5 g of yeast extract 
5 g of NaCl 
Add deionised H2O to final volume of 1 liter 
Adjust pH 7.5 using NaOH 
Autoclave and add the following 
12.5 ml of 1M MgCl2 
12.5 ml of 1M MgSO4 
20 ml of 20 % (w/v) glucose  
 
Annex XVII: Cycler program for amplification of LanM  
Step Temperature  ( °C) Time (s) No. of cycles 
Initial denaturation 97 180 1 
Denaturation 96 20  35 
Annealing 62 ± 6 30  35 
Extension 72 240 35 
Final extension 72 600 2 
Hold 4 ∞ 1 
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Annex XVIII: LC- MS and MS-MS fragmentation of the PseAXa and its mutant peptides 
 
1. PseAXa 
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2. LanAXaC52A 
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3. LanAXaC56A 
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4. PseAXaC62A 
 
 
 
 
5. PseAXaC65A 
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6. LanAXaC70A 
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7. LanAXaC75A 
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Annex XIX: Fragmentation pattern of PseAXa and its mutants  
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Annex XX: MALDI TOF MS of PseAXa mutant peptides after incubation with IAA 
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Annex XXI: MALDI TOF MS of PseAXa mutant peptides after incubation with IAA in 
presence of TCEP 
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Annex XXII: MALDI TOF MS of PseAXa mutant peptides after incubation with βME 
 
10174.2
10245.7
0.0
0.5
1.0
4x10
10172.6 10318.8
10470.5
0.0
0.5
1.0
4
x10
10301.6
0
500
1000
1500
10369.4
0
100
200
300
400
In
te
n
s
it
y
. 
[a
.u
.]
10190.1
10497.3
0.0
0.5
1.0
4x10
10216.0
500
1000
9500 10000 10500 11000 11500 12000
m/z
10225.7
10248.4
10246.4
10224.4
10381.8
10225.2
10208.0
10290.1
10206.8
10225.2
10465.8
C56+ βME
C52+ βME
C70+ βME
C75+ βME
C65+ βME
C62+ βME
0
 
  
1
5
0
 
Annex XXIII: Masses of the PseAXa and its mutant peptides as observed in MALDI TOF MS before and after incubation with different chemicals. 
The possible addition (+) or removal (-) of no. of H2O/ IAA adduct to yield the respective masses are given in an adjacent column ‘Prediction’. The 
overall predictions from the respective reactions are provided in the column ‘Inferences’ 
Peptides 
Control +TCEP +IAA +TCEP+IAA +βME 
Inferences Observed 
mass (Da) 
Prediction 
Observed 
mass (Da) 
Prediction 
Observed 
mass (Da) 
Prediction 
Observed 
mass (Da) 
Prediction 
Observed 
mass (Da) 
Prediction 
PseAXa 10204.3 -4 H2O 10207.1 -4 H2O 10203.9 -4 H2O 10314.3 + 2 IAA 10207.1 -4 H2O 
4 thioether, 
1 disulfide 
PseXaC52A 10227.4 
 
-1 H2O 10173 -4 H2O 10221   10229 +1 IAA 10174 -4 H2O 
1 free Cys 
  10207   10190 -3 H2O 10254 -0 H2O 10249   10189 -1 H2O 
  10190   10207 -2 H2O 10235   10289   10225   
  10176    10226 -1 H2O 10479       10245   
  10484 + 5 Ni  10244 -0 H2O         10480   
PseXaC56A 10225.3 -1 H2O 10172 -4 H2O 10224   10229 +1 IAA 10172 -4 H2O 
1 free Cys, 
1 free Dha 
residue 
  10207   10190 -3 H2O 10480 -2 H2O 10455   10247 -2 H2O 
  10190   10207 -2 H2O 10543 -1 H2O 10529   10252 +1 βME 
  10176   10226 
  
  10381   10318  -1 H2O 
  10485  + 5 Ni 10243 -0 H2O        10470   
PseXaC62A 10225.6 -1 H2O 10228 -1 H2O 10224 -1 H2O 10224 -1 H2O 10224 -1 H2O 
free Cys 
  10289   10245 -0 H2O 10281   10277   10246 -0 H2O 
  10336   10302   10298   10455   10301   
  10517   10319       10513   10363   
      10367           10381   
PseXaC65A 10206 -2 H2O 10206 -2 H2O 10205 -2 H2O 10206 -2 H2O 10208 -2 H2O 
free Cys  
  10281   10281   10281   10282   10225 -1 H2O 
  10723   10725       10437   10290   
  10797   10797            10369   
                      
PseXaC70A 10190.2 -3 H2O 10190 -3 H2O 10186 -3 H2O 10303 +2 IAA 10190 -3 H2O 
2 free Cys, 
3 rings, 
1disulfide 
  10412   10205 -2 H2O 10219   10377   10206 -2 H2O 
      10223 -1 H2O 
 
  10453   10225 -1 H2O 
      10494 + GSH    10510   10497   
                      
PseXaC75A 10224 -1 H2O 10174 -4 H2O 10228 
 
10226 +1 IAA  10216   
1 free Cys 
  10207 -2 H2O 10208 -2 H2O 10242 -0 H2O 10373    10465   
  10190 -3 H2O 10480  +GSH 10475   10447       
  10174 -4 H2O         10589       
  10480 +5 Ni          10519       
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